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1.   Introduction and Theoretical Background 
 
Bionanotechnology as a subdiscipline of nanotechnology covers a variety of sectors 
such as healthcare, electronics, cosmetics, textiles, information technology and 
environmental protection.
[1]
 These areas include for instance biosensors or bioelectronic 
devices, devices for radio frequency engineering or in vivo applications. 
With regard to the latter, bionanotechnology has been used in order to develop drug 
delivery vehicles in e.g. cancer therapy, for in vitro diagnosis, for signal amplification 
within in vitro/in vivo applications
[2]
 or for monitoring intracellular metabolic processes
[3]
 
in tissue engineering and molecular biology.
[4]
 Bionanotechnology is located at the 
interface of chemistry, cell biology and biochemistry and is focused, on the one hand, on 
the formation of composite nanoscale materials displaying novel and unique properties 
and on the other hand on their usage in a biological environment with regard to those 
properties.
[5]
  
 
 
1.1   Bionanomaterials, Bioconjugates and Biohybrid Structures 
 
Since the field of bionanotechnology is an intensively growing field it touches on 
almost all material classes. Normally, these materials are made of “biologicals” and the 
nanoparticles, which can be both hard and soft nanoparticles. The biologicals possess 
active functionalities through e.g. enzymatic, catalytic or therapeutic functions or 
scaffolding building blocks. They include proteins/peptides, nucleic acids, lipids, 
carbohydrates, reporter molecules or contrast agents. The term hard nanoparticles 
summarizes metal nanoparticles (e.g. gold or silver nanoparticles), metal oxides or 
sulfides (e.g. nickel oxide, titanium oxide or copper sulfide) as well as semiconductor 
quantum dots. The term soft nanoparticles, on the other hand, includes i.a. the pivotal 
material classes of (bio-)polymers (cf. Figure 1.1).  
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Figure 1.1 Schematic illustration of a structure formed by the conjugation of “biologicals” and 
nanoparticles.
taken from [6]
 
 
Some of these material classes can be found under both of the defined subcategories, 
which additionally makes it rather difficult to find a proper definition for those composite 
(nano-)materials that are explored in the quite diverse field of bionanotechnology.
[5]
 
These composite (nano-)materials are usually referred to as (bio-)nanomaterials, 
bioconjugates or biohybrid structures (BHS).  
 
 
1.1.1   Formation Strategies for BHS 
 
In general there are two main formation or coupling strategies in order to fabricate 
BHS. These are (i) the covalent and (ii) the non-covalent approach. Concerning the 
covalent synthetic route, reactions such as Michael addition, epoxide opening, amidation, 
imine formation, reductive amination, click chemistry, (thio-)urea bond formation or 
Diels-Alder reactions are frequently used.
[5]
 However, covalent binding of biologically 
active moieties such as antibodies cannot always be well controlled with regard to the 
conjugation efficiency, their activity or orientation.
[7]
 Non-covalent attachment is 
therefore a proper alternative. The class of non-covalent approaches includes weak 
interactions such as hydrophobic interactions, hydrogen bonding or π-π interactions 
ranging from 2 kJ·mol
-1
 for van der Waals interactions up to 300 kJ·mol
-1
 for ion-ion 
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interactions.
[8]
 These weak interactions are used for the attachment or complexation of 
functional (macro-)molecules. Moreover, the selective binding of functional entities can 
be provided by molecular recognition processes (e.g. biotin-avidin, 
adamantane-β-cyclodextrin or His-tag-Ni
II
-Nitrilotriacetic acid). 
 
 
1.1.2   Molecular Recognition Strategies in BHS Formation 
 
Amongst the molecular recognition strategies, which have been applied to drug 
delivery systems, commonly, the avidin-biotin and the Ni
II
NTA-His-tag interaction or the 
inclusion complex formation with e.g. cyclodextrins have been applied. Figure 1.2 shows 
the molecular recognition strategies that were used in this work.  
 
 
Figure 1.2 Schematic illustration of the molecular recognition strategies used in this work: 
a) avidin-biotin and b) adamantan-β-cyclodextrin interaction. Avidin structure was 
taken from [9]. 
 
The avidin-biotin interaction displays a feasible approach to introduce (bio-)molecules to 
soft and hard nanoparticulate plattforms. The avidin´s discovery by E. E. Snell as well as 
the isolation of the vitamin H (biotin) by Vigneaud et al. in the 1940s laid the foundation 
for the tremendously high application of the avidin-biotin interaction to the scientific 
field.
[10]
 Since a wide range of related reagents are commercially available, the 
avidin-biotin technology has not only evolved the (molecular) biological field but also the 
biomedical field e.g. for drug delivery purposes. Avidin was found in hen egg white and is 
a glycoprotein of homotetrameric form. Each subunit possesses a binding site for biotin 
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or related analogues.
[11]
 The avidin-biotin interaction displays a very low dissociation 
constant of 10
-15
 M,
[12]
 which makes it the strongest known non-covalent interaction. The 
avidin´s high carbohydrate content in combination with its high isolelectric point (pI) of 10 
are often considered as drawbacks, since they facilitate also unwanted, secondary 
interactions. Therefore avidin analogues have been invented, which possess lower pI 
values and are deglycosylated or the non-glycosylated streptavidin isolated from 
Streptomyces avidinii is used, which displays similar affinities to biotin. 
Despite the latter and with respect to cancer research it has been found that the 
avidin-polymer conjugates enhance tumour tissue accumulation mediated through the 
enhanced permeability and retention effect (EPR) effect due to their increased molecular 
weights.
[13]
 Furthermore, the N-acetylglucoseamine and mannose residues of avidin bring 
along the ability to bind certain lectins on cancer cell surfaces. Since these residues are 
not required for biotin binding,
[14]
 they can be used as an inherent targeting entity.
[15-19]
  
Cyclodextrins, on the other hand, were discovered and isolated in 1981 as a bacterial 
digestion product.
[20]
 After the elucidation and isolation of more cyclodextrins, genetically 
engineered enzymes have been used in order to produce cyclodextrin subtypes with high 
purities.
[21]
 Nowadays the commonly used types of cyclodextrins are α-, β-, γ-cyclodextrin. 
They are composed of six, seven and eight α-(1,4)-linked glycosyl units, respectively. Its 
primary hydroxyl groups are located at the interior while its secondary ones cover the 
outer surface of the cyclodextrin. Cyclodextrins are water soluble and, in addition, they 
display a hydrophobic cavity.
[22]
 This hydrophobic interior allows the inclusion of lipophilic 
low molecular weight molecules, for instance, adamantane,
[23]
 cholesterol
[24]
 or 
doxorubicin.
[25]
 There are steric and thermodynamical factors that influence the 
formation of such a host-guest inclusion complex. Its formation is driven by certain 
energetically favored interactions. These are (i) the displacement of water molecules 
from the cyclodextrin interior (hydrophobic effect), (ii) reduction of repulsive interactions 
of the guest molecule with the aqueous environment and (iii) an increase of hydrophobic 
interactions of the guest molecule with the hydrophobic cavity of the cyclodextrin.
[22]
 
Due to their exceptional property profile cyclodextrins are widely applied in various life 
science fields such as cosmetics and personal care, foods and flavours, agriculture and 
chemical industry or pharmaceuticals. The latter is mainly driven by their good 
toxicological profile and their ability to improve the property profile (solubility and 
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bioavailability) of the guest molecule in the complex.
[26]
 In addition, a huge research area 
concerns the formation of soft supramolecular structures based on the complex 
formation of cyclodextrin hosts and certain guest molecules. These nanogels combine the 
advantages inherent to their size and gel properties such as the uptake of small molecules 
or even macromolecules and are considered as promising candidates for potential drug 
delivery applications.
[27]
 
 
 
1.1.3   BHS Based on Polymers for Therapeutic Applications 
 
BHS based on polymers have been developed for fields such as biomedical 
applications (e.g. diagnostics or therapy), for information technologies (e.g. organic 
electronics or supramolecular conducting materials) or environmental sciences (e.g. for 
catalysis or detection).
[28]
 
However, one of the most important driving forces for development of polymer 
therapeutics in the field of biomedical application is their promising applicability in the 
field of drug and/or gene delivery. Here, the polymer can either act as the bioactive 
compound or as the inert carrier to which the therapeutic compound is covalently or 
non-covalently attached. The concept of polymer-drug therapeutics through the covalent 
approach was firstly proposed in 1975 by Helmut Ringsdorf (Figure 1.3).
[29]
 His model 
includes a solubilizing entity and the particular drug, whereas the so called “Transport 
System” aims at targeted and tissue selective delivery. 
 
Figure 1.3 Helmut Ringsdorfs concept of a polymer therapeutics.
modified from [29]
 
Polymer Backbone
biodegradable
biostable
Solubilizer Pharmacon Transport System
Drug Fixation 
and Release
Homing Device
Resorption Enhancer
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This model is also based on the concept of a “Magic Bullet” proposed by Paul Ehrlich over 
a century ago.
[30]
 Ringsdorfs model roughly highlights the prerequisites a proper drug or 
gene delivery system has to fulfill. These are good solubility in the physiological medium, 
non-toxicity of their degradation products, monodispersity in molecular weight and size, 
prolonged blood circulation time, which for instance requires an appropriate scaffolding 
material or certain sizes, lack of immunogenicity, appropriate cellular adhesion and 
internalization or controllable drug release features, to name just a few of the vital 
prerequisites of a successful drug delivery system. Consequently, polymers are designed 
and used in order to decrease potential toxicity and enhance e.g. solubility, stability, 
bioavailability and/or release of a drug.
[31]
 The uniqueness of polymers in the field of 
nanoparticles for therapeutic purposes is caused by their structural and chemical 
diversity, e.g. due to different monomers, different architectures and/or tacticity. These 
features are known to have a distinct impact on the characteristics of a drug delivery 
system, such as, for instance, shape, size, charge, solubility and functionality.  
Furthermore, their remarkable flexibility in chemistry offers the opportunity of the 
conversion of consisting functional groups of the polymer into the desired reactive ones 
or the direct incorporation of certain functional groups through the choice of the 
monomer. Consequently, this allows the application of a wide range of conjugation 
chemistry of the (non-)covalent binding strategies in order to attach the functional entity 
of choice, e.g. peptides/proteins as imaging and/or targeting moieties or scaffolding 
material. About two decades before Ringsdorf proposed his concept of polymer 
therapeutics the synthesis of N-vinylpyrrolidine conjugates of glycyl-L-leucine-mescaline 
as a drug depot formulation in 1955 was published and the first clinical testing of the 
synthetic polymeric anticancer agent divinylethermaleic anhydride (DIVEMA) in the 1960s 
started. However, due to its severe toxicity DIVEMA failed the clinical trials.  
In the late 1970s the research activity of Frank F. Davis and Abraham Abuchowski laid the 
groundwork for the rising era of PEG-based polymeric therapeutics by studying the 
pegylation of albumin
[32]
 and bovine liver catalase.
[33]
 Consequently, in the early 1990s 
the approval of the first PEG-protein-conjugates PEG-adenosine deaminase (Adagen®) 
and PEG-asparaginase (Oncaspar®) together with the first polymer-protein conjugate a 
styrene maleic anhydride neocarzinostatin (SMANCS; Zinostatin stimalmer) in Japan took 
place. This was followed by several other clinical trials of PEG-based polymer-anticancer-
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drugs.
[34]
 Subsequently, two PEG-based polymeric therapeutics (PEG-interferon 
conjugates, PEG-Intron® and PEG-ASYS®) for the treatment of chronic hepatitis C were 
approved by the FDA (food and drug administration) in the early 2000s. Meanwhile the 
application of PEG-based therapeutics has broadened to other disease indications, with 
PEG-interferon α-2b (Sylatron™) approved in 2011 as an adjuvant therapy for treatment 
of high-risk melanoma.  
Although PEG-conjugates dominate the field of approved polymer therapeutics, there are 
also some examples of other polymers that have been also approved by the FDA, e.g. a 
random copolymer based on glutamic acid, lysine, alanine and tyrosine for the treatment 
of multiple sclerosis (Copaxone®). Some of them at least reached clinical trials. For 
instance the N-(2-Hydroxypropyl) methacrylamide copolymer palatinate for the therapy 
of ovarian cancer (ProLindac®) reached Phase II or a lysine-based dendrimer, an 
antimicrobial agent, is in Phase III (Vivagel®).
[35]
 
Despite the promising results of PEG-based polymer therapeutics, more and more safety 
concerns have been expressed since some PEG-protein conjugates induced 
infusion-related and hypersensitivity reactions in patients. This is considered to be caused 
by pre-existing anti-PEG antibodies. This clearly emphasizes the urgent necessity for 
developing alternative polymeric vehicles even though, immunosuppressive strategies are 
in development to overcome this problem.
[36]
 Consequently, the research activity is quite 
high, not only in the latter respect, but also in designing more complex BHS through the 
combination of polymers with targeting and imaging moieties, drugs (e.g. low molecular 
weight drugs and/or proteins/peptides) or (poly-)nucleotides for drug or gene delivery. 
The main purpose behind this is to design polymeric, multifunctional drug delivery 
systems that meet the requirements of those ideal concepts as theranostics or 
personalized medicine.  
 
 
1.1.4   BHS Based on Dendritic Polymers for Therapeutic Applications 
 
Among the class of polymers, especially dendritic polymers have gained a great deal 
of attention. Besides the fact that a lot of dendritic polymers are commercially available 
(e.g. Starburst®PAMAM, Astramol®PPI or Priostar®PEHAM/PEA) they possess several 
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advantages over linear polymers. Their perfect structures as well as dispersities below 
1.05 are considered to cause reproducible pharmacokinetics. Furthermore, their structure 
exhibits areas of different densities, which translate into the capability of guest molecule 
complexation. Their defined multivalency offers convenient tailoring of their surface 
functionalities, which can also facilitate the introduction of other interaction properties. 
In contrast to linear polymers dendritic polymers also possess a non-linear relationship 
between viscosity and molar mass as well as a high aqueous solubility. Thus, they are 
considered to have the ability to overcome the obstacles in the development and clinical 
application of drugs based on linear polymers.
[37]
 
30 years after the dendrimer development, the first dendrimer based nanomedicine 
(SPL7013; VivaGel®) has recently been approved in Japan as a protective condom coating 
and is reported to be 99.9% effective against HIV and genital herpes. Currently a 
dendrimer-Docetaxel conjugate, which exhibits enhanced effectiveness against breast, 
prostate, lung and ovarian cancer compared to docetaxel alone, reached now phase I of 
clinical trials. Along with the latter, pre-clinical studies of dendrimer based therapeutics 
cover diseases such as inflammation, cancer or infectious diseases.
[38]
 
Only a few attempts have been taken to combine avidin-biotin technology with the 
superior properties of dendritic polymers in order to investigate their cell uptake and 
biodistribution.
[15, 39-43]
 
Recently, Ng et al. presented the conjugation of the biotinylated cellular tumor antigen 
(p53) to a dendronized streptavidin. This PAMAM-dendron-streptavidin-p53 construct 
displayed an efficient nanocarrier-mediated uptake, which was directly dependent upon 
the presence of a biotinylated dendron. Furthermore, the biological activity of 
cytochrome C in the dendron-streptavidin-cytochrome C construct showed to be 
significantly enhanced compared to the native protein.
[39]
 Xu et al. reported the 
successful targeting and imaging of a supramolecular avidin-biotin-dendrimer-Gd
III
 
complex to ovarian cancer tumors in mice.
[15]
 Furthermore, Xu et al. investigated the 
cellular uptake of a complex of avidin with acetylated, biotinylated and 
99m
Tc-DTPA-
modified G5-PAMAM dendrimer. The authors reported high uptake in the spleen, liver 
and lungs.
[40]
 Moreover, Kobayashi et al. reported the successful internalization of a 
conjugate of avidin with a G6-PAMAM dendrimer functionalized with a gadolinium 
chelate complex, which showed superior results compared to Gadopentetat-Dimeglumin 
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(Magnevist®) or the dendrimer substituted with the gadolinium chelate complex.
[41]
 
Sato et al. investigated the tumor accumulation of the 
111
In-oligonucleotide complexes of 
either a biotinylated 4
th
 generation dendrimer, avidin or the avidin-dendrimer conjugate 
to intraperitoneal disseminated tumors.
[42]
 It was shown that the complex of 
[
111
In-oligonucleotide/avidin/biotinylated G4 dendrimer]
 
showed the highest tumor 
accumulation after 2 h compared to the [
111
In-oligonucleotide/dendrimer] or 
[
111
In-oligonucleotide/avidin] complexes. However, after 24 h 
[
111
In-oligonucleotide/avidin] complexes showed increased tumor accumulation, whereas 
the [
111
In-oligonucleotide/avidin/biotinylated G4-PAMAM dendrimer] complexes 
exhibited decreased tumor accumulation. Although all carriers showed considerable 
tumor uptake the lack of characterization of the probed delivery systems allowed no clear 
explanation of these results. Mamede et al. used a similar drug delivery system: [
111
In-
oligonucleotide/biotinylated G4-PAMAM dendrimer/avidin]. They studied targeted 
delivery to liver cells. Interestingly, they found that only [biotinylated
 
111
In-oligonucleotide/avidin] complex showed a high accumulation in the liver, which they 
attributed to the oligosaccharide moieties of the avidin structure. The 
[
111
In-oligonucleotide/G4-PAMAM dendrimer] complex, in contrast, was mainly found in 
the kidney and spleen, whereas the [
111
In-oligonucleotide/avidin/biotinylated G4-
PAMAM dendrimer] complex tremendously accumulated in the lungs.
[43]
 The latter 
finding was considered to be in line with a finding of Kukowska-Latallo et al. who reported 
high DNA expression in the lung tissue in his DNA delivery trial of a G9-PAMAM 
dendrimer/DNA complex. The authors attributed these findings to the sizes of the 
complexes but, unfortunately, no characterization data were published in order to 
conclusively explain the underlaying driving forces regarding the properties of these 
complexes.
[44]
  
The work of Mamede et al. raises a further issue: How does the sequence of fabrication 
and the properties of the single components of those BHS influence their final properties. 
Despite the promising nature of these results the difficulty to draw conclusive pictures of 
the observed results seems to be rather problematic without a thorough characterization 
of the used materials. Consequently, these reports clearly emphasize the necessity of a 
thoughtful and comprehensive characterization of BHS not only for drug delivery 
purposes - a vital point that has been highlighted by several researchers.
[6, 45-47]
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1.1.5   Enzymes in Drug Delivery 
 
Enzymes are a class of biologically active biomacromolecules that play an important 
role in nature. Due to their ability to catalyze the conversion of specific substrates, they 
are consequently used for biocatalysis or biosensor application.
 
Here, they are mainly 
immobilized on solid particles, but enzymes were also bound to polymers for these 
purposes.
[48]
 Enzymes are also used for the self-assembly of nanostructures,
[49]
 
demonstrated by in vitro and in vivo formation of supramolecular hydrogels for potential 
drug delivery applications.
[50, 51]
 
Enzyme responsive materials in drug delivery are an evolving field in today’s life sciences.  
The particular drug is often somehow attached to the polymeric particle – a so called 
prodrug, which is formed into the desired drug through e.g. endosomal or lysosomal 
enzymes or a hydrolytic environment, after reaching the target tissue. The main aim of 
this approach is to overcome deficiencies in bioavailability or to improve the efficacy or 
the safety profile of otherwise promising drugs.
[52]
 Ester and amide bonds are commonly 
used for this reason.
[53]
 In this regard also self-immolative structures have to be 
mentioned. “Self-immolative” means degradation of the structure triggered by a certain 
stimuli such as the presence of an enzyme. “Self-immolative” can refer to the whole 
structure
[54]
 or only to a certain part of the structure, for instance the attached linker with 
the drug.
[55]
  
The prodrug strategy also includes the directed enzyme prodrug therapy (DEPT). It was 
firstly envisioned by Philpott et al.
[56]
 and termed antibody-directed enzyme prodrug 
therapy (ADEPT) by Bagshawe in the late 1980s.
[57]
 
In the ADEPT concept, the antibody is considered to guide the enzyme specifically to the 
targeted tumor. Apart from the latter, targeting can also be done without antibodies. 
Here, carbohydrates for carbohydrate-lectin interaction in the lectin-directed enzyme-
activated prodrug therapy (LEAPT) or ligands such as folate, which bind to receptors that 
are highly present on the target cells have been used (folate-directed enzyme prodrug 
therapy — FDEPT).
[58]
 All of the constructs made by the latter approaches can be 
categorized as BHS with active targeting units. However, the immunogenicity of a lot of
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protein drugs displays a huge obstacle of the ADEPT concept. Hence other concepts have 
been developed such as gene-directed enzyme prodrug therapy (GDEPT). In GDEPT the 
enzyme is encoded through a gene and upon delivery to the target cells gene expression 
and subsequent enzyme production can take place. However, this strategy also suffers 
from poor transfer and/or short term expression of the genes. The polymer-directed 
enzyme prodrug therapy (PDEPT) takes advantage of the EPR effect of polymer-enzyme 
conjugates ideally resulting in a high accumulation in the target tissue. Moreover, easy to 
tailor polymers may evade such drawbacks as the immunogenicity or toxicity of BHS 
based on the ADEPT concept. After accumulation in the target cells, the required prodrug 
(substrate) can be administered. This substrate/prodrug must be non-toxic in the applied 
dose and can be bound to a polymer or not.
[59]
 A major point that has to be considered is 
that the choice of the enzyme has to be made in a thoughtful way since it has been 
reported that non-human enzymes provide a high specificity but may suffer from their 
immunogenicity. In contrast, human enzymes can activate circulating prodrugs wherever 
they are naturally located. Hence they display a rather low specificity.
[60]
 
BHS of proteins and (dendritic) polymers offer not only high molar masses and sizes 
potentially facilitating the EPR effect. Furthermore, with respect to multivalency they can 
be equipped with targeting moieties as well. In line with the latter it seems likely that 
features of the PDEPT concept can be fulfilled by polymer based BHS. 
 
 
1.2   Classes of Polymers and Dendritic Polymers 
 
Among the material class of polymers one can find a variety of different architectures 
(Figure 1.4). They can further be categorized by their composition (e.g. homopolymer or 
copolymer), tacticity (e.g. isotacticity or syndiotacticity) and functionality (e.g. (semi-) 
telechelic or multifunctional), respectively. In general, polymer architectures consist of 
four major classes: linear chains, cross-linked polymers, branched chains, star and 
comb-like polymers and dendritic polymers. The latter can be subdivided into four sub-
sets: dendrimers, randomly hyperbranched (hb), dendrimer-based star polymers as well 
as dendronized polymers. Linear, cross-linked, branched and hb polymeric architectures 
are all gained from polymerization reactions such as step or chain growth. Although
 
1.2 Classes of Polymers and Dendritic Polymers 
 
  13 
dendrons and dendrimers are created by stepwise reactions – either divergent or 
convergent synthesis – they belong to polymers due to their repetitive and 
macromolecular structures. Compared to their linear analogs dendritic polymers and 
dendrimers especially bear some advantages in the field of drug and/or gene delivery. 
Their defined and high numbers of reactive surface functionalities allow not only the 
attachment of more than one drug but also to tailor their final properties with respect to 
solubility, biocompatibility, size, functionality or blood circulation time. In addition, their 
low dispersity should allow reproducible pharmacokinetic behavior.
[61]
  
 
Figure 1.4 Schematic illustration of different polymer architectures for polymer-protein 
conjugates.
modified from [61]
 
 
 
1.2.1   Definitions 
 
The term dendrimer was created by D. A. Tomalia in 1985 from the greek words 
dendros, which means tree, and meros, which means part.
[62]
 Dendrimers are polymers, 
which are highly uniform, monodispers, three-dimensional and globular in shape and 
their outer scaffold possesses high numbers of reactive functional groups. A schematic 
representation of the structure of a dendrimer is given in Figure 1.5. The dendrimer 
consists of a core that is covered with layers of repeating units, so called generations, and 
of subdivisions called dendrons. The first “cascade molecules” were synthesized by 
Vögtle et al. in the late 1970s,
[63]
 although it was already conceptionalized in the early 
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1940s.
[64-66]
 This was established by the research activity of Tomalia, Turro and 
Goddard et al. (starburst dendrimers),
[62]
 Newkome and Baker et al. (arborols)
[67]
 or 
Fréchet and Hawker et al. (poly(arylalkylether)
[68]
 in the 1980s until the early 1990s and 
gave rise to the era of these unique polymers.
[69]
  
 
Figure 1.5 Structure of a dendrimer of the fourth generation.
taken from [70]
 
 
Compared to the evolving research activity regarding dendrimers up to the early 1990s 
there were only few articles published concerning hb polymers.
[71-77]
 Common 
commercially available dendrimer scaffolds are poly(amido amine) dendrimers 
(Starburst™ PAMAM dendrimers), poly(propylene imine) dendrimers (Astramol™- or DAB-
Am-x- dendrimers) and polyester dendrimers. Hb polymers possess highly random 
structures, imperfect branching but also globular shapes as dendrimers.
[78]
 Well-known 
and commercially available hb polymers are poly(ester amides) (Hybrane® – DSM), 
aliphatic polyethers (Polyglycerol® – Hyperpolymers GmbH), aliphatic polyesters 
(Boltorn®), poly(ethylene imines) (Polymin® – BASF).
[78]
 
To distinguish perfectly branched dendrimers and randomly branched polymers a 
common value is the so called degree of branching (DB). The DB was initially stated by 
Hawker et al.
[71]
 (equation 1) and refined by Hölter et al. (equation 2).
[79]
 
 
DB	= T+D
T+D+L
                    equation 1 
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DB	=	 2·D
2·D+L
                    equation 2 
 
While equation 1 is only applicable to high molecular weight hb polymers, equation 2 
represents an universally applicable formula for low and high molecular weight hb 
polymers.
[79]
 In contrast to dendrimers, which possess a degree of branching of 1 and 
polydispersities ranging from 1.005 – 1.13,
[80]
 hb polymers show polydispersities between 
2-10
[78]
 and DB usually not higher than 0.5.
[79]
 An intermediate class that has been 
proposed by Haag et al. are so called “pseudo-dendrimers”, which are hb polymers 
without linear units and hence a DB of 1.
[81]
 They differ from perfectly branched 
dendrimers since they are not as symmetrically branched as dendrimers.
[82]
 Along with 
special monomer design
[83-86]
 also a complete post-modification of the functional groups 
has been proven to aim a DB of 1 with hb polycarbosilanes,
[87]
 hb polyglycerols, 
[81, 88]
 hb 
polyimides
[89]
 or hb polyesters.
[90]
 
 
 
1.2.2   Synthesis of Perfectly Branched Dendrimers 
 
Traditionally, the synthesis of dendrimers is time-consuming and quite laborious 
and can either be done by a convergent or a divergent approach. Usually the reactive 
monomers are in the form of ABx. A and B denote two different types of functional 
groups. Furthermore, A and B are only able to react with each other. X refers to the 
number of functional groups. Usually when x ≥ 2 highly branched polymers can be 
synthesized. An illustration of both approaches is given in Figure 1.6. The first repetitive 
and stepwise procedure in the synthesis of “cascade molecules” was reported in the late 
1978s.
[63]
 Simultaneously the divergent approach, which was the first route to achieve 
dendrimers, was independently developed by Tomalia et al.
[62]
 and Newkome et al.
[67]
 The 
divergent synthesis starts from a so called focal point possessing a certain multiplicity. 
Each reactive group of the core molecule represents a starting point, from which the 
dendron can grow. The core multiplicity is usually higher than two. Therefore it is 
necessary to prevent the B functionality from reacting with the core unit, allowing only 
the reaction of the A functionality with the core molecule. 
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Figure 1.6 Divergent and convergent approach in dendrimer synthesis with g – dendritic growth, 
a – activation of surface groups and a*
 
- activation of core group.
modified from [70]
 
 
After the generation growth it is necessary to purify the dendrimers from e.g. byproducts, 
unreacted starting material or dendrimers possessing defect structures. The iterative 
procedure of generation growth, protection-deactivation, deprotection-activation and 
purification results in the final dendrimer architecture. The achievement of more or less 
complete conversions has been found to require rather large excesses of monomers. 
Additionally, the higher the generation of the reacting dendrimer the more likely 
incomplete conversion becomes. This leads to increased amounts of defect structures, 
which cannot be removed sufficiently by common purification techniques.
[70]
 Hawker and 
Fréchet, on the other hand, established the convergent approach in the early 1990s.
[68]
 
Here, the dendrons are synthesized in the first place according to the same laborious 
procedures as denoted for the divergent approach. Finally, these dendrons are reacted 
with a reactive core molecule with a certain core multiplicity in order to achieve the 
dendrimer structure. This procedure leads to more precise dendrons due to their less 
complicated structures lowering the partial derivatization. However, steric hindrance 
within the final coupling of those dendrons to the core molecule limits this approach as 
well. Since the imperfections have increased impact on the final molecular weight of the 
achievable structures, purification can be applied more efficiently compared to the 
divergent approach. Even though this approach allows the synthesis of well-defined 
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dendrimers, the achievement of higher generations is limited to generation 6 mainly due 
to nanoscale steric effects.
[91]
 
Taking both routes into account more than one hundred dendrimer families with 
different compositions were synthesized and more than 1000 different surface 
modifications were reported.
[92]
 
 
 
1.2.2.1   Synthesis of Poly(propylene imine) Dendrimers 
 
The synthesis (Figure 1.7) of low molecular weight amines was first reported by 
Vögtle et al. in 1978.
[63]
 The iterative growth sequence was facilitated by a Michael 
addition of acrylonitrile to a diamine and subsequently the resulting nitriles were reduced 
by sodium borohydrid and cobalt chloride. 
 
Figure 1.7 a) Synthesis of low molecular weight amines by Vögtle et al. and b) Synthesis of 
Mülhaupt/Meijer type poly(propylene imine) dendrimers by repeating step 1 and 2 for 
each generation amplification cycle, n = 2.
modified from [93]
 
 
But these cascade molecules were limited to molecular weights not higher than 1000 Da 
or generations G = 1 – 2 and the yield ranged from 12 % up to 92 %. The synthesis of 
poly(propylene imine) dendrimers with up to 5 generations was achieved by the research 
activity of the groups of Mülhaupt
[94]
 and Meijer
[95]
 15 years later. Thus, this dendrimer 
family is usually referred to as the Mülhaupt/Meijer type poly(propylene imine) 
dendrimers.
[93]
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1.2.3   Synthesis of Hyperbranched Polymers 
 
Traditionally hb polymers are close relatives to the dendrimers since they also 
consist of high numbers of reactive surface groups.
[93]
 Compared to the perfectly 
branched dendrimers they are usually quite polydispers and irregular.
[78]
 In general hb 
polymers are made from ABx monomers similar to dendrimers. In contrast to the time 
consuming and tedious synthesis of dendrimers by the convergent or divergent approach, 
hb polymers can easily be synthesized by one pot procedures.
[78]
 Hb polymers are 
composed of dendritic, linear and terminal groups (Figure 1.8) and can possess a focal 
point or not. This depends on the synthetic approach. Common synthetic routes can be 
categorized by e.g. methodological aspect namely step-growth or chain-growth 
approaches, which include the most common routes in hb polymer synthesis.
[96]
 Besides 
this, hb polymers can also be classified by reactions and chemistry. Along with 
polyaddition especially polycondensation represents one of a common route in hb 
polymer synthesis. Other approaches are self-condensing ring-opening polymerization 
(SCROP), proton transfer polymerization (PTP) and self-condensing vinyl polymerization 
(SCVP). All of them are summarized by the single-monomer methodology (SMM), which 
represents the polymerization of ABx, latent AB* or latent ABx molecules. Double-
monomer methodology (DMM) represents the second category of hb polymer synthesis 
methodologies. In DMM, the so called A2 + B3 methodology, either two types of 
monomers or a monomer pair lead to the formation of hb polymers. Finally, the third 
methodology is the couple-monomer methodology (CMM), which represents a sub-
category of DMM with the AB2 + B3 approach with varying reactivities within the 
monomers.
[97]
 Since all hb synthesis routes lead to quite high molar masses and broad 
molar mass distributions, their scope of applications are mainly limited to fields where 
their broader molecular weight distribution does not represent a disadvantage.
[78] 
However, it has been shown that the properties of hb polymers critically depend on the 
synthetic strategy. Here, the combination of multifunctional core molecules and slow 
monomer addition opened the way to well-defined hb polymers with PDIs below 2.0 and 
a broad range of achievable molar masses and DB of up to 1, which was proven 
 
1.2 Classes of Polymers and Dendritic Polymers 
 
  19 
practically,
[98-101]
 as well as through theoretical calculations
[102, 103]
 and computer 
simulation.
[104]
 
 
Figure 1.8 Schematic illustration of the structure of a hb polymer based on AB2 monomer units. 
The A´ represents one unreacted A group.
modified from [105]
 
 
 
1.2.3.1   Synthesis of Hyperbranched Poly(ethylene imine) Polymers 
 
Hb as well as linear poly(ethylene imine) are supposed to be closely related to the 
Mülhaupt/Meijer type poly(propylene imine) dendrimers. The former can easily be 
synthesized via cationic polymerization of aziridine at increased temperatures in aqueous 
or alcoholic solution or in bulk. A schematic illustration of this synthesis of hb 
poly(ethylene imine) is shown in Figure 1.9. Through this kind of reaction weight averages 
of the molar masses in the range of 20 – 50 kDa can be achieved.
[106]
 In order to generate 
higher molar masses bifunctional linkers (e.g. dichloroethane or epichlorhydrine 
derivatives) are required.
[107]
 
 
Figure 1.9 Acid catalyzed ring-opening polymerization of aziridine.
modified from [107]
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Today hb poly(ethylene imine) is commercially manufactured by the company BASF with 
the trade name Lupasol® and offered as e.g. adhesion promoter, compatibilizer or to 
impart paintability.
[108]
 
 
 
1.2.4   Applications of Dendritic Polymers 
 
Since hb polymers possess high numbers of functional surface groups their 
properties with regard to e.g. solubility, compatibility, reactivity, surface adhesion, self-
assembly, chemical recognition or luminescence properties can easily be adapted. 
Additionally their high thermal stability, low solution and melt viscosity allow efficient 
large scale production. This makes them suitable candidates for industrial applications 
such as dispersion agents, rheology modifiers or as cross linkers in elastomers, since here 
their broad molecular weight distribution does not harm their performance.
[78]
 
While the hb polymers still cover more or less the industrial field of applications, 
dendrimers have been extensively explored concerning those fields of precise 
nanotechnology or biomedical applications, where structural perfection displays a 
prerequisite. Hence besides their use as scaffolds for site selective catalysis, as quantum 
dot stabilizers or for artificial light harvesting functions they have encountered especially 
the biomedical field. Here, a variety of functions and applications can be addressed by 
their structural perfection, their high amount of reactive surface functionalities, globular 
shape or complexing as well as encapsulation properties. Thus, they were probed in gene 
transfection, in drug delivery, as imaging agents or as cell targeting agents for more than 
one decade.
[109]
 However, also hb polymers are more and more considered for biomedical 
applications. Especially, since the synthetic routes have facilitated more sophisticated 
systems with regard to such vital properties such as the DB and low polydispersities.
[110]
  
 
 
1.2.5   Dendritic Glycopolymers and Their Applications 
 
In general, dendritic polymers such as dendrimers are considered to have a low 
toxicity and to be non-immunogenic, which make them favorable for biomedical 
 
1.2 Classes of Polymers and Dendritic Polymers 
 
  21 
applications. However, the latter crucially depends firstly on the nature of the terminal 
groups and secondly on the generation. It has been found that cationic dendrimers, e.g. 
amino group terminated dendrimers, exhibit higher destabilizing effects towards the cell 
membrane than their neutral or negatively charged analogs, even though they possess a 
lower toxicity than the more flexible linear amino-functionalized polymers.
[111]
 The lowest 
toxicity was found with anionic (carboxylate-terminated) dendrimers.
[112]
 It has to be 
mentioned, that not only the nature of the surface groups exhibits a substantial influence 
on the cytotoxicity of dendrimers. Dendrimers bearing an aromatic polyether core while 
exhibiting anionic surface groups showed hemolysis of rat cells after 24 h. Dendrimers 
with terminal hydroxyl or methoxyl groups showed quite low cytotoxicities in vitro and in 
vivo. Regarding the generation dependence, lower generations of dendrimers have 
shown lower cytotoxicities than higher generations of dendrimers.
[92]
  
A feasible and common strategy to overcome the cytotoxicity of cationic dendrimers or 
hb polymers, respectively, is surface modification. Here, for instance, (partly) 
amidation,
[53]
 pegylation or the derivatization with fatty acids
[113]
 have proven to reduce 
the cytotoxicity.
[114]
 Another proper way to achieve biocompatibility is the decoration of 
their surface with mono- or oligosaccharides. The latter, however, has not only shown to 
decrease cytotoxicity, but also to introduce further interesting features in these delivery 
systems. The resulting dendritic macromolecules with incorporated carbohydrates within 
their structures are referred to as glycopolymers.
[115]
 Saccharides along with 
proteins/peptides or nucleic acids are an important category of biological compounds 
since protein-saccharide interactions play vital roles in cell adhesion, cell differentiation 
or infection with pathogens like proteins or viruses.
[116]
 A simplified illustration of few 
protein-carbohydrate interactions are given in Figure 1.10. Figure 1.10 shows how 
oligosaccharides (grey ellipses) bind to lectins (white) facilitating cell-cell-adhesion, 
providing receptor sites for bacterial toxins. Furthermore, it also displays the initial step in 
the pathogenic invasion of a virus and a bacterium (events from left to right). Hence 
protein-sugar interactions found applications in important biomedical fields such as tissue 
engineering,
[4]
 drug delivery,
[117]
 medicine or in biosensors.
[118]
 The functionalization with 
oligosaccharides provides, along with potentially increased solubility and bio-
compatibility, also the ability to interact with biologically important proteins e.g. 
lectins.Lectins are known to be located on mammalian cell surfaces or in the extracellular  
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Figure 1.10 Simplified representation of protein-carbohydrate interaction on e.g. cell 
surfaces.
taken from [119]
 
 
matrix. Even though protein-carbohydrate interactions are substantial to plenty of 
biological processes, single interactions are characterized by very low binding affinities (Kd 
in mM to µM range). Moreover, they usually exhibit rather low selectivities between 
analogous carbohydrate motifs.
[119]
 However, the strength of such interactions 
characterized by such low affinities and selectivities mainly arises through the so called 
multivalency and the glycoside cluster effect. This has been defined by Lee and Lee in 
1994 as “binding affinity enhancement exhibited by a multivalent carbohydrate ligand 
over and beyond that expected from the concentration increase resulting from its 
multivalency”.
[120]
 Such an enhancement of binding affinities is considered to be driven by 
two different effects: (i) a high localized concentration of the sugar motif with a distinct 
probability due to statistical effect and (ii) occurring cross-linking of receptors placed very 
close to each other (cf. Figure 1.11b and c) or single receptors by multivalent ligands 
(cf. Figure 1.11a and d).  
Cloninger et al. extensively studied carbohydrate-protein interactions regarding the 
multivalency by taking advantage of the dendrimers ideal size, their low polydispersities 
and their facile to tailor surface groups.
[121-123]
 So far further mechanisms have been 
proposed in order to rationalize the enhancement of lectin binding of glycoconjugates, 
which are heterogeneously functionalized with sugars. Their enhanced binding towards 
lectins is attributed to cooperative binding events. 
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Figure 1.11 The glycoside cluster effect can manifest itself through several mechanisms including: 
(a) arrays of oligosaccharides on glycoproteins providing localized high concentrations 
of ligands at the lectin binding site; (b) glycoproteins cross-linking adjacent 
monovalent lectins, or alternatively, multivalent lectins cross-linking carbohydrate-
binding epitopes; either (c) within individual glycans or (d) between more distant 
oligosaccharides attached to the same or to adjacent glycoproteins. Sketches (c) and 
(d) present illustrations of so-called ‘miniclustering’ and ‘maxiclustering’.
taken from [119]
 
 
The authors coined the terms “carbohydrate module effect” and “heterocluster effect” 
for these observations.
[124]
 Furthermore, the decoration of dendrimers with certain 
saccharides also allows to finetune their complexation behavior towards various metal 
ions.
[125, 126]
  
In general, multivalent glycoconjugates have shown to interfere with pathogen adhesion 
or to stimulate the innate and adaptive immune system. Thus, they can work as 
alternatives to antibiotic treatments.
[127]
 In this regard glycopolymers or glycodendrimers 
can be used as multivalent inhibitors of toxins released by intestinal bacteria, which can 
cause diarrhoeal diseases.
[128]
 With the term glycodendrimer different designs are 
summarized. The first synthesis of a glycodendrimer was reported by Roy et al. in the 
early 1990s.
[129]
 A selection of potential glycodendrimer architectures are shown in 
Figure 1.12. In order to synthesize glycodendrimers the same approaches as for the 
synthesis of dendrimers can be used, namely the divergent and convergent approach. The 
divergent post-modification of commercially available dendrimers such PAMAM 
(Starburst®) dendrimers or PPI (Astramol®) dendrimers has been shown to be a very 
efficient way to decorate the surface of dendrimers with mono- or oligosaccharides since 
both of them display primary amino groups at their surface. 
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Figure 1.12 Glycodendrimer architectures: carbohydrate-coated (left); carbohydrate-centered
and -coated (middle) and carbohydrate based (right).
taken from [130]
 
 
A variety of different strategies have been used in order to modify amino group 
terminated PAMAM dendrimers. For instance, this was done through (thio-)urea linkages 
with isothiocyanated saccharides or through amide bonds e.g. with activated esters of 
saccharides.
[131]
 In context of the latter, especially reductive amination has proven to be a 
quite convenient approach in the divergent post-modification of commercially available 
dendrimers. This type of reaction can be carried out in organic or aqueous solutions and 
under basic or acidic conditions. Moreover, it allows simple mixing of the dendrimer and a 
huge variety of mono-, di- or oligosaccharides.
[132]
 Glycopolymers gained by the reductive 
amination approach have shown to be non-toxic to various cell types.
[133-141]
 
Poly(propylene imine) glycodendrimers with a dense maltose shell even provide potential 
usage as antimicrobial and antiprion agents.
[137]
 Oligosaccharide modified 
poly(ethylene imine) glycopolymers with a low degree of oligosaccharide substitution 
showed no toxicity and successful siRNA delivery to SKOV-3 cells.
[134]
 Furthermore, 
poly(ethylene imine) glycopolymers decorated Ni
II
NTA ligands showed no toxicity against 
immature dendritic cells and allowed the attachment and pH triggered release of 
functional his-tagged peptides making them promising vehicles in potential 
immunotherapies.
[140]
 Furthermore, poly(propylene imine) glycodendrimers 
functionalized with adamantane moieties showed no toxicity against NIH3T3 cells. In 
addition, the host-guest interaction of the adamantane moieties with β-cyclodextrin was 
successfully proven allowing an application as potential nanoparticles in the field of 
healthcare.
[141]
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1.3   Characterization Methods for BHS 
 
1.3.1   UV/Vis Spectroscopy 
 
UV Vis spectroscopy takes advantage of the ability of the electrons in molecules to 
absorb light in order to reach certain excited energy states. Light is characterized by the 
frequency ν and wavelength λ, which is expessed by 
 
c = λ · ν                                                                                                                                 equation 3  
 
whereas c is the velocity of the light. A light quant with the frequency ν	possesses the 
energy with the Plank constant of h = 6.63 · 10
-34
 Js: 
 
E = h · ν                                                                                                                            	   equation 4  
 
Usually the interaction of molecules with light in the range of the ultraviolet or visible 
range facilitates the excitation of valence electrons. If light of a certain spectral color is 
absorbed, the human eye recognizes the complementary color.  
Within a molecule there are usually three types of valence electrons, electrons placed in 
namely -, - or -orbitals. -orbitals are called bonding orbitals, which are referred to as 
single bonds. Usually they need light in the lower range of the ultraviolet region in order 
to get excited, since their ground state possess very low energy states. Hence these 
transitions are quite seldom. -orbitals possess electrons with higher energy of their 
ground state. Thus they can be excited through light in the ultraviolet up to the visible 
region.	 -orbital elctrons (non-bonding electrons or lone pair electrons) exhibit the 
highest ground states and therefore light in the visible range is quite sufficient for their 
excitation. Usual transitions that can be observed are → ∗, → ∗, → ∗	 or 
→ ∗ transitions next to the common exception of →  transitions of the -block 
element complexes. An simplified illustration of possible (non-) radiative transitions of 
valence electrons such as absorption, fluorescence, phosphorescence, intersystem 
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crossing, internal conversion is given by the Jablonski diagram, which was proposed by 
Alexander Jablonski in 1933 (Figure 1.13).
[142]
  
 
 
Figure 1.13 Exemplary electronical states (S0, S1, S2 and T1) of a molecule. Dashed lines represent 
non-radiative transitions, solid lines radiative transitions and the single energy states 
are represented by horizontal lines.
modified from [143]
 
 
Figure 1.14 Schematic experimental set-up with a double beam spectrophotometer for UV/Vis 
measurements. 
 
The absorbed light can be directly referred to certain structural properties of the 
molecule and hence can be used for e.g. the determination of the molecular structure. In 
order to record absorbance spectra single beam, double beam or diode array UV/Vis 
spectrometers can be used. The schematic experimental set-up of a double beam UV/Vis 
spectrophotometer is shown in Figure 1.14. First the light beam, which has to be 
monochromatic, passes through the sample solution. The samples energy can be lowered 
due to absorption besides loss of energy due to reflexion or scattering.  
With the pre-requirement of a dilute solution (c ≤ 10
-2 
M) and monochromatic light the 
following law can be applied.  
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A = log  
I0
I
 = ε · c · d                                                                                                            equation 5 
 
A is the absorbance, the ratio 
I0
I
 is called transmittance, I0 is the incoming light intensity, 
I is the outgoing light intensity, ε the molare absorptivity, c the concentration of the 
sample and d the path length. This equation is known as the Lambert-Beer law.  
 
 
1.3.2   Transmission Electron Microscopy  
 
The electron microscope was invented by Germans Max Knoll and 1931 and Ernst Ruska 
and in 1986. Ernst Ruska was awarded for the Nobel Prize for Physics. In transmission 
electron microscopy an electron beam is accelerated and focussed on the sample and 
transmits the sample. Therefore the sample layer has to be sufficiently thin. When the 
electron beam transmits the thin sample layer usually different events can take place 
such as the appearance of X-rays, light or Auger electrons. The main event that is utilized 
for TEM imaging is elastic and inelastic (back-) scattering of electrons. A schematic 
instrumental set-up of a transmission electron microscope is given in Figure 1.15. The 
electron source in TEM is usually either lanthanium hexaboride or a tungsten filament. 
The emitted electrons are manipulated by the several magnetic lenses and apertures. The 
condenser lens focuses the electron beam on the samples whereas the objective lens 
focusses the electrons that transmit the sample. The imaging or diffraction mode is 
controlled by intermediate lenses, while the projector lenses enlarge the image before it 
is imaged on the phosphorescent screen or a charge-coupled device (CCD) camera. The 
apertures can be used e.g. to manipulate the spot size of the electron beam, to block high 
angle electrons or to define the energy of the electrons arriving the detector. Image 
contrast is mainly caused by the electron scattering by specimen atoms. The electron 
beam transmits through the specimen and interacts with the electrons in the shell or the 
nuclei of the specimen atoms. However, the interaction of the electron beam with nuclei 
electrons contributes most to the final image contrast. When electrons approach the 
positively charged nucleus they scatter. Electrons will be more strongly deflected the 
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higher the positive charge of the nuclei is. Thus, atoms with a high atomic number Z 
provide a high contrast (so called mass thickness contrast). Darker areas represent areas 
where few electrons have transmitted through the sample due to thickness or a high 
atomic number. Another feasible way to image biological specimens is cryoTEM, where 
frozen hydrated samples are imaged. The freezing of samples in vitreous ice usually 
preserves their structural properties and minimizes artefacts from staining or 
dehydration. 
 
Figure 1.15 Schematic image of a transmission electron microscope. 
 
 
1.3.3   Purification Methods – Hollow Fiber Filtration 
 
The conjugation of (bio-)macromolecules by molecular recognition processes 
requires mixing certain amounts of the components. The applied stoichiometry, however, 
is not always reflected in the yielded product. Thus a removal of non-bound particles or 
only partially converted structures is required. The purification method usually applied is 
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dialysis. Here the mixture of the components is placed in a porous dialysis tube with the 
adequate molecular weight cut off (MWCO). (Macro-)molecules, which are small enough, 
pass through the pores and hence will be removed due to occurring osmotic pressure. 
One drawback of this purification method is that it may require several days in order to 
ensure the complete removal of unwanted by-products.  
Another purification technique is size exclusion chromatography. It is also an easy to 
apply method, which can be done in a short time range. However, a dilution of the 
sample or no interactions of fractions in the crude conjugation solution or the desired 
product with the coloumn material cannot always be sufficiently guaranteed leading to 
poor purification efficiencies. Hollow fiber filtration, on the other hand, represents a 
feasible alternative to the above described methods. Here the crude product solution is 
pumped into a circuit connected to a nanoporous membrane. The appropriate choice of 
the MWCO allows the isolation of the wanted product. In contrast to the normal dialysis, 
pressure is applied to the system, which accelerates the purification process drastically. In 
addition, this technique allows also for a convenient solvent exchange, desalting and 
adjustment of the sample concentration.
[144]
 
 
 
1.3.4   Mass Spectrometry 
 
After the discovery of the canal rays by Eugen Goldstein in 1886 the pioneering 
work of Joseph John Thomson resulted in the first mass spectrometer.
[145]
 His mentee 
Francis William Aston reported in 1919 about the first functional mass spectrometer with 
velocity focusing and enhanced resolving power. Aston received in 1922 a Nobel Prize 
"for his discovery, by means of his mass spectrograph, of isotopes, in a large number of 
non-radioactive elements, and for his enunciation of the whole-number rule".
[146]
 Arthur 
Jeffrey Dempster developed the electron ionization source and a design of mass 
spectrometers, which is still widely used. An improved apparatus was invented by 
Kenneth Bainbridge, who provided one of the first experiments proving Einstein´s mass-
energy relation.
[147, 148]
 
Due to the ease to manipulate the motion and/or direction of charged particles mass 
spectrometry deals with ions. In the ionization step the analyte is transformed into an 
 
1.3 Characterization Methods for BHS 
 
  30 
ionic gas-phase species by the addition or removal of protons or electrons. Therefore 
certain energy is required, whereas the excess energy lead to the potential fragmentation 
of the molecule. Afterwards these fragments are separated with regard to their 
mass-to-charge (m/z) ratios. Then the measured ion current is amplified and depicted as a 
mass spectrum.
[149]
 The main components of a mass spectrometer are shown in 
Figure 1.16. Through the inlet the transfer of the analyte from atmospheric pressure to 
the ion-source vacuum has to be ensured. With the aid of the ion source sample 
molecules are converted into gas-phase ions. In general, ionization techniques are 
categorized in hard and soft ionization techniques. Hard ionization methods provoke huge 
fragmentation of the particular molecules due to the high amount of residual energy. An 
example for hard ionization technique is electron ionization. On the other hand there are 
soft ionization techniques. In the following the soft ionization techniques mentioned in 
the discussion or used in this work are briefly presented. One soft ionization technique is 
electrospray ionization (ESI). Thereby the analyte solution is sprayed by a capillary in an 
electric field. Depending on the applied voltage a stable spray with either positive or 
negative ions is formed and transferred into the mass analyzer. This concept was 
proposed by M. Dole
[150]
 and further developed by J. Fenn.
[151]
 He received the Nobel 
Prize together with T. Tanaka in 2002. T. Tanaka was awarded due to his achievements in 
the development of matrix assisted laser desorption/ionization mass spectrometry 
(MALDI MS).
[152]
 MALDI requires an embedding of the analyte into a certain matrix that 
absorbs at the laser wavelength in the infrared or ultraviolet range and consequently 
allows the ionization of the analyte molecules through electron transfer, chemical 
processes and subsequent desorption. ESI and MALDI MS facilitated the analysis of 
biomolecules and even the analysis of non-covalently bound (macro-) molecules.
[153, 154]
  
ESI MS allows the biomolecules (analyte) to stay in their native state while the embedding 
of the biomolecules in a matrix (MALDI) may make them prone for denaturation. 
However, recently an alternative soft ionization technique was invented by 
Brutschy et al.
[155]
 For the so called laser-induced liquid beam ionization/desorption 
(LILBID) analyte ions are desorbed by treating a liquid beam of analyte solution with 
intense, pulsed IR laser radiation.
[156]
 After the analyte is converted to ions in the mass 
spectrometer they are guided to the detector and separated through so called mass 
analyzers by application of electric and magnetic fields. In general, there are six types of 
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mass analyzers. Along with electrostatic and magnetic sector mass analyzers there are 
also mass analyzers based on ion cyclotron resonance as well as quadrupole, ion trap or 
time of flight mass analyzers. Separation of the ion takes place by different separation 
strategies e.g. by the stability of ion trajectories (quadrupol) or the time of flight caused 
by the kinetic energy of the analyte ions.
[157]
 
 
Figure 1.16 Basic components of a mass spectrometer.
modified from [149]
 
 
 
1.3.5   Asymmetrical Flow Field Flow Fractionation 
 
The flow field fractionation (FFF) is a separation technique, which is similar to 
chromatographic separation methods.
[158]
 Its groundwork was laid in 1966 by John Calvin 
Giddings and the related theoretical background in 1968. During the next decades plenty 
of novel FFF techniques were developed, where separation is caused by different forces 
such as thermal FFF, flow FFF, sedimentation FFF or electrical FFF.
[159-161]
 The FFF is the 
most commonly applied technique within all flow fractionation techniques and enables 
the characterization of a broad scope of samples e.g. different polymers,
[162-166]
 
nanoparticles,
[167-171]
 cells,
[172-174]
 proteins
[175, 176]
 or starch.
[177-179]
 
Asymmetrical flow field flow fractionation (AF4) is a sub-technique among the FFF 
family
[161]
 and was utilized in this work in order to characterize the BHS. The 
asymmetrically trapezoidal shaped channel confines the flow and the samples between 
two plates separated by a spacer. The mechanism of separation is illustrated in 
Figure 1.17. The separations of the (macro-)molecules takes place by two counteracting 
mechanisms. Firstly, the particles are forced to the “accumulation wall” by the cross flow. 
ion
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Diffusion causing Brownian motion, on the other hand, provides that smaller particles 
with higher diffusion rates tend to equilibrate at higher positions in the channel where 
the velocity of the longitudinal flow is faster.  
 
Figure 1.17 Schematic illustration of the basic separation principle of FFF.
modified from [161]
 
 
The diffusion coefficient depends on the temperature and the solvent and can be 
described by the Stokes-Einstein equation, where the diffusion coefficient also depends 
on the hydrodynamic radius:
[180]
 
 
D = 
kB · T
6π · η · Rh
																																																																																																																								equation 6 
 
The velocity gradient within the parabolic flow profile separates particles with different 
hydrodynamic radii.  
The main advantages of the FFF techniques are the absence of a stationary phase, which 
minimizes, for instance, adsorption of the probe. A broad variety of eluents can be used 
and the eluents can be changed even during the measurement. Measurements under 
mild conditions facilitate the characterization of fragile samples such as proteins or 
cells.
[181]
 The possibility of online coupling of a number of analytical techniques such as 
viscosity-,
[182] 
gaschromatography-,
[175]
 small angle X ray scattering-,
[183]
 refractive index-, 
infrared-
[184]
 or static
[184, 185]
 and dynamic
[166]
 light scattering allows a comprehensive 
investigations of the sample. 
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1.3.6   Static Light Scattering 
 
Static light scattering is a non-invasive technique and it is commonly used to 
determine the weight average molecular weight of (bio-)polymers.
[186, 187]
 The 
fundamental equation is given by:  
 
RΘ=
4π2·n0
2·
dn
dc
2
λ0
4
·NA
· c · Mw= K · c · Mw                                                                             equation 7 
 
The Rayleigh ratio RΘ depends on the refractive index increment (dn/dc) and the weight 
average of the molar mass.  
Along with the determination of the weight average molar masses information about the 
geometry of the (macro-)molecule can also be gained. This can be done by the 
conformational plot, which is expressed in the following equation: 
 
Rg= K·M
ν                                                                                                                              equation 8 
 
A double logarithmic application of the radius of gyration versus the molar mass allows 
the determination of the scaling factor ν and information about the structure of the 
sample in the solution. The value for ν ranges from 0.33 for hard spheres up to 1.0 for 
rigid rods. Under Θ conditions, linear random coils show a ν value of 0.5 and in a good 
solvent 0.588.
[188]
 The combination of static light scattering with dynamic light scattering 
allows also the determination of the ρ-parameter, which is the ratio of the radius of 
gyration Rg and the hydrodynamic radius Rh:  
 
ρ =
Rg 
Rh
                                                                                                                                  equation 9 
 
For instance, microgels possess a ρ-parameter of 0.3 – 0.6, hard spheres a ρ-parameter of 
about 0.778 and monodispers random coils in a good solvent possess a ρ parameters of 
about 1.78.
[189]
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Another parameter that provides a detailed description of the structure of molecules in 
solution is the apparent density, which is a measure of the compactness of the structure 
in solution. It can be calculated by: 
 
ρ
app
= 
M
V(Rg) · NA
· α   or   ρ
app
= 
M
V(Rh) · NA
		                                                     				        equation 10  
 
where M is the molar mass, V the volume, NA is the Avogadro number and α is given by 
equation 11 where R is the geometrical radius of a sphere. 
α	= Vsphere(Rg)
Vsphere(R)
= 
Rg
3
R3
 = 
(
3
5
 ·R)
3
R3
=
3
5
3
2
                                                                        equation 11   
 
The apparent density is also linked to the branching density as highly branched 
macromolecules are expected to display a higher density than less branched.
[190, 191]
 
 
 
1.3.7   Dynamic Light Scattering 
 
Dynamic light scattering is also known as photon correlation spectroscopy or quasi-
elastic light scattering. It is a frequently used technique for the determination of particle 
sizes. Common samples are polymers, proteins, nanoparticles or colloids. The 
experimental process is characterized by the following points: a solution of the analyte is 
illuminated by a monochromatic and coherent laser beam. When the laser light strikes 
the particles the light is scattered in all directions due to interactions of the light with the 
electric field of the particle. The Brownian motion of the particles in solution additionally 
generates time dependent fluctuations in the scatter intensity since the particles have 
different distances to each other. This enables either constructive or destructive 
interference of the scattered light.
[192]
 Hence the first step is the detection of fluctuations 
in scattered light by a detector. The collected signal is then analyzed using a correlator, 
which constructs the autocorrelation function: 
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G τ = 〈I(t)·I(t+τ)
I(t)
〉                                                                              	                                equation 12 
 
with the intensity I, time t and delay time τ. An appropriate modelling term for the 
correlation function is given by: 
 
G τ =B+A e-2·q
2·D·τ                                                                                          								    equation 13 
 
B is the baseline at infinite time, A the amplitude, q the scattering vector, D the diffusion 
coefficient and τ the delay time. Equation 12 describes the translational diffusion of single 
species. The analysis of the correlation function, which contains information about the 
diffusion coefficient is followed by fitting the correlation function by suitable 
algorithm.
[193, 194]
 Equation 13 contains information about the diffusion coefficient. With 
regard to the Stokes-Einstein equation the hydrodynamic diameter can be calculated. 
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2.   Motivation  
 
The design of versatile biohybrid nanosized materials has revealed itself as a 
promising avenue towards biomedical applications in today´s life sciences. Thus the 
fabrication of higher ordered BHS has provoked a tremendously high research activity in 
the past decades since the combination of components of synthetic and natural origin 
facilitates an applicability, which is supposed to be far beyond the sum of their single 
components.
[5, 6, 195]
 These artificial supramolecular BHS can be built by a huge variety of 
building blocks including solid
[196-198]
 or soft
[61, 199, 200]
 nanoparticles, peptides/proteins, 
polynucleotides or low molecular weight drugs.
[5, 195, 199]
 
Along with the latter the attachment of biologically active entities or imaging moieties, 
e.g. enzymes, fluorescence markers or targeting motifs display thereby a key step 
towards the development of carrier systems for drug delivery purposes. 
Among the soft nanoparticles especially dendritic polymers such as perfectly branched 
dendrimers or hb polymers are considered as ideal building blocks since they allow a 
convenient tailoring of crucial properties such as solubility, biocompatibility, bioactivity or 
carrier properties by means of surface functionalization.
[53, 92, 93]
  
Along with the covalent attachment of bioactive moieties, non-covalent attachment is a 
frequently used approach, because it is assumed to only require stoichiometric mixing. In 
context of the latter, molecular recognition processes such as the avidin-biotin, 
β-cyclodextrin-adamantane or Ni
II
-NTA-histidine-tag interactions have proven to be 
fruitful strategies for the attachment of bioactive entities.
[5, 201, 202]
  
Although the successful attachment of bioactive entities to (dendritic) polymers based on 
the avidin-biotin technology for e.g. targeting or imaging purposes is frequently 
reported
[39, 203-207]
 there are only few reports about vital key factors for the control of 
sizes
[208, 209]
 or about the composition of the final nanostructured materials. 
Especially in the field of targeted drug delivery the crucial role of sizes and size 
distributions of carriers has been highlighted recently, since it critically influences vital 
factors such as circulation time or biodistribution within the body.
[45, 210, 211]
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The development of intravenous formulations and the control of release kinetics lead to 
the fabrication of nanoparticles (< 1 µm). As nanoparticles can escape the circulation 
through so called fenestrations of the endothelial barrier, the optimal size for drug 
delivery applications in cancer research is between 70 – 200 nm,
[45]
 since nanoparticles 
with sizes lower than 200 nm show significantly longer circulation times due to low 
uptake by the reticuloendothelial system (RES). Additionally, particles with sizes beyond a 
certain value are usually prone to opsonization and phagocytosis. The ability of avidin to 
form high molecular weight associates with biotinylated macromolecules as well as its 
carbohydrate content makes it a suitable candidate for passive and active targeting in 
combination with (bio-)polymers. 
 
 
3.   Aims 
 
With regard to the latter, the overall aim of this work was to fabricate dendritic BHS 
with varied sizes as models for drug delivery systems of the next generation.  
Therefore the molecular recognition of avidin with biotin and β-cyclodextrin with 
adamantane will be utilized in order to tailor final sizes, functionality or catalytic activity 
of those BHS. 
As a first step biotinylated glycopolymers (bGP includes PPI-bGP and PEI-bGP), will be 
synthesized and their aggregation with avidin will be tested. 
In order to fabricate more complex structures and to implement biological activity, a 
biologically active entity such as an enzyme will be adopted into the BHS and investigated. 
Here, also the influence of the sequence of fabrication will be addressed. 
Furthermore, the molecular recognition entity adamantane will be further introduced 
into the dendritic glycopolymer structure in order to study their recognition ability and 
polymerization ability with a β-cyclodextrin polymer. Hence adamantylated 
glycopolymers (aGP) as well as biotinylated and adamantylated glycopolymers (baGP 
includes PPI-baGP and PEI-baGP) will be synthesized and their interactions with a 
β-cyclodextrin polymer will be studied. 
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In detail the work will address three main objectives: 
 
1. Probing the polymerization ability of avidin with bGP such as poly(propylenimine) 
dendrimers and hb poly(ethylene imine) bGP. These bGP exhibit different 
biotinylation degrees of 1, 2, 4 or 8 and either shorter, hydrophobic C6-linked or 
longer, hydrophilic PEG12-linked biotin ligands. 
The influence of (i) the biotinylation degree, (ii) the biotin ligand´s chemical 
nature, (iii) the steric demand of the dendritic scaffold and (iv) the stoichiometry 
of avidin to bGP on the BHS formation will be studied. Furthermore, the fabricated 
structures need to be investigated with respect to their stability, size and 
composition, molar mass and scaling properties.  
2. The gained knowledge will be used in the formation of more complex BHS. 
Therefore BHS composed of either a monovalent or a highly valent PPI-bGP, a 
biotinylated enzyme and avidin will be fabricated. Furthermore, the sequential 
(step-wise) approach in the fabrication of those BHS will be studied with regard to 
final enzyme activity and sizes and molar masses.  
3. Finally, highly valent biotinylated and/or adamantylated GP (bGP, aGP and baGP) 
will be synthesized. The recognition ability towards avidin and a 
β-cyclodextrin polymer (pCD) needs to be evaluated. Furthermore, BHS generated 
through the interaction of avidin and the baGP were probed regarding their BHS 
formation with pCD. The BHS will be investigated with regard to the resulting 
sizes. 
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4.1   BHS Based on Avidin and Biotinylated Dendritic Glycopolymers 
 
The avidin-biotin conjugation displays a widely applied conjugation strategy for 
various applications in life science fields. Especially its intense use in the field of drug 
delivery makes it a necessity to investigate the key factors, which are of importance for 
the rational design of tailored BHS based on the avidin-biotin technology. There have 
been made few attempts in order to study the interaction of avidin with polymers from a 
fundamental point of view.
[212, 213]
 However, there is still a need for studying the avidins 
interaction with glycopolymers especially with respect to size, shape and molar masses, 
since their potential to participate in vital biological processes make them attractive for 
targeted drug delivery.  
 
Figure 4.1.1 Potential BHS formed by a) avidin, mono- and bivalent bGP; avidin/bGP, b) with 
avidin as a central unit and c) avidin as a bridging unit. 
 
Starting from the assumption that avidin can work as a central or bridging unit for the 
biotinylated glycopolymers (bGP) (Figure 4.1.1) depending on the degree of biotinylation, 
the influence of critical key factors in the fabrication of BHS was studied. Therefore a 
library of bGP with varied degrees of biotinylation and different dendritic scaffolds was 
synthesized. Subsequently, the interaction with avidin was probed in order to gain 
1/1 1/2 1/3 1/4
1/0.5 1/1 1/1.5
avidin
monovalent bGP
bivalent bGP
a) b)
c)
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knowledge about the successful coupling of the bGP to avidin with respect to the 
inherent bGP properties (e.g. degree of biotinylation or steric demand of the dendritic 
scaffold) and their influence on the conjugation process. 
Furthermore, complementary experimental setups and different analytical tools 
facilitated a thorough investigation of the formed structures. Since the dependence of the 
ratio of avidin and biotinylated compounds in the aggregation or conjugation process has 
been shown to be of importance,
[208, 209]
 the polymerization potential of the bGP with 
avidin in excess, equimolar or in deficit was probed (cf. Table 4.1.1). Subsequently, these 
samples were studied by DLS. Furthermore, the pre-mixing of avidin with the azo dye 
HABA (4-hydroxyazobenzene-2-carboxylic acid) and its displacement by biotin analogues 
provided the successful proof of the avidin-biotin conjugation. 
 
Table 4.1.1 Overview of the molar ratios of avidin and bGP for BHS formation. 
bGP  molar ratio avidin/bGP 
non-valent  1/1 and 1/3 
monovalent  1/1, 1/2, 1/3 and 1/4 
bi-, tetra- or octavalent  1/0.25, 1/0.5, 1/1, 1/1.5 and 1/2 
 
The investigation through the recently developed and sophisticated techniques laser-
induced liquid Bead ion/desorption mass spectrometry (LILBID MS)
[214-216]
 and 
asymmetrical flow field flow fractionation coupled to light scattering (AF4-LS)
[165, 181, 191]
 
gave a deeper view on the fabricated BHS with regard to their uniformity, their scaling 
properties and their molar masses. In order to verify the morphology and dimensions the 
imaging technique transmission electron microscopy was used. Parts of this chapter are 
already published.
[217]
 
  
 
4.1 BHS Based on Avidin and Biotinylated Dendritic Glycopolymers 
 
43 
 
 
4.1.1   Syntheses and Characterization of Biotinylated Dendritic Glycopolymers 
 
In order to gain knowledge about the influence of the dendritic scaffold as well as of 
the biotinylation degree in the avidin bGP conjugation non-, mono-, bi-, tetra- and 
octavalent biotinylated poly(propylene imine) glycopolymers (PPI-bGP) and non-, mono-, 
bi- and tetravalent poly(ethylene imine) glycopolymers (PEI-bGP) were synthesized. These 
bGP will be abbreviated as shown in Figure 4.1.2.  
 
 
Figure 4.1.2 Abbreviations of the synthesized biotinylated dendritic glycopolymers. 
 
Their structures as well as the synthetic route are depicted in Figure 4.1.3. The two step 
synthesis starts with the conversion of poly(propylene imine) of the 4
th
 generation
[218]
 
(PPI) or hb poly(ethylene imine) (PEI) with a weight average molar mass of 25 kDa with 
the biotin ligands and BOP in DMSO in the presence of triethylamine under inert gas 
atmosphere at room temperature for 2 d. Either biotinyl-6-aminocaproic acid (C6B) or 
HOOC-PEG12-biotin (PEG12B) was used as biotin ligands. The second step – the reductive 
amination – leads to the substitution of the residual amino groups by the oligosaccharide 
maltose. The reaction was carried out in sodium borate solution at 50 °C for 7 d followed 
by dialysis in distilled water according to literature.
[125, 219]
 More details of the syntheses 
can be found in the experimental part in chapter 5.3. The synthesized compounds as well 
as their degree of biotinylation, their degree of maltosylation and the molecular weights 
of the precursors (e.g. PPI-C6Bx or PEI-PEG12Bx) and the bGP are summarized in 
Table 4.1.2. Thereby, for instance, the abbreviation PPI-DS-C6B4, is a 
poly(propylene imine) dendrimer of 4
th
 generation (PPI) with a dense maltose shell (-DS) 
and four biotin ligands attached to the dendritic scaffold. The biotin ligand C6B is a six 
carbon atoms containing biotin. The abbreviation PEI-DS-PEG12B2 is a hb 
poly(ethylene imine) polymer with a dense maltose shell (-DS) and two biotin ligands 
attached to the dendritic scaffold. 
[dendritic scaffold] [dense maltose shell] [type and number of biotin ligand]
PPI
PEI
-DS -C6Bx
-PEG12Bx
with x = 1, 2, 4 or 8
- -
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Figure 4.1.3 a) 4
th 
generation of poly(propylene imine) dendrimers and hb poly(ethylene imine)
with Mw of 25 kDa, b) synthetic route to PPI-bGP, c) synthetic route to PEI-bGP with 
(i) coupling of the biotin ligands; (ii) maltosylation by reductive amination.  
Note: The possible substitution of the biotin ligands and the maltose at linear amino 
groups of the hb PEI is not shown to provide a better overview. 
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Table 4.1.2 Overview of synthesized precursors, PPI-bGP and PEI-bGP including their properties. 
bGP Ligand
a
 
Number 
of Ligands 
Mobserved 
[g/mol] 
Number of 
Maltose
 Precursor 
M
g 
[g/mol] 
PPI-DS
 
- 0 46900
d 
122 (128)
f 
PPI 7168
h 
PPI-DS-C6B1
 
C6B        (1) 1.1
b
 46000
d 
118 (126)
f 
PPI-C6B1 7500
i 
PPI-DS-C6B2
 
C6B        (2) 2.1
b
 46100
d 
117 (124)
f 
PPI-C6B2 7850
i
 
PPI-DS-C6B4
 
C6B        (4) 3.6
b
 47650
d 
120 (120)
f 
PPI-C6B4 8500
i 
PPI-DS-C6B8 C6B        (8) 7.9
c 
47200
e 
112 (112)
f
 PPI-C6B8 9850
i
 
PPI-DS-PEG12B1
 
PEG12B (1) 1.1
b
 45900
d 
116 (126)
f 
PPI-PEG12B1 8000
i 
 
PPI-DS-PEG12B2
 
PEG12B (2) 2.0
b
 45700
d 
113 (124)
f 
PPI-PEG12B2 8820
i
 
PPI-DS-PEG12B4
 
PEG12B (4) 4.2
b
 41900
e 
102 (120)
f 
PPI-PEG12B4 10500
i 
PPI-DS-PEG12B8 PEG12B (8) 8.2
c
 43100
e 
90 (112)
f
 PPI-PEG12B8 13 940
i
 
       
PEI-DS - 0 74500
j 
190 (229)
k 
PEI 9600
l 
PEI-DS-C6B1 C6B        (1) 1.0
b 
74000
j 
188 (227)
k 
PEI-C6B1 9940
i 
PEI-DS-C6B2 C6B        (2) 2.1
b 
70700
j 
178 (225)
k 
PEI-C6B2 10280
i 
PEI-DS-C6B4 C6B        (4) 4.0
b
 72100
j 
182 (221)
k 
PEI-C6B4 10960
i 
PEI-DS-PEG12B1 PEG12B (1) 1.0
b 
70300
j 
177 (227)
k 
PEI-PEG12B1 10430
i 
PEI-DS-PEG12B2 PEG12B (2) 2.0
b 
71200
j 
180 (225)
k 
PEI-PEG12B2 11250
i 
PEI-DS-PEG12B4 PEG12B (4) 4.1
b 
72200
j 
155 (221)
k 
PEI-PEG12B4 12900
i 
a 
Number in brackets represents the theoretical number of biotin ligands attached to the PPI or 
PEI scaffold. 
b 
Number of biotin ligands was determined by avidin-4′-hydroxyazobenzene-2-
carboxylic acid (HABA) complex using a specific activity of avidin of 13.6 Units/mg. 
c 
determined 
by an NMR approach. 
d 
determined by LILBID MS (cf. Figure A4.1.9 – A4.1.11).
 e 
determined by 
AF4-LS (cf. Figure A4.1.12 – A4.1.13)
 .f 
Number of maltose units determined through LILBID MS 
or AF4-LS with theoretical values in brackets. 
g 
M is used for estimating the number of maltose 
units. 
h 
M was determined by MALDI-TOF MS. 
i 
M was determined by Mn of particular dendritic 
polymer and attached biotin ligands. 
j 
determined by elemental analysis.
[219]
 
k 
attached maltose 
units were determined by elemental analysis; theoretical number of maltose (number in 
brackets) was determined through quantitative 
13
C NMR analysis with the knowledge of the 
molar mass of dendritic scaffold 9600 g/mol and its degree of polymerization, respectively.
[219]
 
l 
specified by supplier.
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The biotin ligand PEG12B is a twelve poly(ethylene glycol) units containing biotin 
(Figure 4.1.2). A dense maltose shell means that all residual terminal groups were aimed 
to be completely decorated with maltose units. In Table 4.1.2 it can be seen that 
decreased maltosylation degrees were obtained by higher biotinylation degrees. The 
maltosylation degrees of the PEG12B substituted bGP are even lower than those of the 
C6B analogs. Thus the steric shielding of the coupled biotin ligands hampered the 
complete decoration with maltose. Furthermore, the functionalization of the PPI-bGP 
with maltose results in rather rigid structures. In contrast, the PEI-bGP should exhibit a 
more flexible structure due to their more irregular scaffold. 
 
1
H NMR Spectroscopy – Both, the precursors and the (b)GP were characterized by 
1
H NMR spectroscopy. Figure 4.1.4 show the structure of the PPI scaffold and the surface 
species, whereas the PEG12B ligand is denoted as surface species IIb and maltose is 
denoted as surface species III. The 
1
H NMR spectra of PPI-PEG12B2 is depicted in 
Figure 4.1.4a. The 
1
H NMR spectra of PPI-DS-PEG12B2 are shown in Figure 4.1.4b. PPI-DS-
PEG12B2 exhibits the PEG12B ligand and maltose. Figure 4.1.5 represents the structure of 
PEI-C6B4 (Figure 4.1.5a) and PEI-DS-C6B4 (Figure 4.1.5b), respectively. It exhibits the 
dendritic scaffold, the C6B ligand (surface species IIa) and maltose (surface species III). 
Figure 4.1.4a shows a doublet at 2.75 ppm, which indicates that a small amount of PPI-
bonded hexamethylphosphoramide is formed in a side-reaction most probably due to the 
rather large excess of BOP applied for complete conversion of ligands. A correct 
calculation of the number of ligands from signal integrals is hampered by the low signal 
intensity of the biotin ligand protons compared to the high amount of particular PPI 
(Figure 4.1.4a) and PEI (Figure 4.1.5a) core signals. However, with the reasonable 
assumption that one equivalent of ligand is completely converted in the presence of 64-
fold excess of amino end groups, a comparison of the spectra using PEI and PPI signals as 
intensity reference confirms the substitution of the biotin ligands in an approximately 
1:2:4 ratio for the respective -B1, -B2 and -B4 precursors (see also appendix 
Figure A4.1.1 – A4.1.2 and A4.1.5 – A.4.1.6). Few characteristic biotin ligand signals can be 
well observed after the maltosylation. This proves finally the functionalization of both the 
PPI-DS-PEG12B2 and PEI-DS-C6B4 (Figures 4.1.4b, 4.1.5b; cf. also Figures A4.1.3 – A4.1.4, 
A4.1.7 – A4.1.8). 
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Figure 4.1.4 
1
H NMR spectra (solvent: D2O) of a) PPI-PEG12B2 and b) PPI-DS-PEG12B2. The signals 
of the biotin ligand PEG12B and of the PPI-G4 core are assigned in a). Maltosylation 
results in additional broad signals, which are assigned in b) Arrows point to biotin 
ligand signals well observable also after maltosylation. (# hexamethylphosphoramide 
derivative) 
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Figure 4.1.5 
1
H NMR spectra (solvent: D2O) of a) PEI-C6B4 and b) PEI-DS-C6B4. The different 
methylene groups of the substituted PEI core overlap and are not assigned in detail. 
Maltosylation results in additional broad signals and in chemical shift changes for the 
PEI core as shown in b) Arrows point to biotin ligand signals well observable also 
after maltosylation. 
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MALDI-TOF Mass Spectrometry – Selected PPI-samples were additionally examined by 
MALDI-TOF mass spectrometry (Figure 4.1.6). The MALDI-TOF spectrum of PPI-G4 is 
depicted in Figure 4.1.6a. Next to the signal peak at m/z = 7168 representing the perfect 
dendrimer structure also defect structures are assigned. The m/z signals of the most 
abundant defect structures are denoted with b) – h) in Figure 4.1.6a. They are in 
agreement with the findings of Hummelen et al. where also a PPI-G4 was studied by 
electrospray ionization mass spectrometry (ESI MS).
[220]
 Such defect structures have been 
attributed to incomplete Michael addition and/or the formation of cyclic structures 
during the hydrogenation steps within the laborious stepwise growth of the 
dendrimer.
[220]
 In particular, despite the same signal pattern of the defect structures also 
their relative abundances are in agreement with the report of Hummelen et al. In order to 
unravel the decomposition pathways of poly(propylene imine) dendrimers further ESI MS 
studies of generation 0 – 4 were conducted by Weener et al.
[221]
 and McLuckey et al.
[222]
 
Interestingly, only McLuckey et al. referred to the fragments, which denoted with i*) - iii*) 
in Figure 4.1.6a. They ascribed them to defect structures caused through missing Michael 
additions. PPI-C6B1 and PPI-C6B4 (Figure 4.1.6b) were investigated by MALDI-TOF MS in 
order to prove the covalent coupling of the biotin ligand. Interestingly, the typical left 
skewed distribution of the pure PPI-G4 change to a rather non-skewed distribution after 
biotinylation of the PPI-G4. Generally, substituents are considered to be randomly but 
maximally separated distributed over the dendritic scaffold, whereas a normal 
distribution is assumed with respect to the average ligand loading of the dendrimers.
[223]
 
Figure 4.1.6b clearly shows the higher the biotinylation degree is the broader the molar 
mass distribution becomes. This is a typical trend with regard to a normal loading 
distribution of the ligands. Although the obtained molar masses are lower than the 
1
H NMR and HABA displacement titration suggest (cf. Table 4.1.2) PPI dendrimers with up 
to five biotin ligands for PPI-C6B1 and PPI dendrimers with up to seven C6B ligands for 
PPI-C6B4 can be identified even though with decreased abundance. Their m/z values are 
denoted with B1 - B7 in Figure 4.1.6b and apply for the single charged C6B substituted 
PPI-G4 ([M+H]
+
). PPI-C6B1 additionally allowed the identification of fragments of the 
biotin ligand (m/z = 339.5) (Figure 4.1.6c). Moreover, fragments differing in m/z = ~ 58 
were found, which are a result of the removal of a protonated azacyclobutane (cf. 
reference [220-222]). 
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Figure 4.1.6 MALDI-TOF MS spectra of a) PPI-G4, b) PPI-C6B1 and PPI-C6B4, c) selected assigned 
fragments of the bound biotin ligand and the terminal units of the PPI-C6B1, d) PPI-
C6B8 and e) selected assigned fragments PPI-C6B8 in the m/z range of 2000 g/mol –
 4000 g/mol. 
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As already described for polytertiary alkylamines the decomposition pathways are driven 
by intramolecular nucleophilic substitution reactions (SNi).
[224]
 Thereby, for instance, a 
protonated nitrogen of the diaminobutane (DAB) core is attacked by the non-protonated 
nitrogen of the DAB core. This reaction pathway is denoted with G0 in Figure 4.1.7a. Such 
a kind of mechanism leads to two fragments, which differ only in four CH2 units 
(Figure 4.1.7a). But also nitrogens in the dendrimers periphery can be protonated and 
hence become prone for an intramolecular nucleophilic attack of another amino group 
close to it. It has been found that in the case of PPI-G4 dendrimers either the 
fragmentation at the DAB core or degradation of the terminal amino propylene groups 
are the predominant fragmentation pathways during the ionization process 
(Figure 4.1.7b).
[222]
 They are mainly driven by the basicity of the nitrogen atoms and 
electrostatic interactions.
[221]
 These pathways are denoted with G0, G4(A) or G4(B) in 
Figure 4.1.7. G0 were found to be the most abundant pathway. In the case of the G4 
pathways the fragmentation G4(B) is reported to be the more abundant than G4(A).
[221, 222]
 
G4(B) lead to fragments, which differ only in an m/z ~ 58 and also explain the fragments 
found in the spectra of PPI-G4, which are denoted with i*) – iii*) (Figure 4.1.6a). Since the 
measurements were conducted with a molar mass suppression below 2000 g/mol a 
quantitative analysis of the m/z region below 100 g/mol was not possible. Consequently, 
both scenarios have to be taken into account: the fragments i*) – iii*) (Figure 4.1.6a) are 
either yielded by the G4(B) fragmentation and/or are attributed to the inherent defects in 
the pure PPI-G4 batch. The fragmentation pathway G4(B) not only explains the fragments 
in the MALDI-TOF spectra of PPI-C6B1 (cf. Figure 4.1.6c). It holds also as reasonable 
explanation of the lower average molar masses of the PPI-C6B1 (m/z = 7400) and PPI-
C6B4 (m/z = 8100) (cf. Figure 4.1.6b) obtained by MALDI-TOF MS compared to the values 
determined by 
1
H NMR and HABA displacement titrations (cf. Table 4.1.2). However, this 
finding may be additionally caused by the hindered ability of high molecular weight 
compounds to reach the detector, which usually results in decreased signal intensities 
compared to lower molecular weight compounds. But also the lack of complete structural 
homogeneity of the pure PPI-G4 has to be taken into account (cf. Figure 4.1.6a). 
Figure 4.1.6b additionally shows m/z values of about m/z = 3730 for PPI-C6B1 and 
m/z = 4270 for PPI-C6B4.   
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Figure 4.1.7 Most abundant fragmentation pathways of PPI-G4 during mass spectrometry 
measurements.
[222]
 Nomenclature of the pathways under a) and b) are taken from 
reference [222]. 
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Due to the low resolution of the spectra these signals can be either attributed to the 
signals of the double charged PPI-C6B1 and PPI-C6B4, respectively, or they are yielded by 
the G0 fragmentation. As already described by Weener et al. dendrimers in water 
containing solvents (e.g. MeOH/H2O) lead to multiply charged PPI dendrimers, which is 
reflected in the mass spectra by the presence of [M+H]
+
 - [M+6H]
6+
 species.
[221]
 The same 
observation of multiply charged PPI dendrimers were made by McLuckey et al.
[222]
 
Consequently, it is reasonable to assume a similar behavior for the PPI-C6Bx samples, 
which were solved in pure water.  
Figure 4.1.6d depicts the MALDI-TOF spectra of PPI-C6B8 and three signals can be seen at 
m/z ~ 3300, m/z ~ 4550 and m/z ~ 9100. As previously mentioned these signals can be 
attributed to the (multiply) charged [M+H]
+
, [M+2H]
2+
 and [M+3H]
3+
 species. However, 
poor resolution also implies further underlying signals caused by PPI-C6B8 fragmentation. 
In the m/z range of 2000 g/mol – 4000 g/mol also sharp signals were found. A magnified 
picture of this m/z area can be seen in Figure 4.1.6e. The m/z peaks at about 2414, 2753 
and 3092 differ in about m/z ~ 339, which can likely be referred to the C6B ligand, finally 
proving the substitution with the C6B ligands also through MALDI-TOF MS. 
In summary, the biotin ligand substitution was successfully proven by MALDI-TOF MS. 
Solving the PPI-C6Bx with x = 1, 4, 8 in pure water led to differently charged dendrimers 
occurring in the spectra as it was found by other researchers. The m/z peaks at 3730 and 
4270 of PPI-C6B1 and –C6B4, respectively, cannot exclusively be attributed to either the 
formation of a double charged species or to a fragmentation by the G0 pathway. 
However, the broadening of the m/z value distribution upon the substitution of more 
than one biotin ligand and the lack of sharp signals strongly imply several fragmentation 
processes. Especially the G4 fragmentation may also alter significantly the average m/z 
peaks of the [M+H]
+
 species leading to lower m/z values as expected from the 
1
H NMR 
and HABA displacement titrations. 
 
HABA Displacement Titration – Since MALDI-TOF MS cannot be appropriately applied to 
all samples and in order to ensure comparability the degree of biotinylation was 
determined by HABA displacement titrations (Figure 4.1.8) according to literature.
[225]
 
Therefore a preformed [avidin.HABA] complex was titrated with certain amounts of the 
particular samples. The [avidin.HABA] complex was formed by mixing avidin with a 16 fold 
excess of the azo dye HABA. 
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Figure 4.1.8 HABA displacement titrations of a) PPI-DS-C6Bx, b) PPI-DS-PEG12Bx, c) PEI-DS-C6Bx 
and d) PEI-DS-PEG12Bx with x = 1, 2, 4 in 0.1 M TRIS/HCl/NaCl at pH 7.5 determined 
by UV/Vis. 
 
The high excess of the azo dye was used in order to ensure a complete saturation of the 
avidin binding sites. Finally, the biotinylation degrees were obtained by linear regression 
of the lower and higher part of the titration curves. The obtained biotinylation degrees 
are in good agreement with the values obtained by 
1
H NMR spectroscopy (see also 
experimental part). They are summarized in Table 4.1.2. Figure 4.1.8c shows another 
important fact: the titration curves of PEI-DS-C6Bx show a distinct curvature around the 
equivalence point. This lack of a clear endpoint indicates the presence of substances that 
bind relatively weak to avidin. Those substances are known to alter the sharpness of the 
equivalence point but do not affect the titer.
[226]
 In context of the latter, it has been 
shown that only a pretreatment of (strept-)avidin with a high excess of pure maltose 
leads to a significant inhibition of the (strept-)avidin-biotin interaction due to an 
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interaction of maltose units with the binding pockets in (strep-) avidin.
[227]
 Consequently, 
the combination of the flexible PEI-bGP scaffold and the short C6B ligand results in less 
effective binding of the biotin ligand by avidin. Furthermore, it seems reasonable to 
assume that the maltose units attached to the PEI-bGP scaffold compete with the C6B 
ligands for the avidin binding sites. However, the lack of a clear endpoint in the case of 
the PEI-DS-C6Bx samples indicates a dissociation constant in the range of 10
-9
 – 10
-
6
 M.
[225]
 In contrast, a strong interfering interaction of the maltose unit can be excluded 
especially for the C6B substituted PPI-bGP and the PEG12B substituted PPI- and PEI-bGP 
due to their rather sharp endpoints. The titrations with PPI-DS and PEI-DS showed no 
endpoint (cf. Figure A4.1.15b). 
 
 
4.1.2   Characterization of BHS Composed of Avidin and Biotinylated Dendritic 
Glycopolymers 
 
Dynamic Light Scattering – DLS data of the batch measurements were analyzed 
with a focus on the following issues: (i) range of hydrodynamic diameters (Dh, min – Dh, max) 
and (ii) maximum diameter (Dh, max) with respect to ligand-receptor stoichiometry, 
biotinylation degree and (iii) stability of the BHS. Figure 4.1.9 shows the BHS average Dh 
formed by avidin with mono-, bi- and tetravalent bGP after one day of equilibration. In 
general, the size distributions of the avidin/PEI-bGP BHS are not broader than those of 
the avidin/PPI-bGP BHS (cf. appendix of chapter 4.1 Figures A4.1.16 – A4.1.21). 
 
Monovalent bGP – The Dh of the BHS of avidin and monovalent bGP are depicted in 
Figure 4.1.9a – d. The mixing of different molar ratios of avidin (∅ 7 nm) and the 
monovalent PEI-bGP (∅ 11 nm) (cf. Table A4.1.2) resulted in PEI-BHS with a Dh, max of 
more than 20 nm for the 1/3 molar ratios of avidin/PEI-DS-C6B1 (Figure 4.1.9c) as well as 
for the molar ratios 1/3 and 1/4 of avidin/PEI-DS-PEG12B1 (Figure 4.1.9d). The Dh of the 
PEI-BHS are in general higher than the Dh of the analogous PPI-BHS at the same molar 
ratio of avidin/bGP. The conversion of avidin with PPI-DS-C6B1 showed Dh, max of about 12 
nm at both the 1/2 and 1/3 molar ratio (Figure 4.1.9a), whereas the Dh of the single PPI-
bGP is of about 6 nm (cf. Table A4.1.2). This indicates that there are non-bound particles 
present, since DLS size curves present the size distribution of the whole sample.  
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Figure 4.1.9 Average Dh and their corresponding standard deviations (SD) of different BHS 
composed of [avidin.HABA] and bGP after 1 d of equilibration in 0.1 M TRIS/HCl/NaCl 
at pH 7.5 determined by DLS. Examples of the corresponding DLS volume plots can 
be found in the appendix of chapter 4.1 Figures A.4.1.16 – A.4.1.21. 
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If there are populations present that differ only a few nanometers in their Dh, one will 
measure the overlap of the Dh of these populations e.g. avidin, bGP or formed BHS. Thus, 
the higher the amount of non-conjugated bGP is, the lower the Dh of the BHS is.  
In general, the standard deviations (SD) are rather low for almost all molar ratios of avidin 
and the monovalent bGP and the SD do not exceed 3 nm. 
 
Bivalent bGP – The Dh of the BHS of avidin and bivalent bGP are depicted in 
Figure 4.1.9e – h. Dh, max of 23 nm and 29 nm were reached at a molar ratio of 1/1.5 in the 
case of the BHS based on PPI- and PEI-DS-C6B2, respectively (Figure 4.1.9e and g). 
Furthermore, Dh, max of 21 nm and 32 nm of the BHS were obtained at even lower molar 
ratios of 1/2 in the case of the PPI-and PEI-DS-PEG12B2, respectively (Figure 4.1.9f and h). 
All SD of the Dh of the formed BHS are rather low and indicate a good reproducibility.  
 
Tetravalent bGP – The Dh, max that were achieved for BHS consisting of avidin and PPI-DS-
C6B4 or -PEG12B4 are 46 nm and 50 nm, respectively. The Dh, max of the BHS composed of 
avidin and PEI-DS-C6B4 or -PEG12B4 are even higher with 53 nm and 57 nm, respectively 
(cf. Figure 4.1.9i – l). Dh, max was found to be at the 1/1 molar ratio in the most cases. The 
BHS composed of avidin and tetravalent bGP possess higher SD compared to the BHS 
composed of avidin and mono- or bivalent bGP. 
 
Octavalent PPI-bGP – Figure 4.1.10a show the Dh of the single components 
[avidin.HABA], PPI-DS-C6B8 and PPI-DS-PEG12B8 as well as the Dh of the BHS formed by 
different molar ratios of avidin and PPI-DS-C6B8 or PPI-DS-PEG12B8 (Figure 4.1.10b - e). 
The molar ratio of 1/0.25 of avidin and the octavalent PPI-bGP resulted in a broad and 
bimodal size distribution after one day, which was still present after 14 days for both 
avidin/PPI-DS-C6B8 and avidin/PPI-DS-PEG12B8 BHS (Figures 4.1.10b – e – black lines). 
Largest particles with a Dh, max of about 860 nm for PPI-DS-C6B8 based BHS and 1740 nm 
for PPI-DS-PEG12B8 based BHS were obtained at a molar ratio of 1/0.5 after one day 
(Figure 4.1.10b and d – red lines). However, after 14 days they showed either a bimodal 
size distribution (avidin/PPI-DS-C6B8 1/0.5, Figure 4.1.10c, red lines) or instability in size 
(avidin/PPI-DS-PEG12B8 1/0.5, Figure 4.1.10e, red lines). The 1/1 molar ratio resulted in 
Dh of about 20 – 40 nm, which were bimodal and rather stable for up to 14 days 
(Figure 4.1.10 - blue lines). The 1/1.5 and 1/2 molar ratios resulted in even smaller 
particles (Figures 4.1.10b – d – pink and green lines).  
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Figure 4.1.10 Dh of a) avidin, PPI-DS-C6B8 and PPI-DS-PEG12B8; different molar ratios of 
avidin/PPI-DS-C6B8 after b) 1 d and c) 14 d and different molar ratios of avidin/PPI-
DS-PEG12B8 after d) 1 d and e) 14 d in 0.1 M TRIS/HCl/NaCl at pH 7.5 measured by 
DLS in batch (cf. Figure A4.1.22). 
 
The shoulder of the 1/2 molar ratio of avidin/PPI-DS-C6B8 after 14 days indicates the 
presence of single macromolecules (Figure 4.1.10c, green line).  
Another vital point of these BHS is the stability of the Dh over 14 days. The differences of 
the Dh after one day and 14 days (Δ Dh) of the particular PPI- and PEI-BHS are shown in 
Figure 4.1.11.  
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Monovalent bGP – No significant change in the Dh of the BHS based on monovalent bGP 
within 14 days were found (Figure 4.1.11a – d). Thus neither the dendritic scaffold nor the 
chemical nature of the biotin ligand or its length influences significantly the stability of 
the BHS, since the changes in the diameter do not exceed 2 nm.  
 
Bivalent bGP – Comparable low differences in the Dh were found for BHS based on 
bivalent bGP (Figure 4.1.11e – h) apart from few exceptions (cf. Figure 4.1.11e and g). The 
BHS based on PEI-DS-C6B2 showed size growth with up to 5 nm at the molar ratios of 1/1 
and 1/1.5 (Figure 4.1.11g). In contrast, size decrease with up to 5 nm was also observed 
for avidin/PPI-DS-C6B2 at the 1/1 molar ratio.  
 
 
Figure 4.1.11 Change of the hydrodynamic diameters (Δ Dh with ∆Dh= Dh14 d 
 - Dh1 d) of 
avidin/bGP BHS; ratios given as [avidin.HABA]/bGP. 
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Tetravalent bGP – A significant trend to growth of the BHS can be observed in the case of 
the tetravalent bGP. This is, however, more distinct for the PEI-BHS (Figure 4.1.11k and l). 
Here, increased Dh of the BHS among almost all ligand-receptor stoichiometries were 
found. The growth was found to be up to more than 20 nm. In contrast, this trend only 
occurs at certain molar ratios of the PPI-BHS, namely avidin/PPI-DS-C6B4 1/0.5 and 1/1 
ratio as well as for avidin/PPI-DS-PEG12B4 1/1. The maximum size growth amounts up to 
15 nm.  
Octavalent bGP – as can be seen in Figure 4.1.10 monomodal size distributions along with 
stability over a period of 14 days is only given for BHS based on octavalent PPI-bGP at the 
1/1.5 and 1/2 molar ratio. Higher molar ratios resulted in instability and/or bimodality of 
the size distributions (cf. also appendix Figure A4.1.22).  
A few general points can be concluded, the higher the amount of bGP added to avidin is 
or the lower the ligand-receptor stoichiometries of avidin and bGP are, the larger the Dh 
of the BHS are. But importantly, this was found to occur only up to the molar ratio of 
avidin/bGP that corresponds to the Dh, max. Molar ratios that are lower than the molar 
ratio corresponding to the Dh, max resulted in Dh of the BHS, which are smaller than the 
Dh, max. Furthermore, the higher the biotinylation degree is the lower the molar ratio is 
that corresponds to the Dh, max. In this regard no significant dependence on the dendritic 
scaffold (PPI-DS vs. PEI-DS) or the biotin ligand (C6B vs. PEG12B) was observed.  
The chemical nature of the biotin ligand influences the propensity to undergo non-
specific interactions such as H-bonding or van der Waals interactions. For instance, in 
order to reach the Dh, max of the BHS a higher amount of PPI- or PEI-DS-PEG12B1 was 
necessary compared to BHS based on the C6B substituted analogues. Here, the 
avidin/PPI-DS-C6B1 molar ratio of 1/3 resulted in Dh, max, whereas a 1/4 molar ratio of 
avidin/PPI-DS-PEG12B1 was necessary in order to reach the Dh, max (cf. Figure 4.1.9a – d 
and Table 4.1.3). Similar results were obtained for BHS based on bivalent bGP (cf. 
Figure 4.1.9e – h and Table 4.1.3). A reasonable explanation is an increased propensity to 
undergo non-specific interaction of the PEG12B ligand compared to the C6B ligand 
hampering an effective avidin-biotin conjugation. In contrast, the Dh, max of the BHS was 
found to be mainly at the 1/1 molar ratio for BHS based on the PPI- and PEI-DS-C6B4 and 
PPI- and PEI-DS-PEG12B4 (Figure 4.1.9i – l) and at 1/0.5 for BHS based on the PPI- and PEI-
DS-C6B8 and PPI- and PEI-DS-PEG12B8 (Figure 4.1.10b – e).  
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Figure 4.1.9 and Table 4.1.3 elucidate also the influence of the dendritic scaffold. In 
general, PPI-BHS showed lower Dh and Dh, max compared to the analogues PEI-BHS. For 
example, avidin/PPI-DS-C6B2 in a 1/2 molar ratio showed Dh of about 11 nm, whereas the 
avidin/PEI-DS-C6B2 in a 1/2 molar ratio reached 17 nm. This becomes rather conclusive 
considering that the Dh of PEI-bGP are almost twice as high as the Dh of PPI-bGP 
(cf. Table A4.1.2). Furthermore, a better accessibility of the biotin ligand for the avidin 
binding sites has to be taken into account as well. This can be attributed to the higher 
flexibility of the PEI-DS scaffold compared to the rather rigid PPI-DS scaffold. The 
differences in the Dh, max of the PPI- and PEI-BHS decrease from 75 % to down to 15 % with 
higher biotinylation degrees of PPI-DS-C6Bx and PEI-DS-C6Bx after 1 d and 14 d, 
respectively (Table 4.1.3). Consequently, it can be concluded that a higher biotinylation 
degree of the PPI-bGP compensates their smaller Dh that contribute to the Dh of the BHS 
leading to differences in the Dh of the PPI- and PEI-BHS of only about 15 %. 
 
Table 4.1.3 Overview of diameter ranges, corresponding molar ratio of Dh, max and differences in 
Dh, max of the PPI- and PEI-BHS. 
 
BHS based on Dh, min – Dh, max 
Dh, max 
corresponding 
molar ratio
 
Differences in Dh, max 
avidin and 1 d 14 d 1 d 14 d 
PPI-DS-C6B1 9 – 12 nm 9 – 12 nm 
1/3 75 %  75 % 
PEI-DS-C6B1 12 – 21 nm 13 – 22 nm 
PPI-DS-C6B2 8 – 23 nm 12 – 28 nm 
1/1.5 26 % 21 % 
PEI-DS-C6B2 10 – 29 nm 10 – 34 nm 
PPI-DS-C6B4 21 – 46 nm 22 – 59 nm 
1/1 15 % 15 % 
PEI-DS-C6B4 35 – 53 nm 40 – 68 nm 
PPI-DS-PEG12B1 9 – 15 nm 9 – 13 nm 
1/4 40 %  40 % 
PEI-DS-PEG12B1 13 – 21 nm 12 – 21 nm 
PPI-DS-PEG12B2 8 – 21 nm 7 – 20 nm 
1/2 52 % 110 % 
PEI-DS-PEG12B2 9 – 32 nm 11 – 42 nm 
PPI-DS-PEG12B4 43 – 50 nm 45 – 55 nm 
1/1 14 % 40 % 
PEI-DS-PEG12B4 32 – 57 nm 45 – 77 nm 
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Interestingly, this trend was not observed in the case of the BHS based on PEG12B 
substituted bGP. The highest differences in the Dh, max of about 52 % were for the BHS 
bases on PPI- and PEI-DS-PEG12B2 after one day. This observation further supports the 
conclusion of an increased tendency of the PEG12B ligand to undergo non-specific 
interaction either with both avidin and the bGP or only one of them. However, although 
PEG is generally known for its protein repellent properties, it has been reported that PEG 
do interact with certain proteins such as mucin,
[228]
 lysozyme
[229, 230]
 or bovine serum 
albumin.
[230]
 In addition, the either repellant or non-repellant interactions of PEG with 
proteins are critically depending on various factors such as the amount of PEG chains on 
the surface of particles, its length, the protein conformation or the presence of certain 
amino acids.
[204, 213, 228-230]
 
 
Transmission Electron Microscopy – The TEM measurements were carried out in the dry 
state of the particles. Therefore a droplet of the particular sample in 0.02 M 
TRIS/HCl/NaCl at pH 7.5 was placed on a carbon coated gold grid and incubated for up to 
15 s. Afterwards the excess solution was carefully removed with a filter paper and 
subsequently the TEM measurements were conducted. The particle size distributions 
were obtained by the determination of the sizes of at least more than 150 particles. The 
TEM image and particle size analysis of avidin/PPI-DS-PEG12B1 BHS in a 1/1 molar ratio 
shows diameters of 16 – 22 nm (Figure 4.1.12a). These values are higher than the Dh of 
about 8 – 12 nm obtained by DLS. 
 
Figure 4.1.12 TEM images of avidin/PPI-DS-PEG12B1 a) 1/1 (∅ 16 – 22 nm) and b) 1/3 
(∅ 25 - 40 nm). Samples were prepared in 0.02 M TRIS/HCl/NaCl at pH 7.5. 
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Figure 4.1.13 TEM images of a) avidin/PPI-DS-C6B2 1/1 and b) corresponding particle size 
analysis; c) avidin/PPI-DS-PEG12B2 1/1 and d) corresponding particle size analysis; 
e) avidin/PPI-DS-C6B4 1/1 and f) corresponding particle analysis; g) avidin/PPI-DS-
PEG12B4 1/1 and h) corresponding particle analysis. 
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In line with the latter, the 1/3 molar ratio of avidin/PPI-DS-PEG12B1 resulted Dh of only 
11 – 15 nm (cf. Figure 4.1.9b) compared to 25 – 40 nm obtained by TEM (Figure 4.1.12b). 
Similar differences in the Dh obtained by DLS and the diameters determined by TEM were 
found for avidin/PPI-DS-C6B2 (Figure 4.1.13a and b) and avidin/PPI-DS-PEG12B2 
(Figure 4.1.13c and d) in 1/1 molar ratios. They showed both diameters of about 20 nm in 
the TEM images, whereas Dh of about 16 nm were found. As discussed before, one 
reasonable explanation is the presence of non-bound particles within the DLS samples. 
The presence of non-bound particles has more impact on the measured Dh, since the 
imaging of non-stained amorphous particles of about 5 – 7 nm in diameter by TEM is 
rather difficult. Thus the BHS diameters provided by the TEM images should be the more 
reliable. Moreover, the TEM study was done under decreased buffer molarity and higher 
concentration, whereas the DLS study was carried out in the presence of the azo dye 
HABA. Decreased buffer molarity can lead to increased aggregation of the BHS and the 
presence of HABA may inhibit the conjugation of the bGP to avidin. 
The average Dh of avidin/PPI-DS-C6B4 in a 1/1 molar ratio amount to about 46±10 nm 
(Figure 4.1.9i) compared to smaller diameters of 25 – 40 nm measured by TEM 
(Figure 4.1.13e and f). Similar results were obtained for avidin/PPI-DS-PEG12B4 in a 1/1 
molar ratio. Here, the average Dh amount to 40±3 nm (Figure 4.1.9j), whereas TEM 
images show diameters of about 22 nm – 30 nm (Figure 4.1.13g and h). A reasonable 
explanation is the loose of water content due to the drying process of the specimen 
previous to the TEM investigations. However, the presence of single non-bound particles 
(e.g. avidin or bGP) can be neglected. Even though the particles sizes obtained by TEM do 
not match exactly the measured Dh a few general points have to be noted: all particles 
are in spherical shape and the diameters and the size distributions increase with 
increased biotinylation degree at same molar ratios of avidin/bGP. 
 
Amount of bound bGP – A linear regression of the lower part of the titration curve 
(cf. Figure 4.1.8) and the change in absorbances at ʎ = 500 nm after the mixing of 
[avidin.HABA] complex with stoichiometric amount of the bGP were used to determine 
the amount of displaced dye and the amount of bound bGP, respectively. The determined 
values compared to the applied molar ratios are summarized in Table 4.1.4. In general, it 
was found that only about one half of the bGP are bound to avidin. This was surprising, 
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since avidin-biotin conjugation is characterized by a very low dissociation constant of 
10
-15
 M.
[12]
 The much lower binding strength of mono- and bivalent bGP against avidin can 
be explained by the structural properties of avidin and bGP. Avidin and the PPI-bGP 
possess similar dimensions and the PEI-bGP are even larger than avidin. Consequently, 
steric shielding occurs (Figure 4.1.14). In addition, a study of Sinha et al. showed that spin-
labelled biotin derivatives were initially bound in a random fashion and changed slowly 
from cis position to a more favoured trans position of the avidin binding sites 
(Figure 4.1.14b).
[231]
 The rearrangement of biotin derivatives is also discussed by 
Kisak et al.
[209]
 and Connolly et al.
[208]
 Thus it can be proposed that the conjugation 
mechanism for the binding of bGP to avidin takes place in a similar fashion as postulated 
for much larger and similarly sized biotin derivatives. In addition, the potentially 
hampering effect of the azo dye HABA and the lack of complete conversion of avidin with 
bisbiotinyl-functionalized alkanes was also reported by Green et al.
[232]
  
 
Table 4.1.4 Average amount of bound PPI- or PEI-bGP to avidin. 
 
 molar ratio PPI-DS-(…)
 
PEI-DS-(…)
 
(…) =  avidin/bGP bound bGP
a 
SD
b 
bound bGP
a 
SD
b 
C6B1
 
1/1 0.50 0.05 0.50 0.06 
1/2 1.10 0.05 1.06 0.09 
1/3 1.60 0.09 1.50 0.04 
1/4 1.73 0.09 1.75 0.01 
C6B2 
1/0.5 0.29 0.08 0.27 0.01 
1/1 0.48 0.02 0.52 0.02 
1/1.5 0.85 0.04 0.85 0.05 
 
PEG12B1 
1/1 0.45 0.11 0.43 0.04 
1/2 0.92 0.13 1.00 0.04 
1/3 1.36 0.09 1.49 0.08 
1/4 1.78 0.12 1.87 0.06 
PEG12B2 
1/0.5 0.21 0.05 0.22 0.05 
1/1 0.44 0.07 0.48 0.01 
1/1.5 0.65 0.04 0.75 0.01 
a
 based on the HABA amount displaced by biotin ligands; 
b
 SD – standard deviation. 
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Figure 4.1.14 a) Structure and dimensions of avidin
[231-233]
; b) favored coupling of two bGP as 
proposed by Sinha et al.;
[231]
 c) steric shielding of the coupled bGP due to similar or 
even larger sizes of avidin and the bGP. 
 
LILBID-MS and AF4-LS – Two different techniques, LILBID MS and AF4-LS, were applied in 
order to determine the molar mass distributions of the single components and their 
associates. Both of them are rather novel methods and their application on biological and 
biomimetic samples has been recently developed. The molar mass of BHS formed by the 
conversion of 1 or 4 equivalents PPI-DS-C6B1 with 1 equivalent of avidin was determined 
by LILBID MS. Figure 4.1.15a shows mainly 1/1 and 1/2 conjugation adducts next to free 
PPI-DS-C6B1 and avidin. This seems reasonable considering the amount of bound bGP 
(Table 4.1.4) and the stagnation of sizes as found in the DLS study (Figure 4.1.9a). 
However, although the amount of free avidin is significantly lower even a higher amount 
of PPI-bGP of four equivalents lead only to the 1/1 and 1/2 conjugation adducts 
(Figure 4.1.15b). 
 
Figure 4.1.15 LILBID MS spectra of avidin/PPI-DS-C6B1 in a) 1/1 and b) 1/4 molar ratio after 1 d, 
samples were prepared and measured in 5 mM TRIS/HCl/NaCl at pH 7.5. 
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This is supported by the explanations with regard to Figure 4.1.14a as well as by the 
hypothesis of sterically induced stoichiometry based on the findings of Tomalia et al.
[80, 
234-236]
  
The resulting composition of avidin/PPI-DS-C6B1 in an 1/1 and 1/3 molar ratio were 
qualitatively and quantitatively analyzed by AF4-LS. In this regard Linda Scharfenberg is 
gratefully acknowledged for conducting these measurements within her master 
thesis.
[237]
 The determined molar masses of avidin and the selected PPI-bGP are 
summarized in Table 4.1.5. The AF4-LS results of avidin/PPI-DS-C6B1 in a molar ratio of 
1/1 mainly show free PPI-bGP and free avidin next to an 1/1 conjugation adduct of 
avidin/PPI-DS-C6B1 with a Mn of 117000 Da (Figure 4.1.16a and b; Table 4.1.6). A molar 
ratio of 1/3 of avidin/PPI-DS-C6B1 resulted in an almost complete conversion of avidin. In 
contrast, about 35 % of free PPI-DS-C6B1 was still found. Even though avidin was mixed 
with three equivalents of PPI-DS-C6B1 only an 1/2 conjugation adduct was detected. 
Most interestingly, both samples contained about 40 % of high molecular weight 
associates (denoted as nanostructures), which possess moderate up to rather high 
dispersities. However, the samples showed no complete conversion of either avidin or 
PPI-DS-C6B1. This can at least be partly explained by the normal distribution of the biotin 
loading distribution of the PPI-bGP as discussed within the MALDI-TOF results. 
Consequently, there are also non-biotinylated PPI-GP present. Another point is the 
decreased conjugation efficiency of the bGP due to steric reasons. This is substantiated by 
the LILBID MS results (cf. Figure 4.1.15) where signals of the free PPI-bGP and free avidin 
are also present in high intensities. 
 
Table 4.1.5 Average molar masses of avidin and PPI-bGP determined by AF4-LS.
a 
 Mn Mw Ɖ 
 [g/mol] [g/mol] (Mw/Mn) 
avidin 67700 68200 1.01 
PPI-DS-C6B1 44600 45200 1.01 
PPI-DS-PEG12B1 43000 46900 1.09 
PPI-DS-PEG12B2
b 
42600 45600 1.07 
a
 corresponding AF4-LS-fractogramms can be seen in the appendix Figure A4.1.14. 
b
 cf. chapter 4.1.6 
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Although conjugation adducts were formed, even a higher molar ratio of 1/3 of 
avidin/PPI-DS-C6B1 in the AF4-LS study or of 1/4 in the LILBID MS study led only to the 
formation of 1/2 conjugation adducts of avidin and PPI-DS-C6B1. Thus the resulting 
composition does not clearly reflect the molar ratios. But the molar ratios do control the 
final composition. 
 
 
Figure 4.1.16 AF4 results of the conversion of avidin with PPI-DS-C6B1 a) AF4-fractogram with 
light scattering (LS) signal and refractive index (RI) signal as a function of elution 
time, for comparison: RI signal of PPI-DS-C6B1 and avidin; b) molar mass vs. elution 
time plot for the 1/1 molar ratio, c) AF4-fractogram with LS- and RI-signal as a 
function of elution time, for comparison: RI signal of PPI-DS-C6B1; b) molar mass vs. 
elution time plot for the 1/3 molar ratio; The broken lines show the different 
components found in the superimposed peaks; samples were measured in in 50 
mM nitrate buffer (pH of 6.8) and 0.02 % (w/v) NaN3. 
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Additionally the 1/3 ratio of avidin/PPI-DS-PEG12B1 was studied (Table 4.1.6). Similar to 
the above described results of avidin/PPI-DS-C6B1 in an 1/3 molar ratio, free PPI-bGP, a 
conjugations adduct and nanostructures were found in the BHS solution. But, in contrast, 
the 1/3 molar ratio of avidin/PPI-DS-PEG12B1 yielded an 1/3 conjugation adduct, whereas 
avidin/PPI-DS-C6B1 in an 1/3 molar ratio resulted in an 1/2 conjugation adduct. This 
clearly indicates a better conjugation efficiency of the PEG12B ligand compared to the 
C6B ligand.  
The amount of the conjugation adducts and nanostructure is quite similar within all 
investigated samples of avidin/PPI-bGP. About one half of the solution was composed of 
nanostructures.  
 
Table 4.1.6 Average molar masses of the separated components in the biohybrid-associate 
avidin/PPI-DS-C6B1 and avidin/PPI-DS-PEG12B1. 
 
 Mn Mw Ɖ recovery
a 
 [g/mol] [g/mol] Mw/Mn [%] 
avidin/PPI-DS-C6B1 in 1/1 molar ratio 
PPI-DS-C6B1 48200 49000 1.02 21 
avidin 66600 67400 1.01 20 
avidin/PPI-DS-C6B1 
1/1 conjugation adduct 
117000 120000 1.03 20 
nanostructures 325000 585000 1.8 39 
avidin/PPI-DS-C6B1 in 1/3 molar ratio 
PPI-DS-C6B1 49600 49900 1.01 35 
avidin/PPI-DS-C6B1 
1/2 conjugation adduct 
169000 172000 1.02 23 
nanostructures 729000 3930000 5.4 42 
avidin/PPI-DS-PEG12B1 in a 1/3 molar ratio
b 
PPI-DS-PEG12B1 48400 48800 1.03 27
 
avidin/PPI-DS-PEG12B1 
1/3 conjugation adduct 
206000 211000 1.02 17
 
nanostructures 1100000 2480000 2.25 56
 
a 
represents the percentage of the final composition; 
b 
corresponding AF4-LS-fractogramms can 
be seen in the appendix Figure A4.1.15a. 
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In summary, AF4-LS was successfully applied in order to elucidate the final composition of 
the raw conjugation solutions of various molar ratios of avidin/PPI-bGP. The gained 
knowledge was further used to apply a proper purification technique. Furthermore, it has 
to be noted that AF4-LS is an apropriate technique for the analysis of such BHS since it 
allows the fractionation of the crude conjugation solution in one measurement in order 
to gain information about the composition, molar masses and dispersities. The method of 
choice is AF4 in comparison to GPC since it evades the disadvantages of GPC such as 
interactions with the column material or shear forces that alter or harm the samples. 
Moreover, the online coupling of AF4 with dynamic or static light scattering further 
provides access to scaling properties of the particular samples, which will be shown in 
chapter 4.1.6.  
 
 
4.1.3   Summary  
 
In Figure 4.1.17 a summary is given, which highlights the findings of the DLS study 
and the AF4-LS investigation. In summary the following key points were elucidated: 
 
(i) Influence of Biotinylation Degree 
- Increased BHS sizes were obtained with increased biotinylation degree at the 
same molar ratios of avidin/bGP. Consequently, the final diameters of the BHS can 
be controlled by the degree of biotinylation. 
- The SD of Dh of the BHS formed by tetravalent bGP are higher compared to those 
observed for the BHS formed by mono- or bivalent bGP. A rather poor 
reproducibility was also observed for BHS formed by octavalent PPI-bGP. Here, 
stable BHS with monomodal size distributions were only obtained at molar ratios 
1/1.5 and 1/2, respectively. Thus the reproducibility of the sizes of the BHS is 
clearly depending on the degree of biotinylation and increases with decreased 
biotinylation degree. 
- Furthermore, especially for rather large BHS structural rearrangements occur in 
order to reach a sterically less hindered state.  
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(ii) Influence of Ligand-receptor Stoichiometry 
- BHS sizes can also be directed by the molar ratio of avidin/bGP, the ligand-
receptor stoichiometry. 
- Increased Dh can be obtained with decreased molar ratios of avidin/bGP down to 
the molar ratio that corresponds to the Dh, max. Even lower molar ratios yield Dh 
smaller than the Dh, max. 
- The molar ratio of avidin to bGP that is required to obtain the Dh, max was 
decreased with higher biotinylation degrees of the bGP. 
 
(iii) Influence of the Biotin Ligands  
- Dh, max of BHS formed by PEG12B substituted bGP were obtained at lower molar 
ratios of avidin/bGP compared to the BHS formed by C6B substituted bGP in the 
case of mono- and bivalent bGP. 
- BHS composed of avidin and PEG12B substituted bGP showed slightly larger 
diameters than BHS formed by avidin and C6B functionalized bGP even though the 
amount of bound bGP showed quite similar values.  
On the one hand, this can be attributed to the formation of more compact 
structures in the case of BHS composed of avidin and C6B functionalized bGP. On 
the other hand, further non-specific and non-covalent interactions of the PEG12B 
ligands with avidin, the bGP or the BHS facilitating further aggregation may hold as 
an explanation. 
- The PEG12B ligands attached to the bGP were found to promote non-specific 
interaction but showed also a better accessibility for the avidin binding sites 
compared to the C6B ligand. 
 
(iv) Influence of the Dendritic Scaffold 
- Hyperbranched polymers are generally known for their higher dispersities 
regarding their molar masses compared to their perfectly branched dendrimer 
relatives. This is barely reflected in the SD of the Dh of the formed BHS or in their 
size distributions. The size distributions of the PPI-BHS and PEI-BHS showed a 
similar extent.  
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Figure 4.1.17 Schematic summary of the present study for fabricating different nanometer-sized 
BHS controlled by degree of biotinylation on glycopolymer surface and defined 
ligand-receptor stoichiometries. 
 
- The structural rearrangements over 14 days mainly resulted in a growth of the 
BHS. PEI-BHS based on PEI-bGP undergoes the most distinct growth especially in 
the case of the BHS formed by tetravalent PEI-bGP. 
- Since PEI-bGP are larger building blocks than PPI-bGP they contribute more than 
the latter ones to the resulting Dh of the BHS. However, a high degree of biotin 
functionalization of the PPI-bGP results in comparable Dh of the BHS. 
PEG12B more efficient than C6B in case of monovalen bGP
C6B more efficient than PEG12B in case of bi- and tetravalen bGP
bGPs
avidin as central unit
∅ 9 - 15 nm│∅ 12 - 21 nm
avidin as linear unit
with few branches
∅ 8 - 23 nm│∅ 10 - 32 nm
avidin as central, linear 
and branched unit
∅ 14 - 50 nm│∅ 24 - 57 nm
but few up to 100 nm
monovalent
bivalent
tetravalent
NanostructuresBioconjugates
Biohybrid Structures
large BHS especially for
molar ratios of 1/0.5 and 1/1
mainly in solution
mainly in solution
PPI-BHS│PEI-BHS
1/1 or 1/2 adducts
less present in solution
1/1 or 1/2 adducts
less present in solution
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- The biotin functionalization of the high numbers of reactive surface groups of the 
hb polymers results in a loading distribution that is reported to be to be a normal 
distribution.
[223]
 Hence especially in the case of monofunctionalized bGP there are 
non-biotinylated GP present, which are not available for an avidin-biotin 
conjugation. 
 
 
4.1.4   Purification of BHS and Characterization of Purified BHS 
 
The investigation of certain avidin/PPI-bGP BHS by AF4-LS revealed that the conjugation 
solutions consist of three different species: (i) non-conjugated components, 
(ii) conjugation adducts and (iii) high molecular weight associates (denoted as 
nanostructures). In order to isolate the nanostructures from the rest of the components 
in the solution hollow fiber filtration (HFF) was applied to the raw conjugation solutions. 
Therefore the solutions were filtrated with up to 100 mL of a 0.1 M TRIS/HCl/NaCl buffer. 
The purification processes were followed by DLS and UV/Vis. Exemplarily, the HFF 
filtration of avidin/PPI-DS-PEG12B2 in a molar ratio of 1/1 purified with a HFF membrane 
with a molecular weight cut off (MWCO) of 300 kDa is shown in Figure 4.1.18. The DLS 
plot in Figure 4.1.18a shows increased Dh of the retentate with each filtration step, which 
indicates the removal of smaller particles. The comparison of the Dh of the initial particle 
composition with the final structure shows a growth of the BHS of up to ca. 7 nm. The DLS 
measurement of the filtrate shows the removal of particles with a Dh of about 5 - 11 nm 
(Figure 4.1.18b). With regard to the sizes of avidin and PPI-DS-PEG12B2 this can be 
attributed to both of them (Figure 4.1.18b). The UV/Vis measurements of the filtrate 
prooved the removal of avidin with every filtration step indicated by the absorbance at 
ʎ = 280 nm (A280 nm) (Figure 4.1.18c). This is supported by a decreasing A280 nm in the 
retentate with every filtration step (Figure 4.1.18d). The diameters determined by TEM 
match the Dh of the purified BHS (final structure) and show rather narrow particle size 
distribution (Figures 4.1.8e and f).  
Three independed HFF purifications of avidin/PPI-DS-PEG12B2 in 1/1 molar ratio showed 
Dh of about 15 nm and low SD of the initial compositions (Figure 4.1.19). Moreover, they 
are in agreement with the previous measurements shown in Figure 4.1.9. Due to the 
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removal of non-bound particles such as avidin and PPI-DS-PEG12B2, the purified BHS 
exhibit enlarged Dh of about 24 nm and also low SD. The Dh of about 30 nm of the 
resuspended lyophilisate was slightly larger and showed even lower SD than the non-
freeze dried one.  
 
Figure 4.1.18 HFF purification of avidin/PPI-DS-PEG12B2 1/1 with 300 kDa mPES membrane in 
0.1 M TRIS/HCl/NaCl at pH 7.5: a) DLS volume plot shows increase of the Dh of the 
BHS with ongoing filtration steps, b) DLS volume plot shows comparison of the Dh
of the initial compositions (∅ 13 nm), removed particles (∅ 8 nm) and the resulting 
particle composition (∅ 20 nm), c) and d) corresponding UV/Vis spectra of the 
retentates and filtrates of the filtration steps, e) TEM images of purified avidin/PPI-
DS-PEG12B2 and f) corresponding TEM particle size analysis of desalted samples. 
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Figure 4.1.19 Dh of non-purified (initial composition), purified (purified structure) avidin/PPI-DS-
PEG12B2 BHS and its resuspended lyophilisate determined by DLS in batch in 
0.1 M TRIS/HCl/NaCl at pH 7.5. 
 
HFF purification was also applied to other BHS with the main aim to probe whether the 
HFF purification can be applied to different BHS and which MWCO of the mPES 
membranes have to be used in order to ensure successful purifications. The used 
membranes, their MWCO and the Dh of the BHS before and after the purification as well 
as of the removed particles are summarized in Table 4.1.7.  
Purification of BHS of avidin/PPI-DS-PEG12Bx, x = 1 or 2 in an 1/1 or 1/2 molar ratio was 
probed with 100 kDa and 300 kDa HFF membranes. The purification of the BHS of 
avidin/PPI-DS-PEG12B1 in a 1/1 molar ratio resulted in Dh of the purified structures of 
about 14 – 15 nm, whereas the purification of the BHS of avidin/PPI-DS-PEG12B1 in a 1/2 
molar ratio resulted in Dh of the purified structures of about 18 – 21 nm. A similar Dh of 
about 20 – 22 nm was found for the purified avidin/PPI-DS-PEG12B2 in a 1/1 molar ratio 
and the purified BHS of avidin/PPI-DS-PEG12B2 in a 1/2 molar ratio show Dh of even 29 –
 33 nm (Table 4.1.7 and Figures A4.1.23 – A4.1.26). Nevertheless, the purification with the 
higher MWCO 300 kDa membranes should be preferred in order to aim an effective 
removal of smaller particles such as avidin bGP or conjugation adducts and hence a 
sufficient isolation of the nanostructures even though the purification with 100 kDa HFF 
membranes was found to work. 
After the purification of the BHS of avidin and the PPI-DS-PEG12B4 with 100 kDa and 
300 kDa membranes no particles were detected in the filtrates by DLS measurements, 
10
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which imply an insufficient purification process. Increased purification efficiency was 
achieved with the 500 kDa membrane. Particles with a Dh of about 14 nm were found to 
be removed. However, the most satisfying purification was obtained with the 0.2 µm 
membrane. The resulting BHS possessed Dh of about 180 nm and the Dh of about 117 nm 
of the particles in the filtrate.  
 
Table 4.1.7 Overview of Dh of removed particles as well as BHS before and after HFF purification.
a 
 
  MWCO of before HFF after HFF removed particles 
  mPES Dh Dh Dh 
avidin with  membranes [nm] [nm] [nm] 
PPI-DS-PEG12B1 1/1 
100 kDa 8 14 7 
300 kDa 9 15 8 
      
PPI-DS-PEG12B1 1/2 
100 kDa 11 21 8 
300 kDa 10 18 9 
      
PPI-DS-PEG12B2 1/1 
100 kDa 16 22 11 
300 kDa 13 20 8 
      
PPI-DS-PEG12B2 1/2 
100 kDa 25 33 14 
300 kDa 24 29 22 
      
PEI-DS-PEG12B2 1/1 
300 kDa 38 45 14 
500 kDa 37 44 13 
      
PPI-DS-PEG12B4 1/1 
100 kDa 119 131 n.a.
b 
300 kDa 159 138 n.a.
b 
500 kDa 104 112 14 
0.2 µm 142 179 117 
a
 corresponding DLS graphs can be found in appendix of chapter 4.1 Figures A4.1.23 – A4.1.28;
 
b 
n.a. = not available 
 
The raw conjugation solutions prepared for the purification with 100 kDa, 300 kDa, 
500 kDa and 0.2 µm HFF membranes consisted of particles with Dh ranging from about 
100 nm to 160 nm (Table 4.1.7) with multimodal size distributions (cf. Figure A4.1.27 and 
A4.1.28). Increased variations of the Dh of BHS of avidin and tetravalent bGP were already 
discussed in chapter 4.1.2. Moreover, the higher total mass concentration of 2.5 mg/mL 
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of the solutions prepared for the HFF purifications compared to the solutions of the DLS 
study with a total mass concentration of 0.6 mg/mL (cf. Figures 4.1.9j and A4.1.21a) 
caused even higher variations of the Dh of about 131 ± 21 nm. It is reasonable to assume 
that the multimodal size distribution is caused by further non-specific interactions, which 
became more likely due to the high concentration of the solution.  
Table 4.1.7 shows also two further important points: (i) lower molar ratios of avidin/PPI-
bGP facilitate not only the formation of larger BHS but also nanostructures. For instance, 
avidin/PPI-DS-PEG12B2 in an 1/1 molar ratio showed Dh of the nanostructures of about 
20 nm compared to an larger Dh of about 30 nm of purified avidin/PPI-DS-PEG12B2 in an 
applied 1/2 molar ratio. (ii) A higher biotinylation degree of the PPI-bGP resulted also in 
larger BHS at the same molar ratio. The Dh of the nanostructure of avidin/PPI-DS-
PEG12B1 in an 1/1 molar ratio is about 15 nm, whereas the nanostructure of avidin/PPI-
DS-PEG12B2 in an 1/1 molar ratio possess a Dh of about 20 nm. 
 
Figure 4.1.20 HFF purification in 0.1 M TRIS/HCl/NaCl at pH 7.5 of avidin/PEI-DS-PEG12B2 1/1 
with a) 300 kDa and b) 500 kDa mPES membranes; c) TEM image of avidin/PEI-DS-
PEG12B2 1/1 purified with 500 kDa mPES membranes, d) corresponding TEM 
particles size analysis of desalted samples. 
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The successful purification of avidin/PEI-DS-PEG12B2 in an 1/1 molar ratio with 300 kDa 
and 500 kDa membranes was proven by DLS as well (Figure 4.1.20). After the purifications 
size increase of the BHS to up to about 44 nm was found. The TEM images show rather 
monodisperse, spherical particles with a diameter range of about 30 – 40 nm 
(Figure 4.1.20c).  
In summary hollow fiber filtration was used in order to remove free avidin, PPI-bGP and 
their conjugation adducts from the crude conjugation solution and to isolate the 
nanostructures. The purification process followed by UV/Vis and DLS measurements 
confirmed the success of the particular purifications. Furthermore, it was shown that the 
HFF purification leads to reproducible Dh of the purified avidin/PPI-DS-PEG12B2 BHS, 
which showed even after lyophilization and resuspension Dh with low SD. Since HFF was 
successfully applied to a variety of differently composed and sized BHS, it has proven 
itself as a suitable technique for the isolation of such nanostructures. It was shown that 
BHS formed by mono- and bivalent PPI-bGP were properly purified by 300 kDa 
membranes.  
 
Table 4.1.8 Overview of conducted HFF purification with mPES membranes of different MWCOs 
and their purification efficiency.
 
 
  mPES membranes with MWCOs of 
  100 kDa 300 kDa 500 kDa 0.2 µm 
avidin with  Dh
b
 removal
c
 Dh
b
 removal
c
 Dh
b
 removal
c
 Dh
b
 removal
c
 
PPI-DS-PEG12B1 1/1 ☺ ☺ ☺ ☺
 
n.d. n.d. n.d. n.d. 
PPI-DS-PEG12B1 1/2 ☺ ☺ ☺ ☺ n.d. n.d. n.d. n.d. 
          
PPI-DS-PEG12B2 1/1 ☺ ☺ ☺ ☺ n.d. n.d. n.d. n.d. 
PPI-DS-PEG12B2 1/2 ☺ ☺ ☺ ☺ n.d. n.d. n.d. n.d. 
          
PEI-DS-PEG12B2 1/1 n.d. n.d. ☺ ☺ ☺ ☺ n.d. n.d. 
          
PPI-DS-PEG12B4 1/1 
 
   
c 
☺ ☺ ☺ 
 b
size increase of BHS, 
c
removal of smaller particles, n.d. not determined.  
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In the case of avidin/PPI-DS-PEG12B4 a removal of particles from the crude conjugation 
solution required purifications with 500 kDa and 0.2 µm membranes (cf. Table 4.1.8). 
Importantly, control of the sizes by the degree of biotinylation and ligand-receptor 
stoichiometry was also found for purified nanostructures. Furthermore, it was also shown 
that this purification technique can also be applied to BHS formed by avidin and PEI-bGP, 
which was additionally proven by TEM particle size analysis. 
 
 
4.1.5   Scaling Properties of BHS 
 
The successful isolation of the nanostructures was further studied by AF4-LS. The 
coupling of AF4 to dynamic and static light scattering was used in order to elucidate the 
scaling properties of the non-purified BHS and the purified BHS (nanostructure). The 
comparison of the AF4-LS-fractogram of the non-purified and purified BHS of avidin/PPI-
DS-PEG12B2 in a 1/1 molar ratio are shown in Figure 4.1.21. The RI-signal as well as the 
LS-signal of the non-purified BHS shows free PPI-DS-PEG12B2, free avidin, avidin/PPI-DS-
PEG12B2 conjugation adducts as well as nanostructures (Figure 4.1.21; blue line). This is 
in line with the findings of chapter 4.1.2 where the BHS of avidin/PPI-DS-C6B1 were 
investigated (cf. Figure 4.1.16). The reaction of avidin with PPI-DS-PEG12B2 in a 1/1 molar 
ratio resulted in an almost complete conversion of avidin and PPI-DS-PEG12B2 (Table 
4.1.9). Only 7 % of free PPI-DS-PEG12B2 and 11 % of free avidin were found in the crude 
conjugation solution. The increased conversion of both avidin and PPI-DS-PEG12B2 can be 
likely attributed to the higher biotinylation degree of the bivalent PPI-DS-PEG12B2. This is 
supported by the lower conversion of avidin and monovalent PPI-DS-C6B1 
(cf. Table 4.1.6).  
Furthermore, the conversion of avidin with PPI-DS-PEG12B2 in a 1/1 molar ratio yielded a 
1/1 conjugation adduct. The dispersities of almost one of the single components as well 
as of the 1/1 conjugation adduct reflect their well-defined nature (Table 4.1.9). The 
AF4-LS fractogram also indicates the formation of larger conjugation adducts, which were 
eluted at elution times between 15 – 17.5 min. However, the largest part of the total 
composition with almost 50 % is the nanostructure. The Rg values were determined for 
the conjugation adduct and the nanostructures. They are about 11 nm and 13 nm, 
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respectively. The Rh for the 1/1 conjugation adduct could not be properly determined 
since the Rh values showed a high scattering.  
The peaks of the single components such as avidin or PPI-DS-PEG12B2 of the RI- and 
LS-signals completely vanished after the purification step. Only a single peak of the 
nanostructures was detected (Figure 4.1.21 – blue lines vs. red lines). The dispersity of the 
purified nanostructure is higher compared to those of the single components and the 
conjugation adduct, which reflects the nanostructure´s irregular shape and high molar 
masses (Table 4.1.9).  
AF4 coupled to static and dynamic light scattering also provides important 
conformational information. One conformational parameter is the ratio between Rg and 
Rh, the so called ρ-parameter (cf. Table 4.1.9). The Rg/Rh values of the non-purified and 
purified nanostructures are both higher than 1.7, which indicates anisotropic or 
elongated shapes.
[238]
 
 
Figure 4.1.21 AF4-LS fractogram with RI- (dashed lines) and LS-signals (solid lines) and molar 
masses (squares) of non-purified (blue) and purified (red) avidin/PPI-DS-PEG12B2 
BHS. Samples were measured in 50 mM nitrate buffer (pH of 6.8) and 0.02 % (w/v) 
NaN3. 
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Table 4.1.9 Summary of molar masses, dispersity, radius of gyration (Rg) and hydrodynamic 
radius (Rh) of single components and resulting (non-)purified nanostructures. 
 
 
By plotting Rg or Rh vs. molar mass, the conformational factor ν can be determined as the 
slope of the plot. The ν factor of the non-purified sample is about 0.35 for both Rg and Rh 
plotted vs. molar mass (Figure 4.1.22a and b – blue closed squares). These values are very 
close to 0.33, which is attributed to a hard sphere, whereas for instance a value of 
0.5 - 0.6 represents random coil macromolecules in a good solvent.
[191]
  
In the case of the purified nanostructure ν (Rg) and ν (Rh) are about 0.36 and 0.48, 
respectively. Consequently, an intermediate conformation between a hard sphere and a 
random coil can be assumed such as branched structures.  
The Rg values of the non-purified BHS range between 10 – 20 nm and continiously merge 
in the Rg values of the purified BHS, which range from 20 – 100 nm (Figure 4.1.22a). The 
Rh values, in contrast, are lower than the corresponding Rg values. They display sizes 
between 3 – 8 nm for the non-purified BHS and about 9 – 60 nm for the purified ones 
(Figure 4.1.22b).  
A third conformational parameter is the so called apparent density, which is a measure of 
the molecular compactness of the structures in solution. With increased molar mass the 
apparent densities decrease in the case of both the non-purified and purified BHS 
(Figure 4.1.22). 
 Mn Mw Ð part
a 
Rh Rg Rg/Rh 
 [g/mol] [g/mol] Mw/Mn [%] [nm] [nm]  
non-purified 
PPI-DS-PEG12B2 47500 48800 1.02 7 - - - 
avidin 69400 69800 1.01 11 - - - 
avidin/PPI-DS-PEG12B2 
1/1 conjugation adduct 
134000 138000 1.03 36 -
b 
11 - 
nanostructure 381000 521000 1.37 46 5 13 2.50 
purified 
nanostructure 7030000 20180000 2.87 100 34 60 1.76 
a 
represents the percentage of the final composition; 
b
 correct determination hampered due to 
high scattering of the Rh values. 
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Figure 4.1.22 Scaling properties of non-purified (blue) and purified (red) BHS of avidin/PPI-DS-
PEG12B2 in an 1/1 molar ratio a) Rg (closed squares) and corresponding apparent 
density (open squares) vs. molar mass and b) Rh (closed squares) and 
corresponding apparent density (open squares) vs. molar mass of the non-purified 
and purified structures determined by AF4-LS. 
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This is reasonable considering that in the non-purified conjugation solution a conjugation 
adduct is present, which possess molar masses of about 134000 g/mol. This implies a 
structural change from a rather compact, less flushed shape (single components, 
conjugation adduct) into looser arranged associates formed by further non-specific 
interactions such as hydrogen bonding (nanostructure).  
 
 
4.1.6   Summary 
 
In summary bGP were synthesized, which exhibit 1, 2, 4 or 8 biotin ligands. The 
biotin ligands possess either a short C6- or a longer PEG12-spacer. The dendritic scaffold 
was either a 4
th
 generation perfectly branched poly(propylene imine) dendrimer or a 
hyperbranched poly(ethylene imine) polymer. The bGP were characterized by a variety of 
analytical methods such as NMR spectroscopy, AF4-LS, LILBID MS, elemental analysis and 
HABA titrations in order to prove the coupling of the surface species and to determine the 
molar masses of the precursors as well as of the bGP. MALDI-TOF MS was additionally 
used in order to prove the covalent binding of the biotin ligands to the PPI scaffold and to 
gain insight about the loading distribution of the biotin ligands. Additionally, the 
fragmentation mechanisms of the investigated PPI-C6Bx were discussed and attributed to 
the most abundant fragmentation pathways. 
Furthermore, the size of various avidin/bGP stoichiometries were investigated in three 
independent trails and measured after one day and 14 days in order to probe the stability 
of BHS. The DLS study showed that BHS formed by avidin and mono- or bivalent bGP 
showed good stability and reproducibility in sizes, which was not dependent on the 
dendritic scaffold.  
Increased SD of the Dh were mainly found in the case of BHS based on tetravalent bGP. In 
this regard, the PEI-BHS revealed higher changes in Dh after 14 d than the PPI-BHS. Dh of 
BHS based on avidin and octavalent PPI-bGP with molar ratios larger than 1/1.5 possessed 
little reproducibility and/or partly bimodal size distributions. However, Dh of more than 
1 µm were obtained for the 1/1 molar ratio.  
Selected avidin/bGP BHS were additionally imaged by TEM. These results showed that in 
the case of the BHS based on mono- and bivalent PPI-bGP the particle sizes obtained by 
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TEM are larger than those observed by DLS. This was a further indication for the presence 
of non-bound particles in the conjugation solution. This assumption was further 
consolidated through the determination of the amount of bound bGP to avidin. The 
conducted HABA displacement assay revealed that only one half of the bGP are coupled 
to avidin although a hampering effect of HABA cannot be ruled out. 
LILBID MS and AF4-LS studies of selected BHS were conducted in order to get deeper 
insight in the composition of the conjugation solution. It revealed that different 
components are present in solution. Next to free avidin and free bGP also smaller 
conjugation adducts and high molecular weight nanostructures were found. 
Consequently, a purification method was applied to the raw conjugation solution in order 
to isolate the nanostructures, which was the largest fraction. HFF membranes possessing 
different MWCO were used in order to purify differently sized nanostructures. Here, it 
was additionally found that the sizes and size distributions of the BHS composed of avidin 
and PPI-DS-PEG12B4 are concentration dependent. High concentrations caused 
multimodal size distributions, which can be preferentially attributed to additional 
aggregation processes taking place in solution at high concentrations.  
The successful purification of selected BHS was proven by DLS, UV/Vis and TEM. 
Furthermore, lyophilization of the purified avidin/PPI-DS-PEG12B2 BHS was successfully 
applied. Even though the Dh of resuspended sample was found to be slightly larger 
compared to the Dh of the non-freeze dried sample they showed lower SD.  
Finally, the non-purified and purified avidin/PPI-DS-PEG12B2 BHS was profoundly 
investigated with regard to its scaling properties. The purified BHS was found to be a 
highly hydrated, loose and complex network possessing a geometry between a sphere 
and a random coil with anisotropy in shape. 
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4.2   Enzymatic BHS Based on Avidin and Biotinylated Dendritic Glycopolymers 
 
The previous chapter showed that the sizes of avidin/bGP BHS can be fine-tuned by 
the bGP´s degree of biotinylation and the ligand-receptor stoichiometry. Furthermore, 
along with the fact that BHS composed of avidin and bGP possess the potential to 
facilitate passive and active targeting – due to their high molecular weights and their 
inherent targeting moieties – the additional attachment of an enzyme makes them 
suitable vehicles in directed enzyme prodrug cancer therapies (DEPT). For this purpose, 
the choice of the enzyme is of great importance. So far different enzymes of mammalian 
and non-mammalian origin have been investigated such as the mammalian enzyme 
cathepsin B or non-mammalian enzyme β-lactamase. The use of cathepsin B for DEPT 
requires the bridging of e.g. doxorubicin, a widely known anticancer agent, with a 
cleavable peptide sequence. β-lactamase can be used to cleave β-lactam rings containing 
prodrugs e.g. cephalosporine containing doxorubicin.
[239]
  
In general, human enzymes may seem to be a good choice since they possess less 
potential to provoke immunogenic reactions. However, a main drawback is their ability to 
activate circulating prodrugs wherever they are naturally located. Non-human enzymes, 
on the contrary, offer a high specificity once they have reached the target tissue, but may 
exhibit higher toxicity and induce an immune response.
[58]
 One enzyme-prodrug system 
of interest is horseradish peroxidase/indole-3-acetic acid. It was found that neither the 
horseradish peroxidase (HRP) nor the indole-3-acetic acid (IAA) harm cells.
[59]
 
Furthermore, the HRP/IAA is very attractive since there is no need for the addition of 
H2O2. Even though IAA was reported to induce some reduction in the glucose levels, it 
was found to be non-toxic for the human body even if applied in high dosis.
[240]
 Since HRP 
transforms IAA into cytoxins, this enzyme prodrug combination has been proposed for 
anticancer therapy.
[241]
 The apoptotic effects of HRP/IAA have been studied in vitro on 
various cell types such as human melanoma cells,
[242, 243]
 pancreatic cancer cells,
[244, 245]
 
human leukemia cell line K562
[246]
 or in human urinary bladder carcinoma cells.
[247]
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HRP is a commercially available protein and finds manifold applications in biology or 
biochemistry, in chemiluminescent or immunoassays. HRP contains heme and 
carbohydrates and is found in the roots of the plant horseradish. Its first denoted 
observation was by Louis Antoine Planche in 1810. HRP has the ability to oxidize certain 
substrates in the presence of hydrogen peroxide. Common substrates of HRP are, for 
instance, phenolic acids, indoles, amines, sulfonates and aromatic phenols.
[248]
  
In this part of the work different enzymatic BHS were fabricated and analyzed with 
respect to their properties such size, shape or enzymatic activity by different analytical 
methods such DLS, (cryo)TEM and AF4-LS. UV/Vis spectroscopy was used in order to 
determine the amount of bound bGP and biotinylated horseradish peroxidase (bHRP) 
attached to avidin by HABA displacement assay as well as to measure the enzymatic 
activities. 
Importantly, for an adoption of the DEPT strategy into avidin/PPI-bGP/enzyme BHS the 
enzyme activity is a crucial factor. Furthermore, it is known that the immobilization of 
enzymes may restore and/or enhance the enzymatic activity
[249]
 – an important 
prerequisite for an effective DEPT. In this respect, the attachment of bHRP to avidin layers 
has shown to preserve or even enhance the bHRP´s activity.
[250]
 Thus, in this chapter it 
was evaluated to what content the attachment of the enzyme alters its enzymatic 
activity. 
As a substrate pyrrogallol was chosen, which is converted to purpurrogallin in the 
presence of (b)HRP and H2O2. The absorbance maximum of purpurrogallin at ʎ = 420 nm 
(A420 nm) allows observing its production by UV/Vis spectroscopy. The bHRP is a conjugate 
of HRP substituted by 6-((6-((biotinoyl)amino)hexanoyl) amino)hexanoic acid (C6-C6B) at 
the N-terminus of the enzyme. The biotin ligand´s chemical structure is shown in 
Figure 4.2.1. The degree of biotinylation was specified by the supplier to be 2.4.  
This chapter is divided into three main parts and deals with the interaction of avidin and 
the compounds summarized in Table 4.2.1.  
 
Figure 4.2.1 Chemical structure of the HRP´s biotin ligand (C6-C6B). 
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Table 4.2.1 Overview of components used for the fabrication of enzymatic BHS including their 
properties. 
 
component Ligand 
Number of 
Ligands 
M 
[g/mol] 
Number of 
Maltose
 Precursor 
M
e 
[g/mol] 
proteins       
avidin - - 66000
a
 - - - 
HRP - - 44000
a
 - - - 
bHRP C6-C6B 2.4
a 
45300
a
 - - - 
PPI-bGP       
PPI-DS-PEG12B1
 
PEG12B 1.1
b
 45900
c 
116 (126)
d 
PPI-PEG12B1 8000
e 
PPI-DS-C6B4
 
C6B 3.6
b
 47650
c 
120 (120)
d 
PPI-C6B4 8500
e 
a 
specified by supplier.
 b 
Number of biotin ligands was determined by avidin-4′-hydroxyazobenzene-
2-carboxylic acid (HABA) complex using a specific activity of avidin of 13.6 Units/mg. 
c 
determined 
by LILBID MS (cf. Figure A4.1.10b and A4.1.11b).
 d 
Number of maltose units determined through 
LILBID MS with theoretical values in brackets. 
e 
M was determined by Mn of particular dendritic 
polymer and the attached ligands. 
 
The first part of this chapter concerns BHS composed of avidin, bHRP and PPI-DS-
PEG12B1. A schematic picture of the conversion of avidin with bHRP and PPI-DS-PEG12B1 
is given in Figure 4.2.2. The chapter deals with: (i) probing the successful coupling of the 
enzyme to the avidin/PPI-bGP BHS; (ii) time stability of enzymatic activity of the BHS; (iii) 
influence on the enzymatic activity, when the enzyme is coupled to or only mixed with 
the avidin/PPI-bGP BHS. For this purpose (biotinylated) bHRP and (non-biotinylated) HRP 
were used, respectively.  
The second part deals with larger BHS, composed either of avidin/PPI-DS-C6B4/bHRP or 
of avidin/bHRP/PPI-DS-C6B4 BHS fabricated by different stepwise approaches.  
In this part the following tasks will be processed: (i) applying different formation 
approaches in the sequential fabrication of the enzymatic BHS and elucidation of its 
influence on e.g. the coupling efficiency or sizes of the BHS, (ii) enzymatic activity of the 
BHS. A schematic representation of the formation of avidin/PPI-DS-C6B4/bHRP and 
avidin/bHRP/PPI-DS-C6B4 BHS is shown in Figure 4.2.3.  
In the third part the avidin/PPI-DS-C6B4/bHRP and avidin/bHRP/PPI-DS-C6B4 BHS were 
chosen for HFF purification. The purification process was followed by DLS and UV/Vis 
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spectroscopy. The purified BHS were analyzed with respect to their enzymatic activity and 
were imaged by TEM and cryoTEM, respectively. Moreover, a selected purified enzymatic 
BHS were analyzed by AF4-LS with respect to their molar mass, PDI, Rg and Rh.  
It has to be noted that Figure 4.2.2 and Figure 4.2.3 mainly aim to describe formation 
approaches and do not demand to illustrate the real composition of the formed BHS with 
respect to the results of chapter 4.1, which showed the conversion of avidin with bGP 
yields conjugation adducts and nanostructures of avidin and the bGP. 
 
Figure 4.2.2 Schematic representation of the conversion of avidin with bHRP and PPI-DS-
PEG12B1. The conversion of avidin with non-biotinylated HRP and PPI-DS-PEG12B1 
is not shown. 
 
 
Figure 4.2.3 Schematic representation of the formation of a) avidin/bHRP/PPI-DS-C6B4 and 
b) avidin/PPI-DS-C6B4/bHRP BHS. 
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4.2.1   Time Stability and Influence of the Attachment of Biotinylated Horseradish 
Peroxidase on the Enzymatic Activity 
 
BHS composed of avidin/bHRP/PPI-DS-PEG12B1 in a 1/0.25/1 molar ratio – In the 
case of the enzymatic BHS two different compounds were coupled to avidin. Therefore a 
stepwise fabrication approach was used. The first investigated enzymatic BHS was 
composed of avidin, monovalent PPI-DS-PEG12B1 and the bivalent bHRP. Avidin was first 
converted with bHRP. The conjugation solution was allowed to equilibrate for about one 
day before the PPI-DS-PEG12B1 was added. The resulting conjugation solution composed 
of avidin/bHRP/PPI-DS-PEG12B1 was investigated by DLS and HABA displacement assay 
after one more day of equilibration. The same formation approach was used for 
avidin/HRP/PPI-DS-PEG12B1. Since HRP contains no biotin ligand it can be assumed that 
the final solution is composed of avidin/PPI-DS-PEG12B1 BHS next to free HRP. This 
sample was only studied with regard to its enzymatic activity. The investigated BHS and 
the amount of bound biotinylated compound are summarized in Table 4.2.2. In line with 
the findings of chapter 4.1, the HABA displacement assay results indicate no complete 
conversion of the enzyme and of the PPI-DS-PEG12B1 after the reaction with avidin. The 
amount of bound biotinylated macromolecules indicates that only about one half of the 
compounds are coupled to avidin.  
 
Table 4.2.2 Investigated BHS based on avidin, monovalent PPI-DS-PEG12B1 and (b)HRP and 
amount of bound biotinylated compounds.
a
 
 
 amount of bound biotinylated compounds 
BHS applied molar ratio real molar ratio 
avidin/HRP/PPI-DS-PEG12B1 1/0.25/1 n.d. 
avidin/bHRP/PPI-DS-PEG12B1 1/0.25/1 1/0.12/0.4 
a
 based on the titration of [avidin.HABA] with biotin. 
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Figure 4.2.4 shows the DLS results of the stepwise conversion of avidin with PPI-DS-
PEG12B1 and bHRP. The intermediate avidin/bHRP BHS and the final avidin/bHRP/PPI-DS-
PEG12B1 BHS showed increased Dh compared to the Dh of the single components (avidin, 
bHRP and PPI-DS-PEG12B1) of about 5 – 7 nm. They possessed Dh of 10 nm and 13 nm, 
respectively. Despite the results of the HABA displacement assay this clearly indicates the 
formation of BHS. 
 
Figure 4.2.4 DLS volume plot of the single components avidin, bHRP, PPI-DS-PEG12B1, 
intermediate avidin/bHRP BHS and final avidin/bHRP/PPI-DS-PEG12B1 BHS in 0.1 M
TRIS/HCl/NaCl at pH 7.5. 
 
Enzymatic activities of avidin/(b)HRP/PPI-DS-PEG12B1 BHS – The conversion of 
pyrrogallol to purpurogallin in the presence of (b)HRP and H2O2 is illustrated in 
Figure 4.2.5. Purpurrogallin absorbs at ʎ = 420 nm, which can be used in order to follow 
the conversion of pyrrogallol. As a first step, the appropriate concentration of the enzyme 
for the conversion of pyrrogallol to purpurogallin in the presence of hydrogen peroxide 
was determined. 
 
 
Figure 4.2.5 Conversion of pyrrogallol to purpurogallin by (b)HRP in the presence of H2O2. 
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In order to ensure a linear increase of A420 nm of purpurrogallin in the range of 0.1 – 0.6 for 
the first 20 s an enzyme concentration of 0.005 mg/mL was found to be appropriate. The 
A420 nm values of the first four minutes of the conversion of pyrrogallol to purpurogallin in 
the presence and absence of 0.005 mg/mL (b)HRP promoted by H2O2 is shown in 
Figure 4.2.6. A linear fit of the first 20 s was applied in order to verify the linear increase 
of A420 nm. The obtained regression equations of the conversions of pyrrogallol in the 
presence of H2O2, HRP with H2O2 and bHRP with H2O2 are also depicted in Figure 4.2.6. 
The determination coefficients (R
2
) are very close to 1, indicating that the absorbance 
values of the first 20 s can be fitted properly by a linear regression. 
 
Figure 4.2.6 Conversion of pyrrogallol to purpurrogallin by H2O2, H2O2 with HRP and H2O2 with 
bHRP in 0.1 M phosphate buffer at pH 7.4 results in an increase of A420 nm. The red 
lines represent the linear regressions of the first 20 s. 
 
The slope of the first 20 s was used in order to determine the activity values of the (b)HRP 
containing samples. As expected, the conversion of pyrrogallin was tremendously 
accelerated in the presence of the enzyme. In the following, relative activities were 
determined in order to compare the activity levels of avidin/HRP/PPI-DS-PEG12B1 with 
avidin/bHRP/PPI-DS-PEG12B1. The results of the investigation of the enzymatic activity 
over seven days of avidin/HRP/PPI-DS-PEG12B1 and avidin/bHRP/PPI-DS-PEG12B1 are 
shown in Figure 4.2.7. 
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Figure 4.2.7 a) Relative enzymatic activity of HRP in avidin/HRP/PPI-DS-PEG12B1 and b) Relative 
enzymatic activity of bHRP in avidin/bHRP/PPI-DS-PEG12B1 compared to pure 
(b)HRP. The conversion of pyrrogallol to purpurogallin were measured in 0.1 M 
phosphate buffer at pH 7.4 at room temperature after 1 d, 2 d, 4 d and 7 d by UV/Vis 
spectroscopic measurements at A420 nm. All samples possessed the same content of 
(b)HRP. 
 
The relative enzymatic activity of HRP in avidin/HRP/PPI-DS-PEG12B1 showed values in all 
probed intervals, which were similar to or even higher as the pure HRP (Figure 4.2.7a). 
The bHRP in avidin/bHRP/PPI-DS-PEG12B1 show a rather different behavior 
(Figure 4.2.7b). The activity values of avidin/bHRP/PPI-DS-PEG12B1 are not as stable as in 
the case of avidin/HRP/PPI-DS-PEG12B1. After one day and four days the activity values 
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dropped down to almost 80 %. By contrast, at two days and seven days the activity rose 
even above 100 %. The observed variations of the enzymatic activity are in the range 
82 % - 107 % in the case of avidin/bHRP/PPI-DS-PEG12B1 compared to 96 % - 109 % for 
avidin/HRP/PPI-DS-PEG12B1. This indicates a dependence of the enzymatic activity on the 
bound or non-bound state of bHRP to avidin/PPI-DS-PEG12B1 BHS inducing higher 
variations in the average enzymatic activities over seven days. The higher variations of 
enzymatic activities of avidin/bHRP/PPI-DS-PEG12B1 are contrasted by the rather stable 
enzymatic activities of avidin/bHRP. Thus the attachment of the PPI-DS-PEG12B1 alters 
the stability of the enzyme embedded in the avidin/bHRP/PPI-DS-PEG12B1. This may be 
caused by a change in the tertiary structure of the enzyme due to structural rigidity. A 
suboptimal orientation of the enzyme bound to avidin/PPI-DS-PEG12B1 due to changes in 
its tertiary structure may also lead to decreased enzymatic activity. Consequently, the 
variations in the enzymatic activity may be also a result of structural rearrangements of 
the avidin/bHRP/PPI-DS-PEG12B1 BHS. Those structural rearrangements of the 
avidin/bGP BHS were already discussed in chapter 4.1.  
In this regard it can be concluded that bHRP in an unbound state or placed in an optimal 
orientation, for instance in the outer sphere of the avidin/bHRP/PPI-DS-PEG12B1 BHS, 
should provide a higher enzymatic activity. This is additionally supported by the finding 
that HRP in the avidin/HRP/PPI-DS-PEG12B1 mixture showed rather stable enzymatic 
activities over 7 days. Despite these variations in the activity values the BHS composed of 
avidin/bHRP/PPI-DS-PEG12B1 showed no persistent loss of enzymatic activity for up to 
seven days.  
 
 
4.2.2   Influence of Different Sequential Conjugation Steps on BHS Properties 
 
BHS composed of avidin/bHRP/PPI-DS-C6B4 or avidin/PPI-DS-C6B4/bHRP in a 
1/0.5/0.5 molar ratio – Another pivotal question was, whether the formation sequence 
or the valence of the biotinylated PPI-bGP has any impact on the properties of the 
enzymatic BHS. Therefore two systems were probed: (i) avidin/bHRP/PPI-DS-C6B4 and 
(ii) avidin/PPI-DS-C6B4/bHRP. Both of them are fabricated with the bivalent bHRP and the 
tetravalent PPI-DS-C6B4. As a first step, the stepwise formation of these BHS were 
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investigated by HABA displacement assay (Table 4.2.3) and DLS (Figure 4.2.8). Here again 
no complete conversions of the biotinylated compounds were observed. But, in general, 
the amount of bound PPI-DS-C6B4 was higher than that of the bHRP irrespective of 
whether it was added to pure avidin or to the intermediate avidin/PPI-DS-C6B4 BHS. The 
lower amount of attached bHRP in the intermediate BHS avidin/bHRP of 0.11, compared 
to an amount of 0.2 of PPI-DS-C6B4 in the intermediate avidin/PPI-DS-C6B4 BHS, is also 
reflected by the Dh of these intermediate BHS.  
Avidin/bHRP possess a Dh of 14 nm (Figure 4.2.8b), whereas avidin/PPI-DS-C6B4 has 
almost a twice as large Dh of about 26 nm (Figure 4.2.8a). Also the final BHS of 
avidin/bHRP/PPI-DS-C6B4 shows smaller Dh of about 21 nm compared to avidin/PPI-DS-
C6B4/bHRP BHS with a Dh of 35 nm. Compared to avidin/bHRP BHS, the size increase of 
avidin/bHRP/PPI-DS-C6B4 BHS amounted to about 7 nm (Figure 4.2.8a). The size increase 
from avidin/PPI-DS-C6B4 BHS to avidin/PPI-DS-C6B4/bHRP BHS was larger and about 
10 nm (Figure 4.2.8b). 
 
Table 4.2.3 Investigated BHS based on avidin, PPI-DS-C6B4 and bHRP and amount of bound 
biotinylated compounds.
a
 
 amount of bound biotinylated compounds 
BHS applied molar ratio real molar ratio 
avidin/PPI-DS-C6B4/bHRP 1/0.5/0.5 1/0.2/0.15 
avidin/bHRP/PPI-DS-C6B4 1/0.5/0.5 1/0.11/0.32 
a
 based on the titration of [avidin.HABA] with biotin. 
 
The lower increase in size of the intermediate avidin/bHRP BHS to the final 
avidin/bHRP/PPI-DS-C6B4 BHS compared to the size increase of the intermediate 
avidin/PPI-DS-C6B4 BHS to the final avidin/PPI-DS-C6B4/bHRP BHS can be explained by 
the length of the biotin ligand attached to the HRP. This longer C6-C6B ligand attached to 
bivalent bHRP facilitates a better access to the avidin binding sites. In opposite, the short 
C6B ligands of the tetravalent PPI-DS-C6B4 are shielded by the maltose shell resulting in a 
lower accessibility for the avidin binding site in the final conjugation step. Thus the 
sequence of bHRP and PPI-DS-C6B4 addition to avidin influences the size of the final Dh of 
the BHS with respect to the length of the biotin ligands of bHRP and PPI-DS-C6B4. As one 
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reason for the low conversion of bHRP with avidin electrostatic repulsion can be 
considered. Both of them are positively charged at a pH of 7.5 since avidin possess an 
isoeletric point of 10
[251]
 and bHRP one of > 9.
[252]
 The PPI-bGP, on the other hand, 
exhibits a zetapotential of zero at a pH of approximetly 8 (Figure A4.2.1). Consequently, 
the electrostatic repulsion of avidin and the PPI-bGP is lower, compared to avidin and 
(b)HRP. This result in a higher amount of PPI-DS-C6B4 bound to avidin compared to the 
amount of bound bHRP in the respective avidin/PPI-DS-C6B4 and avidin/bHRP BHS. 
Moreover, it can be assumed that the lower degree of biotinylation of 2.4 of bHRP 
compared to the tetravalent PPI-DS-C6B4 lowers the bHRP´s prospensity to undergo 
avidin-biotin conjugation.  
 
Figure 4.2.8 DLS volume plots of the single components avidin, bHRP and PPI-DS-C6B4 with
a) intermediate avidin/bHRP BHS as well as avidin/bHRP/PPI-DS-C6B4 BHS and 
b) intermediate avidin/PPI-DS-C6B4 BHS as well as avidin/PPI-DS-C6B4/bHRP BHS in 
0.1 M TRIS/HCl/NaCl at pH 7.5. 
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Enzymatic activities of BHS composed of avidin, bHRP and PPI-DS-C6B4 – In Figure 4.2.9 
it can be seen that the enzymatic activities of avidin/bHRP/PPI-DS-C6B4 and avidin/PPI-
DS-C6B4/bHRP BHS are rather stable and very close to the reference values of bHRP. The 
enzymatic activity of avidin/bHRP/PPI-DS-C6B4 amounts to 89 % - 96 % whereas 
enzymatic activity of avidin/PPI-DS-C6B4/bHRP is in the range of 94 % - 109 %. 
Interestingly, the enzymatic activity of avidin/PPI-DS-C6B4/bHRP BHS is slightly higher 
than those of avidin/bHRP/PPI-DS-C6B4 BHS. Since both BHS showed very similar 
enzymatic activities compared to pure bHRP and no substantial loss of them, they were 
chosen for HFF purifications. 
 
Figure 4.2.9 Relative enzymatic activity of bHRP in avidin/bHRP/PPI-DS-C6B4 or avidin/PPI-DS-
C6B4/bHRP compared to bHRP after 1 d and 2 d. Activity values were obtained by 
the conversion of pyrrogallol to purpurogallin by bHRP in the presence of H2O2 in 
0.1 M phosphate buffer at pH 7.4 at room temperature. The conversion was 
measured by the A420 nm by UV/Vis spectroscopic measurements. All samples
possessed the same content of bHRP. 
 
 
4.2.3   Purification and Characterization of Purified Enzymatic BHS 
 
In chapter 4.1 it was shown that the raw conjugation solution consists of free bGP 
and/or avidin, conjugation adducts and nanostructures. Taking this into account, it is 
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likely to assume such heterogeneity in composition for the enzymatic BHS as well. 
Consequently, HFF purification was applied to avidin/bHRP/PPI-DS-C6B4 and avidin/PPI-
DS-C6B4/bHRP BHS. Furthermore, it had to be considered that also conjugation adducts 
composed of avidin, bHRP and/or PPI-DS-C6B4 may be present in the solution. Hence a 
HFF membrane was chosen with a MWCO of 500 kDa in order to ensure a sufficient 
isolation of the nanostructures. According to chapter 4.1, the HFF purifications were 
conducted by filtration of the crude conjugation solution with about 100 mL of 0.1 M 
TRIS/HCl/NaCl buffer at a pH of 7.5.  
 
DLS and UV/Vis results of the purification process – The crude conjugation solution 
(initial composition of the BHS), the purified conjugation solution (final structure or 
retentate) and the removed particles in the filtrate were examined by DLS and UV/Vis 
spectroscopy. The corresponding DLS results of the non-purified and purified enzymatic 
BHS as well as of the removed particles are shown in Figure 4.2.10. Figure 4.2.10a shows 
the corresponding DLS results of the HFF purification of avidin/bHRP/PPI-DS-C6B4. The 
removed particles exhibit Dh of about 15 nm and possess a monomodal size distribution. 
Since the single components have a Dh of about 5 – 7 nm (cf. Figure 4.2.8), it seems likely 
that the removed particles with an Dh of 15 nm also consist of conjugation adducts such 
as avidin/bHRP, avidin/PPI-DS-C6B4 or avidin/bHRP/PPI-DS-C6B4 next to free avidin, 
bHRP and/or PPI-DS-C6B4. The crude conjugation solution (initial composition) of 
avidin/bHRP/PPI-DS-C6B4 BHS shows a bimodal size distribution, which reflects the 
heterogeneity of the sample. Furthermore, the DLS volume distribution of the 
non-purified avidin/bHRP/PPI-DS-C6B4 BHS (Figure 4.2.10a) hardly match the DLS volume 
distribution of [avidin.HABA]/bHRP/PPI-DS-C6B4 BHS shown in Figure 4.2.8a. One 
important point that has to be taken into account is that the solution of avidin/bHRP/PPI-
DS-C6B4 BHS for the HFF purification is prepared with a higher total mass concentration 
(ca. 2.5 mg/mL) than the [avidin.HABA]/bHRP/PPI-DS-C6B4 BHS (ca. 0.6 mg/mL). Such an 
observation of multimodal size distributions caused by high concentrations was already 
discussed in chapter 4.1, concerning the purifications of the avidin/PPI-DS-PEG12B4 BHS 
(cf. Figures A4.1.21 vs. A4.1.27 and A4.1.28). The first peak of the bimodal size 
distribution of the non-purified avidin/bHRP/PPI-DS-C6B4 BHS has a Dh of about 12 nm 
and indicates the presence of smaller non-bound particles. The second peak possess a Dh 
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of about 32 nm, which is even larger than the monomodal peak obtained for the 
[avidin.HABA]/bHRP/PPI-DS-C6B4 BHS of about 21 nm (Figure 4.2.8a). However, this 
bimodal size distribution completely vanished after the purification and a size increase of 
up to 34 nm was observed. The formation of avidin/PPI-DS-C6B4/bHRP BHS at higher 
total mass concentration of about 2.5 mg/mL resulted even in a trimodal size distribution. 
 
Figure 4.2.10 DLS volume plots of HFF purification samples of a) avidin/bHRP/PPI-DS-C6B4 BHS 
and b) avidin/PPI-DS-C6B4/bHRP BHS in 0.1 M TRIS/HCl/NaCl at pH 7.5. 
HFF purification was done with a 500 kDa mPES membrane. 
 
Dh of about 22 nm, 100 nm and 290 nm were found in the DLS volume plot 
(Figure 4.2.10b). This is contrasted by the monomodal size distribution of the 
[avidin.HABA]/PPI-DS-C6B4/bHRP BHS with an Dh of about 35 nm at lower total mass 
concentration (Figure 4.2.8b). The conversion of avidin with bHRP and PPI-DS-C6B4 at 
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higher total mass concentration mainly led to BHS with a Dh of about 22 nm 
(Figure 4.2.10b), compared to a Dh of about 35 nm in the case of [avidin.HABA]/PPI-DS-
C6B4/bHRP BHS (Figure 4.2.8b). Furthermore, it facilitated the formation of larger 
aggregates with Dh of 100 nm and almost 300 nm. The multimodal size distribution 
vanished as well after the purification step and a monomodal size peak of the purified 
avidin/PPI-DS-C6B4/bHRP BHS of about 83 nm in Dh were found. Purified avidin/PPI-DS-
C6B4/bHRP BHS possess a larger Dh of 83 nm compared to 34 nm of the purified 
avidin/bHRP/PPI-DS-C6B4 BHS (Figure 4.2.10).  
The formation of larger BHS composed of avidin/PPI-DS-C6B4/bHRP compared to 
avidin/bHRP/PPI-DS-C6B4 BHS was also found at lower total mass concentrations 
(cf. Figure 4.2.8). 
The corresponding UV/Vis spectra of the retentates and filtrates of the particular 
filtration steps are shown in Figure 4.2.11. Due to aromatic amino acids the presence of 
proteins in the retentates and filtrate solutions can be identified through A280 nm. 
Furthermore, bHRP can further be identified by its maximum absorbance at ʎ = 400 nm 
(A400 nm). An overview spectrum of bHRP at different concentrations is given in the 
appendix of chapter 4.2 in Figure A4.2.2. Figure 4.2.11a shows decreased A280 nm of 
avidin/bHRP/PPI-DS-C6B4 BHS within the first two filtration steps. Since this indicates the 
removal of proteins it can be attributed to avidin and/or bHRP. The removal of bHRP is 
also indicated by the decreased A400 nm within the first two purification steps. In the next 
three purification steps the A280 nm and A400 nm stagnated. The absorbance spectra of the 
filtrates (solution with removed particles) show also a decreased A280 nm and A400 nm with 
every particular filtration step (Figure 4.2.11b). This implies a diminished amount of 
removed avidin and/or bHRP with every filtration step as well, strongly indicating no need 
for further purification.  
Similar results were found for the purification of avidin/PPI-DS-C6B4/bHRP BHS. 
Figures 4.2.11c and d depict the corresponding UV/Vis spectra of the retentates and 
filtrates. Perceptible drops in A280 nm and A400 nm values imply a distinct removal of 
proteins within the first two purification steps. The values of A280 nm and A400 nm stagnated 
at almost constant levels for next the three purification steps. Figure 4.2.11d also shows 
that with every purification step the amount of removed avidin and bHRP was lowered.  
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The stagnating A280 nm and A400 nm values in the UV/Vis spectra of the retentates of 
avidin/bHRP/PPI-DS-C6B4 and avidin/PPI-DS-C6B4/bHRP samples within the last three 
filtration steps (Figure 4.2.11a and c) as well as the vanished multimodal size distributions 
of the purified nanostructures (cf. Figure 4.2.10) together with their increased Dh 
compared to the non-purified BHS clearly verify the success of the purification. 
 
Figure 4.2.11 UV/Vis spectra of a) retentates and b) filtrates of avidin/bHRP/PPI-DS-C6B4 BHS as 
well as c) retentates and d) filtrates of avidin/PPI-DS-C6B4/bHRP BHS in 0.1 M 
TRIS/HCl/NaCl at pH 7.5. 
 
TEM and cryoTEM results of the purified enzymatic BHS – The purified enzymatic BHS 
were additionally imaged by TEM (Figures 4.2.12 and 4.2.13) in the dry state and in 
vitrified ice by cryoTEM (Figures 4.2.14 and 4.2.15). In Figure 4.2.12 images of the purified 
BHS of avidin/bHRP/PPI-DS-C6B4 and the corresponding particle size analyses are shown. 
TEM images of the BHS in the dry state show particles, which are rather spherical in shape 
with diameters of about 35 – 45 nm. These values nicely match the Dh of 34 nm obtained 
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from the DLS volume distribution. In contrast, the diameters measured by cryoTEM are 
larger than those obtained by DLS and dry TEM (Figure 4.2.14). They possess diameters in 
the range of mainly 40 – 75 nm. Furthermore, aggregates are visible with diameters of up 
to 100 nm. The shape of the avidin/bHRP/PPI-DS-C6B4 BHS, appear compact in the core 
but rather branched in their outer sphere. Similar findings were obtained for the purified 
avidin/PPI-DS-C6B4/bHRP BHS (Figure 4.2.13 and Figure 4.2.15).  
 
 
Figure 4.2.12 a) TEM image of purified avidin/bHRP/PPI-DS-C6B4 BHS and b) corresponding 
particle size analysis. TEM measurements were conducted with desalted samples. 
 
 
Figure 4.2.13 a) TEM image of purified avidin/PPI-DS-C6B4/bHRP BHS and b) corresponding 
particle size analysis. TEM measurements were conducted with desalted samples. 
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Figure 4.2.14 a) CryoTEM images of purified, desalted and concentrated avidin/bHRP/PPI-DS-
C6B4 BHS and b) corresponding particle size analysis. 
 
4.2 Enzymatic BHS Based on Avidin and Biotinylated Dendritic Glycopolymers 
 
103 
 
Figure 4.2.15 a) CryoTEM images of purified, desalted and concentrated avidin/PPI-DS-
C6B4/bHRP BHS and b) corresponding particle size analysis. 
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TEM images of dried particles show diameters of about 44 – 60 nm. Here again the 
shapes of the BHS appear rather spherical in the dry state. In contrast, cryoTEM images 
(Figure 4.2.15) show particles of about 70 – 100 nm. Here, even larger branched 
structures with irregular shapes were found with diameters of about 130 nm and 220 nm, 
respectively. The differences between the sizes obtained by dry TEM measurements 
compared to the DLS measurements conducted in buffer solution were already discussed 
in the previous chapter 4.1 concerning the avidin/PPI-DS-C6B4 and avidin/PPI-DS-
PEG12B4 BHS. These differences were attributed to a loss of water content of the BHS 
during the drying process of the specimen previous to the TEM measurements. This 
explanation can be assumed for the enzymatic BHS as well.  
Furthermore, it has to be taken into account that the Dh obtained by DLS displays an 
equivalent diameter of spherical particles. Thus the less the shape of the particles is close 
to a sphere the more it deviates from the diameter obtained by (cryo)TEM. In addition, 
the cryoTEM measurements were done with samples of increased concentrations, which 
may further contribute to (non-specific) aggregation. Additionally, it has to be noted that 
the contrast of the cryoTEM images is rather low. Since the contrast in cryoTEM is mainly 
caused by the differences in the electron density of the vitrified ice compared to the 
electron density of the particular structure, a high water content of the BHS lowers the 
contrast. This is in line with the AF4 investigation of the scaling properties of purified 
avidin/PPI-DS-PEG12B2 BHS in chapter 4.1.5, which revealed nanostructures with high 
water content refelected low apparent densities. The assumption of a similar constitution 
of the enzymatic BHS is substantiated by the following findings: (i) low contrast of the 
cryoTEM images and (ii) smaller diameters of the BHS in the dry state than in solution. 
 
Enzymatic activity of the purified enzymatic BHS – The enzymatic activity of the purified 
BHS was probed. Therefor the concentration of bHRP was determined by A400 nm and the 
standard curve of bHRP, which is depicted in Figure 5.4.2 of the experimental part in 
chapter 5.4.2. The concentration of the bHRP within the BHS was subsequently adjusted 
to 0.005 mg/mL in order to study the enzymatic activity. The obtained enzymatic 
activities of the avidin/bHRP/PPI-DS-C6B4 and avidin/PPI-DS-C6B4/bHRP BHS are depicted 
in Figure 4.2.16. Avidin/PPI-DS-C6B4/bHRP BHS show mainly enzymatic activity values, 
which are stable during the seven days and are at about 100 % compared to single bHRP 
over the seven days. 
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Figure 4.2.16 Relative enzymatic activity of bHRP in avidin/bHRP/PPI-DS-C6B4 or avidin/PPI-DS-
C6B4/bHRP BHS compared to bHRP after 1 d, 2 d, 3 d and 7 d. Activity values were 
obtained by the conversion of pyrrogallol to purpurogallin by bHRP in the presence 
of H2O2 in 0.1 M phosphate buffer at pH 7.4. The conversion was measured by the 
A420 nm by UV/Vis spectroscopic measurements. All samples possessed the same 
content of bHRP. 
 
Only after one day the enzymatic activity rose up to 114 %. Avidin/bHRP/PPI-DS-C6B4 BHS 
show enzymatic activities at all measured intervals within the seven days, which are in the 
range of 110 % - 125 %. Compared to the first day, the enzymatic activity slightly 
decreased at the second day and then increased up to 125 % at the seventh day. This 
indicates that the enzymatic activity is not only restored within the enzymatic BHS, 
furthermore, when the enzyme is added as the first component to avidin in the 
fabrication the enzymatic activity is even enhanced. The higher enzymatic activity of 
purified avidin/bHRP/PPI-DS-C6B4 BHS compared to the enzymatic activity of purified 
avidin/PPI-DS-C6B4/bHRP BHS at least allow to draw the conclusion that the bHRP in the 
avidin/bHRP/PPI-DS-C6B4 BHS is optimally oriented facilitating a higher conversion of the 
substrate than the bHRP in the avidin/PPI-DS-C6B4/bHRP BHS. One of the most important 
factors in order to preserve or even enhance enzymatic activity is to ensure structural 
flexibility of the particular enzyme immobilized on either particles or surfaces. If the bHRP 
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is located closer to the core of the avidin/bHRP/PPI-DS-C6B4 or avidin/PPI-DS-C6B4/bHRP 
BHS, it can be assumed that it is prone to structural rigidity. Thereby an enhancement of 
the enzymatic activity will not occur. In contrast, if the enzyme is located in the outer 
sphere of the BHS, structural flexibility is given and an optimal catalytic reaction can take 
place.  
 
Molar masses and dispersities of purified enzymatic BHS – Finally, avidin/bHRP/PPI-DS-
C6B4 BHS were characterized by AF4-LS in order to prove the applicability of the 
developed AF4-LS technique and to determine its molar masses, dispersity and radii. 
Table 4.2.4 summarizes the number and weight averages of the molar mass and the 
corresponding dispersity of the purified avidin/bHRP/PPI-DS-C6B4 BHS. The number 
average molar mass is about 600 kDa. The dispersity of 2.15 appears moderate. The Rh 
determined by online DLS coupled to AF4-LS was determined to 35 nm, which roughly 
matches the Dh of 83 nm measured in batch and the diameters determined by cryoTEM. 
The rather high Rg/Rh value of 2.67 strongly indicates anisotropic shapes, which 
additionally reflect the irregular, elongated and partly aggregated structures of the 
purified avidin/bHRP/PPI-DS-C6B4 BHS that were found in the cryoTEM image 
(Figure 4.2.14). 
 
Table 4.2.4 Molar masses, dispersity, Rh and Rg of purified avidin/bHRP/PPI-DS-C6B4 BHS 
determined by AF4-LS.
a
 
 
 
 
4.2.4   Summary 
 
The fabrication of avidin/bHRP/PPI-DS-PEG12B1 BHS was shown. Avidin/bHRP/PPI-
DS-PEG12B1 BHS were further characterized by HABA displacement assay and DLS. The 
DLS results clearly indicated the formation of larger avidin/bHRP/PPI-DS-PEG12B1 BHS, 
 Mn Mw Ð Rh Rg Rg/Rh 
Nanostructure of [g/mol] [g/mol] Mw/Mn [nm] [nm]  
avidin/bHRP/PPI-DS-C6B4 586000 1259000 2.15 35 94 2.67 
a 
corresponding AF4-LS fractogram can be found in the appendix of chapter 4.2 Figure A4.2.3. 
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despite the incomplete conversion of both bHRP and PPI-DS-PEG12B1 found with the 
HABA displacement experiments.  
The investigation of the enzymatic activity of avidin/HRP/PPI-DS-PEG12B1 mixture 
revealed that the presence of avidin and PPI-DS-DS-PEG12B1 did not significantly alter the 
enzymatic activity of HRP within seven days. In contrast, the enzymatic activity of bHRP in 
avidin/bHRP/PPI-DS-PEG12B1 BHS showed increased variations reflected by enzymatic 
activities ranging from 80 % to more than 100 %. These variations of the enzymatic 
activity can be attributed to structural rearrangements of the avidin/bHRP/PPI-DS-
PEG12B1 BHS. However, in general the enzymatic activity retained rather stable for the 
avidin/bHRP/PPI-DS-PEG12B1 BHS. 
Furthermore, the fabrication of avidin/bHRP/PPI-DS-C6B4 BHS and avidin/PPI-DS-
C6B4/bHRP BHS were reported. They were formed by different stepwise fabrication 
approaches. These BHS were characterized by HABA displacement assay and DLS as well. 
Here, again, no complete attachment of both bHRP and PPI-DS-C6B4 to avidin was found. 
A clear dependence of the final sizes of the enzymatic BHS on the formation sequence 
was found. This was attributed to the difference in length of the biotin ligands attached to 
the bHRP and PPI-DS-C6B4. Since their enzymatic activity showed values of more than 
90 % in the first two days, they were chosen for HFF purification. 
In line with the findings of chapter 4.1 regarding BHS composed of avidin and tetravalent 
PPI-bGP, a strong concentration dependence of the sizes and their distributions of the 
enzymatic BHS was found. High total mass concentrations resulted in multimodal size 
distributions of the enzymatic BHS due to the formation of aggregates. After HFF 
purification these multimodal size distributions completely vanished.  
The purified avidin/bHRP/PPI-DS-C6B4 and avidin/PPI-DS-C6B4/bHRP BHS were further 
studied by TEM in the dry state and in water by cryoTEM. CryoTEM images showed partly 
compact structures with branches in the outer sphere. But also larger aggregates were 
formed. It was found that the Dh of these BHS obtained by DLS in batch were more or less 
supported by the TEM and cryoTEM results, taking into account that in the case of DLS 
spherical particles are in general assumed and the cryoTEM images were taken with 
samples with increased concentrations. The poor contrast of the cryoTEM images further 
supports the finding of highly hydrated BHS as it was found in chapter 4.1 within the 
AF4-LS investigations of the scaling properties of the purified avidin/PEG12B2 BHS. 
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The enzymatic activity of the purified enzymatic BHS was found to be preserved and in 
the case of the purified avidin/bHRP/PPI-DS-C6B4 BHS even enhanced, which can 
preferentially be attributed to an optimal orientation of the enzyme in the BHS. 
Finally, the developed AF4-LS technique was successfully applied and the molar masses, 
the dispersity as well as the Rh and Rg of the avidin/bHRP/PPI-DS-C6B4 BHS were 
determined. The Rg/Rh value revealed anisotropic shapes, which further evidenced the 
finding of the cryoTEM study.  
The successful formation of those enzymatic BHS, their convenient purification and 
characterization by various complementary methods e.g. DLS, UV/Vis spectroscopy, 
(cryo)TEM and AF4-LS along with their preserved or even enhanced enzymatic activity for 
up to seven days make these enzymatic BHS interesting new candidates for directed 
enzyme prodrug therapies (DEPT). In that respect biotinylated HRP as the enzymatic 
component is very attractive, since it is commercially available and has shown to be very 
promising in cancer treatment in combination with indole-3-acetic acid (IAA).
[241, 243, 244, 
246, 247]
 The adjustable sizes of the presented enzymatic BHS, through e.g. the biotinylation 
degree, chemical structure of the biotin ligand, ligand-receptor stoichiometry or the 
formation sequence, display tools for the rational design of tailored enzymatic BHS.  
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4.3   BHS Based on Different Molecular Recognition Events 
 
In comparison to covalent attachment of functional entities to hard or soft 
nanoparticulate carriers non-covalent interactions are promising tools in the formation of 
multifunctional nanostructures for biomedical applications. They are not only considered 
to preserve the native structure of biologically active proteins/peptides.
[7]
 Furthermore, 
they also facilitate the implementation of stimuli responsiveness in certain platforms such 
as delivery vehicles. In that regard the stability of the Ni
II
NTA-His-tag interaction is known 
for its pH dependence,
[140]
 the β-cyclodextrin-adamantane interaction for its temperature 
dependence and the β-cyclodextrin-azobenzene interaction for its light 
responsiveness.
[253]
 
Cyclodextrin based inclusion complexation has been utilized for various applications. For 
instance the inclusion complexation of β-cyclodextrin (β-CD) and adamantane was used 
to form supramolecular diblock polymers
[254]
 or in the dual recognition of mannose 
functionalized β-CD by adamantylated PEG chains and concanavalin A.
[255]
 Cyclodextrins 
are used to form hydrogels, which feature in various applications, namely self-healing, 
sensors or delivery.
[253]
 In this context, a β-CD polymer has shown to form biocompatible 
hydrogels with a hydrophobically modified polysaccharide. It was stated that these 
hydrogels are superior to other depot systems or microspheres since they can simply be 
fabricated in situ in aqueous solution, excluding the need for difficult to remove and/or 
toxic organic solvents during their preparation. These hydrogels showed to be 
biocompatible and were additionally able to incorporate hydrophobic molecules with 
high loading efficiencies and released them in a sustained fashion.
[256]
 So far the 
implementation of the two recognition pairs (strept-)avidin-biotin and β-CD-adamantane 
has been mainly shown in the formation of layers,
[257-261]
 but also their introduction in 
hydrogels for sensing applications has been reported.
[262]
  
As it was shown in chapter 4.1, one of the main influences on the final size of the 
avidin/bGP BHS is the degree of biotinylation and the ligand-receptor stoichiometry. A 
high degree of biotinylation of the bGP has shown to facilitate larger BHS even at high 
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ligand-receptor stoichiometries. It seems reasonable to assume such a dependence not 
only for the (strept-)avidin-biotin interaction but also for other non-covalent interactions 
such as β-CD-adamantane interaction, when either the adamantane-containing 
compound or the β-CD-containing compound display a valence higher than two. 
Larger BHS were formed by adding a higher amount of bGP to avidin. This trend was 
observed until a certain Dh, max was reached. An even higher amount of bGP to avidin 
resulted in the formation of BHS with Dh smaller than the Dh, max. This trend was called 
“self-limiting aggregation by defined ligand-receptor stoichiometry” by Kisak et al.
[209]
 
On the one hand this self-limitation in aggregation with its dependence on the ligand-
receptor stoichiometry limits the sizes of the BHS, as was shown by the elucidation of the 
Dh, max values and their corresponding molar ratios of avidin/bGP. Indeed, the limitation of 
the BHS sizes can be evaded by higher biotinylation degrees of the bGP or any other 
biotinylated functional or bioactive compound. But, as was shown in chapter 4.1, high 
biotinylation degrees also result in less reproducible sizes of the BHS. On the other hand it 
consequently allows only a limited amount of biotinylated (macro-)molecules to be 
incorporated in the BHS. An alternative route is to make use of a further non-covalent 
interaction in order to fabricate larger BHS with defined dimensions. Thus the main aim of 
this chapter was to introduce two different moieties into the glycodendritic scaffolds that 
facilitate different molecular recognition processes in order to fabricate supramolecular 
assemblies, which additionally display the possibility for a further post-modification of the 
BHS by either the avidin-biotin conjugation or inclusion complex formation with β-CD. 
The formation of supramolecular assemblies through β-CD-adamantane host-guest 
interaction based on dendritic (glyco-)polymers has been shown only by a few 
researchers.
[141, 263-265]
 
Michels et al. showed the solubilization of adamantane-modified dendrimers by inclusion 
complex formation with β-CD.
[263]
 Based on the latter, the authors reported the usage of 
such complexes of β-CD and adamantane-functionalized dendrimers in the in the 
preparation of gold and platinum nanoparticles in water.
[264]
 This was further adopted to 
thin films composed of β-CD-modified gold nanoparticles and adamantane-terminated 
dendrimers by Crespo-Biel et al.
[265]
 Paolino et al. successfully showed the interaction of 
adamantane surface species of PPI-G3 and PPI-G4 glycodendrimers with β-CD by 
1
H NMR. 
The accessibility of the adamantane groups for β-CD was reported to be dependent on (1) 
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the dendrimer generation: higher generations of adamantylated glycodendrimers showed 
hampered β-CD loading. (2) The number and type of oligosaccharide molecules: complete 
substitution of surface amino groups of the dendrimers with maltose showed less 
inclusion complex formation of the adamantane moieties than dendrimers with lower 
maltosylation degrees possessing the same number of adamantane moieties. 
Furthermore, trisaccharides, such as maltotriose attached to the dendrimer surface, 
additionally hampered the inclusion complex formation due to increased steric hindrance 
compared to the disaccharide maltose. (3) The number of adamantane units on the 
surface of the dendrimers: high amounts of adamantane moieties on the glycodendrimer 
surface also hampered inclusion complex formation with β-CD due to steric reasons. 
Moreover, the authors were able to prove the interaction of an adamantylated PPI-G3 
glycodendrimer with a β-CD polymer (pCD) by DLS. Supramolecular aggregates based on 
adamantane-modified PPI-G3 glycodendrimer and pCD were observed at least in the 
intensity plot of the DLS results. However, the volume plot showed low abundance of 
those structures. The authors attributed this to the low molecular weight of the pCD and 
hence its low amount of β-CD moieties per pCD as well as to the low number of 
adamantane moieties attached to the PPI-G3 glycodendrimer surface.
[141]
 Even though 
these conclusions are reasonable, adamantane accessibility by β-CD may also be 
increased by the implementation of a linker between the dendritic scaffold and 
adamantane. The pCD used by the authors as well as in the work presented in this 
chapter is a commercially available, water-soluble polymer yielded by the reaction of 
β-CD with epichlorohydrin (cf. Figure 4.3.1a).
[266]
 This β-cyclodextrin model polymer 
possesses β-CD units randomly located between oligomeric 2-hydroxypropyl ether chains. 
It has a broad molecular weight distribution (2000 − 15000 g/mol) and an average 
molecular weight of 3500 g/mol. It is reported that the β-CD content is about 63.5% in 
weight determined by 
1
H NMR analysis.
[141]
. Consequently, this value was taken into 
account for the calculation of the concentration of the pCD solutions.  
The main aim of this chapter was to synthesize biotinylated and adamantylated 
glycopolymers (baGP), which form supramolecular structures based on the molecular 
recognition of avidin and biotin as well as the of β-CD and adamantane (Figure 4.3.1a and 
b). A schematic illustration of the interactions facilitated by the baGP with avidin and pCD 
is given in Figure 4.3.1. It has to be noted that Figure 4.3.1c and the other schemes 
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regarding the fabrication of BHS in this chapter mainly aim to describe formation 
approaches and do not demand to illustrate the real composition of the formed BHS.  
 
 
Figure 4.3.1 a) Chemical structure
modified from [141]
 and schematic illustration of β-cyclodextrin 
polymer (pCD) and the β-CD-adamantane complex, b) the avidin-biotin complex and 
c) Schematic illustration of the formation of a BHS composed of avidin, biotinylated 
and adamantylated GP (baGP) and pCD. 
 
Based on the previous this chapter deals with the following points: 
 
(i) Functionalization of adamantane moieties with a linker in order to ensure a 
sufficient accessibility of the adamantane moieties attached to the 
glycodendritic surface for pCD.  
(ii) Syntheses of biotinylated and/or adamantylated glycopolymers based on PPI-
G4 and PEI-25k. 
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(iii) Investigation of whether the ligand-receptor stoichiometry is also a decisive 
step in the formation of BHS based on the interaction of adamantane-linked 
glycopolymers and pCD. Investigation of the interaction of bGP with pCD, since 
also an interaction of biotin with β-CD was reported.
[267]
 
(iv) Study of the interaction of avidin with baGP.  
(v) Investigation of the interaction of selected avidin/baGP BHS with pCD.  
(vi) Study of the interaction of a purified avidin/baGP with pCD. 
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4.3.1   Syntheses and Characterization of Biotinylated and Adamantylated 
Dendritic Glycopolymers 
 
Dendritic glycopolymers, which exhibit moieties that enable molecular recognition 
with β-CD as well as with avidin, require the attachment of adamantane ligands and 
biotin ligands to the dendritic scaffold. As a first step an adamantane ligand was 
synthesized that provides a better accessibility for the pCD. For the synthesis of 11-(N-
(adamantane-1-yl-thiocarbamoyl)amino)-undecanoic acid 1-adamantyl isothiocyanate 
was reacted with 11-aminoundecanoic acid in the presence of triethylamine in dry DMF 
under inertgas atmosphere (Figure 4.3.2). The suspension was stirred at elevated 
temperatures until the solution got clear. In the next step either a poly(propylene imine) 
dendrimer of the 4
th
 generation or a hyperbranched poly(ethylene imine) was reacted 
with the biotin ligand (C6B) and subsequently with the adamantane ligand (C10A). 
Therefore an adamantane content of about five to six adamantane ligands per dendritic 
scaffold was chosen, with respect to the report of Paolino et al.
[141]
 Finally, the decoration 
of the residual amino groups with maltose was done by reductive amination. Further 
details of the syntheses can be found in the experimental part chapter 5.3.2. The overall 
procedure is depicted in Figure 4.3.3. 
 
Figure 4.3.2 Reaction scheme of 11-(N-(adamantane-1-yl-thiocarbamoyl)amino)-
undecanoic acid. 
 
All compounds that were investigated with respect to their interaction features toward 
avidin and/or pCD are summarized in Table 4.3.1. In general, the values of both the biotin 
and the adamantane ligand substitution determined by 
1
H NMR are in good accord with 
the theoretical ones in the case of the PPI based compounds. The amount of coupled 
maltose matches the expected values for PPI-DS and PPI-DS-C10A6. 
HO NH2
O SCN
HO N
H
N
H
SO
NEt3, DMF, 70°C
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Figure 4.3.3 Reaction scheme of a) adamantylated and biotinylated poly(propylene imine) 
glycodendrimers (PPI-baGP) and b) adamantylated and biotinylated hb 
poly(ethylene imine) glycopolymers (PEI-baGP) with (i) coupling of the biotin ligand,
(ii) coupling of the adamantane ligand and (iii) maltosylation by reductive amination. 
Note: The possible substitution of the biotin and/or adamantane ligands and the 
maltose at the linear amino groups of the hb PEI is not shown in order to provide a 
better overview. 
 
In contrast, in the case of PPI-DS-C6B4-C10A6 the maltosylation degree is significantly 
lower compared to the theoretical ones. This can be explained by means of a steric 
shielding due to the high amount of attached biotin and adamantane ligands hampering 
the complete substitution of the residual terminal aminigroups of the dendritic scaffold 
by maltose.  
A similar trend was found for the PEI-(ba)GP. Here, the degree of maltosylation 
determined by elemental analysis is lowered with higher degrees of ligand substitutions 
as well. The functionalization of PEI with adamantane (C10A) and biotin ligands (C6B) was 
determined by elemental analysis, 
1
H NMR and HABA displacement titrations for 
comparison. The obtained values of ligand functionalization of PEI-C10A6 and PEI-C6B4-
C10A6 are summarized in Table 4.3.2. Values of six and seven adamantane ligands for PEI-
C10A6 were obtained by elemental analysis and 
1
H NMR, respectively.  
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Table 4.3.1 Overview of synthesized (ba)GP and their properties. 
 
(ba)GP 
Ligands Mobserved
 
Number of
 
Precursor 
M 
C6B
a 
C10A
b 
[g/mol] Maltose
 
[g/mol] 
PPI-DS
 
0 0 46900
c 
122 (128)
e 
PPI 7168
g 
PPI-DS-C6B4
 
4 - 47650
c
 120 (120)
e
 PPI-C6B4 8500
h
 
PPI-DS-C10A6
 
0 6 45500
c 
115 (116)
e 
PPI-C10A6 9400
h 
PPI-DS-C6B4-C10A6
 
4 6 31400
c 
  64 (108)
e 
PPI-C6B4-C10A6 10800
h 
       
PEI-DS
 
0 0 74500
d 
190 (229)
f 
PEI 9600
i 
PEI-DS-C10A6
 
0 7 69100
d 
176 (215)
f 
PEI-C10A6 12200
h 
PEI-DS-C6B4-C10A6
 
4 7 67700
d 
159 (209)
f 
PEI-C6B4-C10A6 13900
h 
a 
Determined by HABA displacement titrations. 
b 
Determined by an 
1
H NMR approach. 
c 
determined by LILBID-MS (corresponding spectra can be seen in Figures A4.1.9a and A4.1.11b 
in the appendix of chapter 4.1) or AF4 (corresponding fractogramms can be seen in Figure 
A4.3.4 in the appendix of chapter 4.3). 
d 
determined by elemental analysis.
[219]
 
e 
Number of 
maltose units determined through LILBID MS or AF4-LS with theoretical values in brackets. 
f 
attached maltose units were determined by elemental analysis; theoretical number of maltose 
(number in brackets) was determined through quantitative 
13
C NMR analysis with the 
knowledge of the molar mass of dendritic scaffold 9600 g/mol and its degree of polymerization, 
respectively.
[219]
 
g 
M was determined by MALDI-TOF MS. 
h 
M was determined by Mn of particular 
dendritic polymer and degree of ligand substitution. 
i 
specified by supplier. 
 
Table 4.3.2 Comparison of the degrees of C6B or C10A ligand substitution of PEI-C10A6 and PEI-
C6B4-C10A6 determined by elemental analysis, 
1
H NMR or HABA displacement 
titrations. 
 
 compounds and theirsubstituted ligands 
 PEI-C10A6 PEI-C6B4-C10A6 
method C10A C6B C10A 
elemental ananlysis 6 5 6 
1
H NMR 7 5 7 
HABA displacement titration - 4 - 
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They are in agreement. The amount of bound C6B ligands was determined to be five 
through both elemental analysis and 
1
H NMR. They are slightly higher than the values 
obtained by the HABA displacement titration. Since the HABA displacement titrations 
were done with the maltosylated PEI-DS-C6B4-C10A6, it seems reasonable that the 
amount of accessible biotin ligand is lower due to steric reasons. However, the amount of 
attached C10A ligand on PEI-DS-C6B4-C10A6 determined by elemental analysis and by the 
NMR approach shows values of six and seven, respectively. These values are in agreement 
considering the accuracy of both methods. The determination of the degree of biotin 
ligand substitution by HABA displacement titrations are shown in Figure 4.3.4. Both 
compounds PPI-DS-C6B4-C10A6 and PEI-DS-C6B4-C10A6 gave a distinct equivalence 
point, which refers to a biotin substitution of four per GP, even though slight curvature at 
the equivalence point of the PEI-DS-C6B4-C10A6 can be observed.  
 
 
Figure 4.3.4 HABA displacement titrations of PPI-DS-C6B4-C10A6 and PEI-DS-C6B4-C10A6 in 
0.1 M TRIS/HCl/NaCl at pH of 7.5. 
 
1
H NMR Spectroscopy – The structure of the adamantane ligand and the structures of the 
precursors (PPI-C6Bx-C10A6 and PEI-C6Bx-C10A6 with x = 0 or 4) as well as of the (b)aGP 
(PPI-DS-C6Bx-C10A6 and PEI-DS-C6Bx-C10A6 with x = 0 or 4) were proven by 
1
H NMR. 
Figure 4.3.5 depicts the 
1
H NMR spectrum of the synthesized 11-(N-(adamantane-1-yl-
thiocarbamoyl)amino)-undecanoic acid in DMSO-d6. Signals at δ = 6.81 ppm and 
δ = 7.14 ppm, which are denoted as w and v in Figure 4.3.5, clearly prove the formation of 
the thiourea bond formation between 11-aminoundecanoic acid and the adamantane 
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isothiocynate and thus the successful attachment of the C10-linker to the adamantane. 
Figure 4.3.6 displays the structure of the surface species C10A ligand (surface species IIc) 
and maltose (surface species III) attached to the PPI scaffold. Characteristic signals of the 
adamantane ligands were also found in the 
1
H NMR spectrum of PPI-C10A6 
(Figure 4.3.6a). Furthermore, the successful amide bond formation between the terminal 
amino groups of the PPI-G4 and the acid group of 11-(N-(adamantane-1-yl-
thiocarbamoyl)amino)-undecanoic acid was also proven by 
1
H NMR (cf. appendix 
Figure A4.3.1). In addition, the attachment of the C10A ligand was also proven by 
MALDI-TOF MS, which will be discussed later. 
In chapter 4.1 it was shown that the values of the amount of bound biotin ligands 
determined by 
1
H NMR and by the HABA displacement titrations were in agreement. 
Consequently, the amount of the adamantane ligands attached to the PPI or PEI scaffolds 
were estimated by a 
1
H NMR approach and the obtained values are summarized in 
Table 4.3.1. Signals of the C10A ligand, which are even observable after maltosylation, are 
assigned by arrows in Figure 4.3.6b. Figure 4.3.7 depicts the 
1
H NMR spectra of 
PPI-C6B4-C10A6 (Figure 4.3.7a) and PPI-DS-C6B4-C10A6 (Figure 4.3.7b).  
 
Figure 4.3.5 1H NMR spectrum (solvent: DMSO-d6) of 11-(N-(adamantan-1-yl-thiocarbamoyl) 
amino)-undecanoic acid. 
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Figure 4.3.6 
1
H NMR spectrum of a) PPI-C10A6 (solvent: DMSO-d6 with additional TFA-d) and 
b) of PPI-DS-C10A6 (solvent: D2O). The signals of the adamantane ligand (C10A) and 
of the PPI-G4 core are assigned in a). Maltosylation results in additional broad 
signals, which are assigned in b). Ligand signals that are well observable also after 
maltosylation are assigned in b) (# hexamethylphosphoramide derivative). 
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Figure 4.3.7 
1
H NMR spectrum of a) PPI-C6B4-C10A6 (solvent: DMSO-d6 with additional TFA-d)
and b) of PPI-DS-C6B4-C10A6 (solvent: D2O). The signals of the adamantane ligand
(C10A), the biotin ligand (C6B) and of the PPI-G4 core are assigned in a). 
Maltosylation results in additional broad signals, which are assigned in b). Ligand 
signals that are well observable also after maltosylation are assigned in b)
(# hexamethylphosphoramide derivative). 
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The structures of the surface species are depicted along with the dendritic scaffold of PPI-
G4. The biotin ligand (C6B) is denoted as surface species IIa, the adamantane ligand 
(C10A) as surface species IIc and maltose as surface species III. 
Characteristic signals of the C6B ligand and the C10A ligand can be observed well next to 
signals of the PPI scaffold (Figure 4.3.7a). Maltosylation of this precursor led to a 
broadening of signals (Figure 4.3.7b). However, few but characteristic signals of both the 
C6B and the C10A ligand can be found even after this reaction step.  
Along with the latter the 
1
H NMR spectra of PEI-C10A6 and PEI-DS-C10A6 (Figure A4.3.2) 
as well as of PEI-C6B4-C10A6 and PEI-DS-C6B4-C10A6 (Figure A4.3.3) can be found in the 
appendix of chapter 4.3. Even though a correct calculation of the amount of bound biotin 
and adamantane ligands is hampered by the low signal intensity of the biotin and/or 
adamantane ligand protons, compared to the high amount of particular PPI and PEI core 
signals, the estimated values showed to be in agreement with the expected ones. 
 
MALDI-TOF MS – In order to prove the functionalization of the PPI scaffold with biotin 
ligands (C6B) and adamantane ligands (C10A) MALDI-TOF measurements were 
conducted. The corresponding MALDI-TOF spectrum of PPI-C10A6 is depicted in 
Figure 4.3.8a. It shows the signal at m/z = 7780, which can be referred to the [M+H]
+
 
species of the compound. Furthermore, signals of the [M+2H]
2+
 are observable as well at 
m/z ratio of about 3840. Additionally, a signal at m/z of about 2910 can be seen, which 
either can be attributed to a fragment probably yielded by various fragmentation 
pathways of the G0 and G4 types or displays a [M+3H]
3+
 species (cf. chapter 4.1.1). The 
m/z peak of the [M+H]
+
 species indicates a functionalization of the PPI scaffold with only 
about two C10A ligands, which is rather low compared to the degree of adamantane 
ligand substitution determined by 
1
H NMR. As already discussed in chapter 4.1, in context 
of the MALDI-TOF results of the biotinylated PPI-G4, the broad molar mass distribution, 
the low resolution in combination with the lack of sharp signals, strongly indicate several 
fragmentation processes of the PPI-C10A6 scaffold. Consequently, the higher m/z value of 
the [M+H]
+
 of PPI-C10A6, compared to the m/z value of PPI-G4 (cf. Figure 4.1.6a in 
chapter 4.1), may only account for a qualitative proof of the successful substitution of the 
PPI-G4 by the adamantane ligand. In Figure 4.3.8b the MALDI-TOF spectrum of 
PPI-C6B4-C10A6 is presented. Additionally, the MALDI-TOF spectrum of its precursor 
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PPI-C6B4 is shown for comparison. It can be clearly seen that a shift to higher m/z values 
of the [M+H]
+
 species of PPI-C6B4-C10A6 took place after the substitution of the PPI-C6B4 
precursor with the C10A ligand. The shift from a m/z of about 8100 to m/z of about 9960 
rather implies a substitution of not more than five adamantane ligands, which is 
surprisingly in agreement with the value of the adamantane ligand substitution 
determined by
 1
H NMR. However, as discussed in chapter 4.1 in the MALDI-TOF MS part, 
it seems likely that the m/z value of 8100 of PPI-C6B4 does not represent the actual molar 
mass of the PPI-C6B4, since it contradicts the obtained biotinylation levels determined by 
1
H NMR and by the HABA displacement titration, respectively. 
 
Figure 4.3.8 MALDI-TOF MS spectra of a) PPI-C6B4 and b) PPI-C6B4-C10A6. 
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4.3.2   Formation and Characterization of BHS Composed of Avidin, Biotinylated 
and Adamantylated Dendritic Glycopolymers and β-Cyclodextrin Polymer 
 
Interaction of PPI-DS-C10A6 and PPI-DS-C6B4 with pCD – As the first decisive 
investigation the interaction of PPI-DS-C10A6 and PPI-DS-C6B4 with pCD was studied by 
DLS (Figure 4.3.9). The main purpose was to evaluate whether the 
ligand-receptor stoichiometry can be used as a measure in order to control the sizes of 
BHS composed of PPI-DS-C10A6 or PPI-DS-C6B4 with pCD. Therefore a solution of the 
particular glycodendrimer was converted with pCD. As can be seen in Figure 4.3.9 both 
PPI-DS-C10A6 as well as PPI-DS-C6B4 show the formation of BHS after mixing with pCD 
indicated by increased Dh. Figure 4.3.9 show a simplified illustration of the conversion of 
PPI-DS-C10A6 (aGP) and PPI-DS-C6B4 (bGP) with pCD, the DLS volume plots of the single 
components PPI-DS-C10A6, PPI-DS-C6B4 and pCD for comparison (Figure 4.3.9a and c) 
along with DLS volume plots of the BHS formed by different molar ratios of PPI-DS-C10A6 
or PPI-DS-C6B4 with pCD (Figures 4.3.9b and d). Similar molar ratios of PPI-DS-C10A6/pCD 
led to larger Dh of their BHS than those formed by PPI-DS-C6B4 and pCD. This is 
reasonable when the association constant of adamantane and β-CD in water is compared 
to that of biotin and β-CD. The adamantane-β-CD complex possess an association 
constant of 1 × 10
-5
 M
-1
,
[268]
 whereas the biotin-β-CD complex is characterized by a lower 
association constant of 3 × 10
-2
 M
-1
.
[267]
 However, Figures 4.3.9b and d clearly show that 
the ligand-receptor stoichiometry directs the sizes of the final BHS. The Dh, max of the PPI-
DS-C10A6/pCD BHS is about 25 nm and the corresponding molar ratio was found to be 
1/14. A Dh, max of about 16 nm was observed for the PPI-DS-C6B4/pCD BHS at the same 
molar ratio of 1/14. In the appendix of chapter 4.3 the Dh values of the single components 
and different molar ratios of them are summarized in Tables A4.3.1 and A4.3.2, 
respectively. In order to verify that the results are not caused by an interaction of the pCD 
with bare PPI-DS, certain ratios of PPI-DS/pCD were investigated by DLS and no significant 
size increase upon addition of pCD to PPI-DS was found (cf. Table A4.3.5). The control of 
the sizes of the BHS formed by PPI-DS-C10A6 or PPI-DS-C6B4 by the ligand-receptor 
stoichiometry displays a necessary starting point for the following investigations. 
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Figure 4.3.9 Schematic illustration of the conversion of PPI-DS-C10A6 (aGP) with pCD (left) and 
of PPI-DS-C6B4 (bGP) with pCD (right) and DLS volume plots of a) PPI-DS-C10A6 and 
pCD, b) different molar ratios of PPI-DS-C10A6/pCD, c) PPI-DS-C6B4 and pCD and 
d) different molar ratios of PPI-DS-C6B4/pCD in 0.1 M TRIS/HCl/NaCl at pH 7.5 
measured by DLS in batch. The corresponding Dh values of single components and 
their mixtures can be found in appendix of chapter 4.3 Tables A4.3.1 and A4.3.2, 
respectively. 
 
Interaction of PPI-DS-C6B4-C10A6 and PEI-DS-C6B4-C10A6 with avidin – In the next step 
the interaction of avidin with PPI- and PEI-DS-C6B4-C10A6 was investigated. Therefore 
avidin was mixed in different molar ratios with the baGP. Figure 4.3.10 shows a simplified 
illustration of the conversion of avidin with baGP (PPI-DS-C6B4-C10A6 or PEI-DS-C6B4-
C10A6) with pCD, the DLS volume plots of the educt components and of the formed BHS 
of them. Thereby it was tested whether there are any differences in the Dh of the formed 
BHS of avidin or [avidin.HABA] with PPI- or PEI-DS-C6B4-C10A6.  
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Figure 4.3.10 Schematic illustration of the conversion of avidin with baGP (top) and DLS volume 
plots of a) [avidin.HABA], avidin and PPI-DS-C6B4-C10A6 and different molar ratios 
of b) [avidin.HABA]/PPI-DS-C6B4-C10A6 and c) avidin/PPI-DS-C6B4-C10A6; DLS 
volume plots of d) [avidin.HABA], avidin and PEI-DS-C6B4-C10A6 and different 
molar ratios of e) [avidin.HABA]/PEI-DS-C6B4-C10A6 and f) avidin/PEI-DS-C6B4-
C10A6 in 0.1 M TRIS/HCl/NaCl at pH 7.5 measured by DLS in batch. The 
corresponding Dh values of single components and their mixtures can be found in 
appendix of chapter 4.3 Tables A4.3.1, A4.3.3 and A4.3.4, respectively. 
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Avidin, [avidin.HABA] and PPI-DS-C6B4-C10A6 possess all Dh of about 7 – 8 nm whereas 
the PEI-DS-C6B4-C10A6 exhibit a Dh of about 16 nm (Figure 4.3.10a and d). Figure 4.3.10b 
shows the DLS volume plots of the BHS of [avidin.HABA] with PPI-DS-C6B4-C10A6 in 
different molar ratios. It was found that the Dh, max of about 160 nm was obtained by the 
1/1 molar ratio. Lower molar ratios of [avidin.HABA]/PPI-DS-C6B4-C10A6 resulted in 
smaller Dh of their BHS. Such a trend was hardly observed for the complexes of 
[avidin.HABA] with PEI-DS-C6B4-C10A6. Consequently, the Dh, max cannot be exactly 
determined even though increased Dh in the range of 50 – 90 nm were found. In addition, 
Figure 4.3.10e shows also the presence of shoulders of the size distribution curves of the 
1/1 and 1/1.5 molar ratios of [avidin.HABA]/PEI-DS-C6B4-C10A6. They are in the range of 
100 nm – 1000 nm, which indicates the formation of even larger BHS. A small amount of 
larger aggregates were also formed in the Dh range of 10
3
 – 10
4
 nm but their volume 
fractions are rather low (cf. Table A4.3.4). 
The hindered formation of larger BHS composed of avidin and PEI-DS-C6B4-C10A6 in the 
presence of HABA is also reflected in the results of the amount of bound baGP 
(Table 4.3.3) determined by HABA displacement assay and HABA displacement titrations, 
respectively.  
 
Table 4.3.3 Average amount of bound PPI- or PEI-baGP. 
 
  bound baGP
a 
 
 
molar ratio 
avidin/bGP 
PPI-DS-C6B4-C10A6 PEI-DS-C6B4-C10A6  
 1/0.25 0.16 0.10  
 1/0.50 0.30 0.18  
 1/1.0 0.44 0.39  
 1/1.5 0.61 0.53  
 1/2.0 0.64 0.56  
 
a
 average value of a twofold determination based on the HABA 
amount displaced by biotin ligands. 
 
 
It was found that the amount of bound PEI-DS-C6B4-C10A6 is lower than the amount of 
bound PPI-DS-C6B4-C10A6 at similar molar ratios of avidin/baGP. Figures 4.3.10c and f 
show the results of the BHS formation of avidin with PPI-DS-C6B4-C10A6 and PEI-DS-
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C6B4-C10A6, respectively. Here, the Dh, max was determined to be at the 1/1 molar ratios 
for both the avidin/PPI-DS-C6B4-C10A6 and the avidin/PEI-DS-C6B4-C10A6 BHS. The 
avidin/PPI-DS-C6B4-C10A6 BHS in a 1/1 molar ratio occur rather monomodal with a Dh of 
about 1150 nm and a very little amount of a second fraction at about 100 nm. All other 
molar ratios of avidin and PPI-DS-C6B4-C10A6 led to size distributions, which are at least 
bimodal (Figure 4.3.10c). Despite these multimodal size distributions, decreased Dh of the 
1/1.5 and 1/2 molar ratio of avidin/PPI-DS-C6B4-C10A6 were found. Bimodal size 
distributions were also observed for avidin/PEI-DS-C6B4-C10A6 BHS (Figure 4.3.10f). Here 
the Dh, max was found to be at the 1/1 molar ratio when the most abundant fraction of 
avidin/PEI-DS-C6B4-C10A6 was taken into account, which possesses an Dh of about 
520 nm. Few but not very frequent aggregates can also be seen in both DLS plots of 
avidin/PPI-DS-C6B4-C10A6 BHS and avidin/PEI-DS-C6B4-C10A6 BHS in the range of about 
10
3
 nm – 10
4
 nm. 
 
Interaction of PPI-DS-C6B4-C10A6 and PPI-DS-C6B4-C10A6 with avidin and pCD – In the 
next step the interaction of avidin/PPI-DS-C6B4-C10A6 BHS and avidin/PEI-DS-C6B4-
C10A6 BHS with pCD was investigated by DLS batch measurements. Therefore the 1/1.5 
molar ratios of avidin/PPI-DS-C6B4-C10A6 and avidin/PEI-DS-C6B4-C10A6 BHS were 
mixed with increasing equivalents of pCD in order to probe whether rather defined 
microparticles can be formed. Upon the adding of pCD to the slightly turbid solution the 
turbidity of the solution increased. Subsequent DLS measurements showed no defined 
particle formation for molar ratios of 1/1.5/1 – 1/1.5/21 in the case of avidin/PPI-DS-
C6B4-C10A6/pCD and 1/1.5/1 – 1/1.5/32 in the case of avidin/PEI-DS-C6B4-C10A6/pCD. 
However, adding of a higher amount of pCD resulted in microparticulate structures with a 
Dh range about 500 nm –10 µm (Figure 4.3.11). For comparison the size distribution of the 
single components are shown in Figures 4.3.11a and c, respectively. It was found that the 
Dh of the avidin/baGP/pCD BHS decreased the higher the amount of added pCD was. This 
implies control of the sizes of those microparticles by the amount of added pCD. The 
comparison of the sizes of the avidin/PPI-DS-C6B4-C10A6/pCD BHS (Figure 4.3.11b) with 
avidin/PEI-DS-C6B4-C10A6/pCD BHS (Figure 4.3.11d) at the same molar ratios showed 
larger microparticles in the case of avidin/PEI-DS-C6B4-C10A6/pCD BHS. In order to verify 
that the obtained particles were formed by the interaction of the adamantane moieties 
and pCD certain control experiments were conducted. 
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Figure 4.3.11 Schematic illustration of the conversion of avidin/baGP BHS with pCD (top) and DLS 
volume plots of a) avidin, PPI-DS-C6B4-C10A6 and pCD; b) different molar ratios of 
avidin, PPI-DS-C6B4-C10A6 and pCD; DLS volume plots of c) avidin, PEI-DS-C6B4-
C10A6 and pCD; d) different molar ratios of avidin, PEI-DS-C6B4-C10A6 and pCD in 
TRIS/HCl/NaCl at pH 7.5 measured by DLS in batch. The corresponding Dh values of 
single components and their mixtures can be found in appendix of chapter 4.3 
Tables A4.3.1 and A4.3.6, respectively. 
 
It was found that no significant interaction of avidin, PPI-DS or PEI-DS with pCD took 
place. Moreover, no displacement of the azo dye HABA from the avidin binding sites by 
PPI-DS-C10A6 or PEI-DS-C10A6 was found and no size growth were observed by mixing 
avidin with PPI-DS-C10A6 was observed. Consequently, the size growth after mixing 
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avidin with either PPI-DS-C6B4-C10A6 or PEI-DS-C6B4-C10A6 in different molar ratios as 
well as the size growth found by mixing preformed avidin/PPI-DS-C6B4-C10A6 in 1/1.5 
molar ratio with pCD can be likely attributed to interactions based on the avidin-biotin 
and the adamantane-pCD complex formation. Moreover, the adamantane moieties are a 
necessary entity in order to form inclusion complexes with pCD (cf. Table A4.3.5). 
However, inclusion complex formation by free biotin ligands with pCD can not be ruled 
out (cf. Figure 4.3.9d). 
 
Purification of avidin/PPI-DS-C6B4-C10A6 BHS – The findings of chapter 4.1 showed that 
the fabrication of avidin/PPI-bGP BHS yielded nanostructures next to conjugation adducts 
but also free avidin and PPI-bGP were found in the conjugation solution. Free avidin and 
PPI-bGP as well as the conjugation adducts were successfully removed by HFF 
purification. Consequently, this procedure was applied to the avidin/PPI-DS-C6B4-C10A6 
BHS in a 1/1.5 molar ratio as well. Figure 4.3.12a shows the DLS volume plots of the initial 
composition, the purified BHS (final structure) as well as the purified and concentrated 
avidin/PPI-DS-C6B4-C10A6 BHS along with the solutions of sample (1) and (2) in micro-
cuvettes. The non-purified avidin/PPI-DS-C6B4-C10A6 BHS possesses a bimodal size 
distribution with average Dh of these two fractions of about 260 nm and 40 nm, 
respectively. The purification of the avidin/PPI-DS-C6B4-C10A6 BHS resulted in a 
monomodal size distribution with an average Dh of about 300 nm, which is larger than the 
second size peak of the non-purified BHS. The turbidity of the purified avidin/PPI-DS-
C6B4-C10A6 BHS (Figure 4.3.12a – sample (2)) solution is decreased compared to the non-
purified BHS (Figure 4.3.12a – sample (1)).  
In order to prepare a solution with a concentration suitable for TEM measurements the 
purified structure was concentrated and desalted. The resulting concentration was 
approximately three times higher than the initial one. The corresponding DLS volume plot 
shows again a bimodal size distribution with Dh of 330 nm and 80 nm, respectively, which 
implies structural rearrangements. The corresponding TEM image of the desalted and 
purified BHS is depicted in Figure 4.3.12b and reflects the multimodality of the size 
distribution found by the DLS measurements. The TEM image of the BHS shows 
structures, which possess diameters of 100 nm, 200 nm, 300 nm and 450 nm. The shapes 
of the BHS with diameter larger than 200 nm appear irregular and partly elongated, 
whereas the particles of about or smaller than 100 nm appear rather spherical in shape.  
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Figure 4.3.12 a) DLS volume plots of non-purified (initial composition), purified avidin/PPI-DS-
C6B4-C10A6 BHS (final structure) and the concentrated purified BHS in 
TRIS/HCl/NaCl at pH 7.5 measured by DLS in batch and the solution of the sample 
(1) and (2) in cuvettes. The corresponding Dh values of the presented samples can 
be found in appendix of chapter 4.3 in Table A4.3.7; b) TEM image of the purified 
desalted and concentrated avidin/PPI-DS-C6B4-C10A6 BHS. Purification of the BHS 
was done by HFF with mixed cellulose ester membranes with a MWCO of 0.1 µm. 
 
Interaction of purified avidin/PPI-DS-C6B4-C10A6 with pCD BHS – Finally, it was proven 
whether interactions of the purified BHS with pCD can be observed by means of 
microparticle formation or at least by observing increased turbidity of the solutions. 
Therefore the purified solution was mixed with up to 87 equivalents of pCD. It was found 
that the turbidity was very strong for samples where up to 21 equivalents of pCD were 
added. In that case it was not possible to get reliable DLS data from the DLS batch 
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measurements. A higher amount of pCD resulted in decreased turbidity and the 
formation of microparticles (cf. Figure 4.3.13a). Figure 4.3.13b shows the DLS volume 
plots for the DLS batch measurements of different molar ratios of the purified avidin/PPI-
DS-C6B4-C10A6 BHS and pCD. Along with the decreased turbidity of the samples also the 
sizes decreased the higher the amount of added pCD was. Thereby Dh were measured, 
which were decreased from 5.3 µm to 4.3 µm down to 1 µm. Upon adding 87 equivalents 
of pCD the Dh was lowered even down to 450 nm. The Dh values of the formed BHS are 
summarized in Table A4.3.8 in the appendix of chapter 4.3. 
 
Figure 4.3.13 Schematic illustration of the conversion of purified avidin/baGP BHS with pCD (left)  
and a) Samples containing purified avidin/PPI-DS-C6B4-C10A6 BHS mixed with 
increasing amounts of pCD and b) DLS volume plots of avidin/PPI-DS-C6B4-
C10A6/pCD BHS in 0.1 M TRIS/HCl/NaCl at pH 7.5 measured by DLS in batch. The 
corresponding Dh values of the presented samples can be found in appendix of 
chapter 4.3 Table A4.3.8. 
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4.3.3   Summary 
 
In this chapter the successful synthesis of PPI and PEI based glycopolymers 
functionalized with C6-linked biotin ligands and/or C10-linked adamantane ligands was 
shown. The characterization of the baGP and their precursors was done by analytical 
techniques such as 
1
H NMR, MALDI-TOF MS, elemental analysis and AF4-LS. Thereby the 
degrees of functionalization and the molar masses were determined.  
As a first step it was proven that by a defined ligand-receptor stoichiometry of 
adamantylated or biotinylated poly(propylene imine) glycodendrimers to pCD the sizes of 
the resulting BHS can be controlled. It was found that a molar ratio of 1/14 of PPI-DS-
C10A6/pCD yielded the largest BHS. As reported by Holzinger et al. biotin has also the 
ability to form an inclusion complex with β-CD, even though their interaction is 
characterized by a very low association constant of 3 × 10-2 M
-1
.
[267]
 The molar ratio of 
1/14 of PPI-DS-C6B4/pCD showed the largest BHS, confirming a complex formation of PPI-
DS-C6B4 with pCD.  
It was further shown that the interaction of avidin with baGP yielded BHS with Dh of up to 
1 µm for avidin/PPI-DS-C6B4-C10A6 BHS and 520 nm for avidin/PEI-DS-C6B4-C10A6 BHS. 
Furthermore, the specific interaction of the adamantane moieties of the baGP with pCD 
was proven by control experiments. Neither avidin, PPI-DS nor PEI-DS showed significant 
interaction with pCD. Moreover, no displacement of the azo dye HABA from the avidin 
binding sites by PPI-DS-C10A6 or PEI-DS-C10A6 and no size growth were observed by 
mixing avidin with PPI-DS-C10A6. 
Size control of the BHS composed of avidin/baGP by the ligand-receptor stoichiometry 
was found. The Dh, max of about 1150 nm in the case of the avidin/PPI-DS-C6B4-C10A6 BHS 
and about 520 nm in the case of the avidin/PEI-DS-C6B4-C10A6 BHS were formed by the 
1/1 molar ratio.  
In contrast, in the presence of the azo dye HABA lower Dh, max of [avidin.HABA]/PPI-DS-
C6B4-C10A6 BHS (∅ ca. 160 nm) and of [avidin.HABA]/PEI-DS-C6B4-C10A6 BHS 
(∅ ca. 90 nm) were observed at the 1/1 molar ratio. This implies either a hampering effect 
of the azo dye HABA or its presence in the solution minimizes non-specific interactions. 
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A hampered avidin-biotin conjugation for avidin/PEI-DS-C6B4-C10A6 BHS was indicated 
by two findings: (i) the avidin/PEI-DS-C6B4-C10A6 BHS was only about half as large in size, 
compared to the avidin/PPI-DS-C6B4-C10A6 BHS at the 1/1 molar ratio. (ii) The lower 
values of bound PEI-baGP to avidin compared to PPI-baGP. However, the HABA 
displacement assay showed that specific interactions of avidin with both PPI-baGP and 
PEI-baGP took place although the amount of bound PEI-baGP was slightly lower than the 
amount of bound PPI-baGP.  
In general, the mixing of avidin with baGP resulted in larger BHS compared to the BHS 
composed of avidin and bGP. With respect to the sizes of the single components, this 
implies that the BHS formation by avidin and the baGP is driven by further non-specific 
interactions. 
The adding of certain amounts of pCD to preformed avidin/baGP BHS showed hydrogel 
formation indicated by a strong turbidity. This turbidiy decreased the higher the amount 
of added pCD was. Microparticles were only obtained upon an avidin/PPI-DS-C6B4-
C10A6/pCD molar ratio of 1/1.5/32 and 1/1.5/43 for avidin/PEI-DS-C6B4-C10A6/pCD. 
In consequence of the results of chapter 4.1, hollow fiber filtration was applied to 
avidin/PPI-DS-C6B4-C10A6 BHS. Even though the bimodal size distribution of avidin/PPI-
DS-C6B4-C10A6 vanished, the concentrated and desalted sample showed again a bimodal 
size distribution indicating structural rearrangements. The presence of these two main 
populations was further proven by TEM measurements, where irregular shaped BHS with 
diameters up to 450 nm and rather spherical BHS with diameter up to 100 nm were 
found.  
Finally, the interaction of purified avidin/PPI-DS-C6B4-C10A6 BHS with pCD was studied 
by DLS. Here again it was found that at least an amount of 32 equivalents of pCD was 
required to yield microparticles. Their sizes were shown to be controlled by the amount 
of added pCD.  
In summary, it was shown that even those complex biotin and adamantane functionalized 
dendritic glycopolymers possess the ability to form BHS with avidin. The increased Dh of 
the avidin/baGP BHS can be partly attributed to specific interactions as was shown by the 
HABA displacement assay. However, the presence of other non-covalent interactions is 
strongly indicated due to their much larger sizes compared to the avidin/bGP BHS. Finally, 
even more complex structures were formed by adding pCD to pre-formed avidin/baGP 
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BHS. As a result microparticulate structures ranging from 450 nm up to 5 µm were 
observed, whereas a higher amount of added pCD yielded smaller BHS. 
In this chapter the surface functionalities of the baGP were proven by different 
non-covalent interactions of avidin-biotin and β-cyclodextrin (polymer)-adamantane. The 
formation of BHS consisting of baGP, avidin and pCD with sizes up to the micrometer 
range are a promising finding. The formation of such microparticulate BHS potentially 
allow further functionalization with biotinylated and/or adamantylated compounds, 
either within their structures or at their outer sphere by free avidin binding sites or free 
β-CD moieties.  
Furthermore, in chapter 4.1 it was shown that avidin/PPI-DS-PEG12B2 BHS is a rather 
loose and highly hydrated network. In consequence of this finding, it seems rational to 
assume an even looser and hydrated structure in the case of the avidin/baGP/pCD BHS 
taking into account that the interaction of β-cyclodextrin with hosts is frequently used in 
order to form hydrogels.
[27, 269]
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4.4   Conclusion and Outlook 
 
4.4.1   Conclusion 
 
The main goal of this work was the fabrication of BHS by molecular recognition 
processes such as the avidin-biotin or the β-cyclodextrin-adamantane interaction 
(Figure 4.4.1), which possesss sizes in the nano- or micrometer range. Thereby the BHS 
composed of two or even more components such as glycopolymers or proteins were 
formed. 
 
Figure 4.4.1 Schematic illustration of the molecular recognition processes used in this work: 
a) avidin-biotin and b) adamantan-β-cyclodextrin interaction. Avidin structure was 
taken from [9]. 
 
Biotinylated dendritic glycopolymers (bGP) were synthesized (Figure 4.4.2) in order to 
study their polymerization ability with the protein avidin, which possesses a 
tremendiously high association constant towards biotin (chapter 4.1). 
The main aim of this study was to elucidate measures that allow controlling the sizes of 
the BHS composed of avidin and the bGP and whether defined archtitectures can be 
formed. Thereby, it was investigated to what extent (i) the size of the dendritic scaffold, 
(ii) the length and/or chemical structure of the biotin ligand, (iii) the degree of 
biotinylation of the bGP and (iv) the ligand-receptor stoichiometry of avidin to bGP 
influence the properties of the formed avidin/bGP BHS. The biotinylated dendritic 
glycopolymers possessed a dense maltose shell surrounding their dendritic core, which 
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was either a poly(propylene imine) (PPI) of the 4
th
 generation or a hyperbranched (hb) 
poly(ethylene imine) (PEI) with a Mw of about 25 kDa. In the case of the biotinylated 
poly(propylene imine) glycodendrimer (PPI-bGP), the degree of biotinylation was 1, 2, 4 
or even 8 biotin ligands per glycodendrimer scaffold whereas the degree of biotinylation 
of the hb PEI glycopolymers (PEI-bGP) was set to be 1, 2 or 4. The biotin ligand was either 
hydrophobic and C6-linked or hydrophilic and PEG12-linked. 
 
  
Figure 4.4.2 Description of the compartments and structural properties of the biotinylated 
dendritic glycopolymers (bGP). 
 
BHS of avidin and bGP with various diameters between 10 nm to 100 nm (Tables 4.4.1 
and 4.4.2) or even 1 µm in the case of the octavalent PPI-bGP were formed. The sizes of 
the BHS were found to be mainly controlled by two decisive key points: 
 
(i) degree of biotinylation  
(ii) ligand-receptor stoichiometry 
 
Higher degrees of biotinylation of the bGP yielded larger BHS with avidin at the same 
ligand-receptor stoichiometry. As reported by Kisak et al. the aggregation of avidin with 
biotinylated compounds with a certain sterical demand limits itself.
[209]
 Consequently, a 
certain Dh, max and its corresponding molar ratio of avidin/bGP was determined, which was 
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found to be crucially dependend on the degree of biotinylation. The higher the degree of 
biotinylation of the bGP is the higher the molar ratio of avidin/bGP is that corresponds to 
the Dh, max. Molar ratios lower than the molar ratio that corresponds to the Dh, max resulted 
in BHS with Dh smaller than the Dh, max. This can be rationalized by the fast saturation of 
the avidin binding sites by the higher content of bGP.  
 
Table 4.4.1 Overview of fabricated avidin/PPI-bGP BHS and their average dimensions.
a 
 
BHS based on avidin and molar ratio Dh, min – Dh, max 
PPI-DS-C6B1 1/1 – 1/4 9 – 12 nm 
PPI-DS-C6B2 1/0.25 – 1/2 8 – 23 nm 
PPI-DS-C6B4 1/0.25 – 1/2 21 – 46 nm 
PPI-DS-PEG12B1 1/1 – 1/4 9 – 15 nm 
PPI-DS-PEG12B2 1/0.25 – 1/2 8 – 21 nm 
PPI-DS-PEG12B4 1/0.25 – 1/2 43 – 50 nm 
a
 BHS based on avidin and octavalent bGP not shown. 
 
Table 4.4.2 Overview of fabricated avidin/PEI-bGP BHS and their average dimensions.
 
 
BHS based on avidin and molar ratio Dh, min – Dh, max 
PEI-DS-C6B1 1/1 – 1/4 12 – 21 nm 
PEI-DS-C6B2 1/0.25 – 1/2 10 – 29 nm 
PEI-DS-C6B4 1/0.25 – 1/2 35 – 53 nm 
PEI-DS-PEG12B1 1/1 – 1/4 13 – 21 nm 
PEI-DS-PEG12B2 1/0.25 – 1/2 9 – 32 nm 
PEI-DS-PEG12B4 1/0.25 – 1/2 32 – 57 nm 
 
All bGP showed polymerization potential with avidin and the size distributions of 
avidin/PEI-bGP BHS were not found to be distinctly broader than those of the 
avidin/PPI-bGP. In general, the sizes of the BHS of avidin/PEI-bGP are larger than their 
avidin/PPI-bGP analogs, since the larger dimension of PEI-bGP contribute more to the 
formed BHS than the smaller PPI-bGP. The instabilities are of the BHS reflected mainly by 
their growth within 14 days were dependend on the bGP´s degree of biotinylation. The 
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stability of the BHS decreased with increased degree of biotinylation of the bGP. Such a 
variation in the sizes of the BHS can be explained by means of frequently occurring intra- 
and intermolecular association and dissociation processes caused by a lowered 
association constant of the avidin-bGP complex compared to that of 
avidin-biotin complex. Since it has been reported that the association constant of avidin 
and biotinylated high molar mass compounds decreases, the higher the molar mass of the 
biotinylated compound is,
[213]
 it is reasonable to assume such a dependence for the 
avidin-bGP complexes as well.  
Most importantly, selected BHS were thoroughly investigated by AF4-LS. Thereby it was 
found that the PEG12B ligand provides a better accessibility for the avidin binding sites 
compared to the C6B ligand. Furthermore, next to free avidin and/or bGP, conjugation 
adducts and nanostructures with increased molar masses were found. The presence of 
free avidin and bGP and hence a lack of their complete conversion can be explained by 
the size of the bGP, which are either similar in the case of avidin and the PPI-bGP or even 
higher in the case of avidin and the PEI-bGP. The sterical demands of the bGP do not only 
hamper their complete attachment to avidin, moreover, it can be assumed that the 
sterical demand force the bGP to be located in a sterically less hindered trans position 
(Figure 4.4.3).  
 
 
Figure 4.4.3 a) Favored coupling of two bGP as proposed by Sinha et al.,
[231]
 b) Steric shielding of 
the coupled bGP due to similar or even larger sizes of avidin and the bGP. 
 
The nanostructures were found to be the largest fraction in the raw conjugation solution. 
Subsequent purification of the raw conjugation solution by hollow fiber filtration (HFF) 
allowed the isolation of the nanostructures. The investigation of their scaling properties 
revealed that they are anisotropic in shape, possess geometry between a sphere and a 
a) b)
cis position trans position
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random coil and can be described as a highly hydrated, loose and complex network. A 
schematic section of the structure is shown in Figure 4.4.4. 
 
 
Figure 4.4.4 Section of the hydrated, rather loose network of the avidin/bGP BHS formed by 
specific interactions as well as of further non-covalent bindings (avidin: violet, 
bGP: black). 
 
 In the second part of the thesis (chapter 4.2) the formation of BHS composed of 
avidin, biotinylated horseradish peroxidase (bHRP) and mono- or tetravalent PPI-bGP 
were shown. Their sizes are summarized in Table 4.4.3. Thereby the bivalent bHRP was 
equipped with a C6-C6B ligand. At first it was probed to what content the coupling of the 
bHRP influences its enzymatic activity. Furthermore, it was investigated how the 
sequence of adding either the PPI-bGP or the bHRP influences the properties of the 
enzymatic BHS. Therefore, avidin/bHRP/PPI-DS-C6B4 BHS and avidin/PPI-DS-
C6B4/bHRP BHS were fabricated.  
 
Table 4.4.3 Overview of fabricated (non-)purified enzymatic BHS and their average dimensions. 
 
  non-purified purified
a 
BHS molar ratio Dh Dh 
avidin/bHRP/PPI-DS-PEG12B1 1/0.25/1 13 nm - 
    
avidin/bHRP/PPI-DS-C6B4 1/0.5/0.5 21 nm 34 nm 
avidin/PPI-DS-C6B4/bHRP 1/0.5/0.5 35 nm 83 nm 
a 
purification by hollow fiber filtration (HFF) 
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The sequence of fabrication with regard to the length of the attached biotin ligands (C6B 
or C6-C6B) revealed to be a pivotal step in controlling the final sizes of BHS. Consequently, 
from the findings of the interaction of avidin with bGP (chapter 4.1), HFF purification was 
applied in order to yield the pure nanostructure. These nanostructures were investigated 
with regard to their shapes, sizes, molar masses and enzymatic activities. Moreover, it 
was found that the enzymatic activity was not only retained but even enhanced in the 
case of the purified avidin/bHRP/PPI-DS-C6B4 BHS. In addition, cryoTEM measurements 
indicated that even these more complex BHS possess a highly hydrated state. A schematic 
section of the enzymatic BHS is shown in Figure 4.4.5.  
 
 
Figure 4.4.5 Section of the hydrated and rather loose network of BHS composed of avidin 
(violet), bGP (grey) and bHRP (green) formed by specific interactions as well as of 
further non-covalent bindings. 
 
In summary, it was found that the following key points allow the convenient tailoring of 
pivotal characteristics, such as size and molar masses of the formed (enzymatic) BHS 
formed by avidin-biotin conjugation: 
 
(i) degree of biotinylation  
(ii) ligand-receptor stoichiometry 
(iii) length of the hydrophobic biotin ligand (C6B or C6-C6B) 
(iv) sequence of BHS formation 
 
In the final part of the thesis (chapter 4.3) the fabrication of BHS based on both the 
avidin-biotin and β-cyclodextrin-adamantane interaction was shown (cf. Figure 4.4.1).  
As a first step glycopolymers were synthesized containing biotin and adamantane ligands 
(PPI-baGP and PEI-baGP) (Figure 4.4.6). The biotinylated and adamantylated dendritic 
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glycopolymers possessed a dense maltose shell surrounding their dendritic core. The 
dendritic core was either a poly(propylene imine) (PPI) of the 4
th
 generation or a 
hyperbranched (hb) poly(ethylene imine) (PEI) with a Mw of about 25 kDa. The degree of 
ligand substitutions were set to be about 4 biotin ligands (C6B) and about 6 adamantane 
ligands (C10A). At first these baGP were investigated with regard to their interaction with 
avidin in order to fabricate avidin/baGP BHS. Secondly, the interaction of the avidin/baGP 
BHS with a β-cyclodextrin polymer (pCD) was studied (Figure 4.4.7).  
 
  
Figure 4.4.6 Description of the compartments and structural properties of the biotinylated and 
adamantylated dendritic glycopolymers (baGP). 
 
 
Figure 4.4.7 a) Chemical structure
modified from [141]
 and schematic illustration of β-cyclodextrin 
polymer (pCD; 2−15 kDa) and the β-cyclodextrin-adamantane complex. 
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The influence of the ligand-receptor stoichiometry was probed once more and was found 
to be crucial in controlling the sizes of both avidin/baGP BHS and avidin/baGP/pCD BHS. 
The fabrication of both BHS was done under mild conditions without the use of toxic or 
difficult to remove solvents or agents. In dependence on the ligand-receptor 
stoichiometry avidin/PPI-baGP BHS were fabricated ranging from 70 – 1150 nm, whereas 
avidin/PEI-baGP BHS were found to be smaller at similar molar ratios. They possessed Dh 
of about 90 – 520 nm. Consequently, a hampering influence, due to the increased sterical 
demand and the increased structural flexibility of the PEI glycodendritic scaffold, can be 
assumed. The adding of increasing equivalents of pCD to the preformed avidin/baGP BHS 
allowed the tailoring of the sizes of the avidin/baGP/pCD BHS in the nano- and 
micrometer range (Table 4.4.4). In consequence of the investigation of the avidin/bGP 
BHS (chapter 4.1), HFF purification was applied to pre-formed avidin/PPI-baGP BHS. Even 
though growth of the structure was observed the desalting and increase of the 
concentration of the conjugation solution resulted in structural rearrangements of the 
purified BHS. The monomodal size distribution of the purified BHS changed to a bimodal 
size distribution. The presence of these two main populations was further proven by TEM 
images, where irregular shaped BHS with diameters up to 450 nm and rather spherical 
BHS with diameter up to 100 nm were found. Nevertherless, these purified avidin/PPI-
baGP BHS were investigated concerning their interaction with pCD and their Dh could be 
tailored in the range of 450 nm – 5.4 µm. 
 
Table 4.4.4 Overview of fabricated avidin/baGP and avidin/baGP/pCD BHS and their average 
dimensions. 
 
BHS molar ratio Dh, min – Dh, max 
avidin/PPI-baGP 1/0.5 – 1/2 70 – 1150 nm 
avidin/PEI-baGP 1/0.5 – 1/2 90 – 520 nm 
   
avidin/PPI-baGP/pCD 1/1.5/32 – 1/1.5/54  0.8 – 1.8 µm 
avidin/PEI-baGP/pCD 1/1.5/43 – 1/1.5/65 1.1 – 2.6 µm 
   
avidin/PPI-baGP/pCD
a 
1/1.5/21 – 1/1.5/87 0.45 – 5.4 µm 
a 
BHS were fabricated with purified avidin/PPI-baGP and pCD. 
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The formation of hydrogel particles based on host-guest interaction with (β-)cyclodextrin 
has been widely shown and with respect to the investigations in chapter 4.3, it is rational 
to assume such a loose network of the avidin/baGP/pCD BHS as well. A schematic section 
of the avidin/baGP/pCD BHS is shown in Figure 4.4.8. 
 
 
Figure 4.4.8 Section of the hydrated and rather loose network of BHS composed of avidin 
(violet), baGP (black) and pCD (green). 
 
This work provides a toolbox for the fabrication of BHS composed of avidin and bGP 
the sizes and consequently, the molar masses of the BHS were shown to be conveniently 
tailored by the (i) degree of biotinylation, (ii) ligand-receptor stoichiometry, (iii) length of 
biotin ligand and (iv) sequence of BHS formation. Furthermore, it was shown that a 
biotinylated enzyme can be incorporated with retained or even enhanced enzymatic 
activity. The introduction of functional entities such as biotin and adamantane into the 
dendritic structures facilitating different molecular recognition processes allowed even to 
tailor the sizes in the nano- and micrometer range. 
 
 
4.4.2   Outlook 
 
 The ability to control the sizes and, consequently, the molar masses along with the 
properties of the isolated nanostructures imply that those BHS are suitable candidates for 
drug uptake and release studies. In addition, the easiness of the decoration of 
maltosylated dendritic glycopolymers with imaging moieties provide the possibility to 
study the cellular uptake by different cell lines in order to evaluate their potential as drug 
delivery vehicles.
[140]
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The convenient fabrication and purification of the enzymatic BHS as well as the potential 
to control important properties of the enzymatic BHS make them promising candidates 
for e.g. directed enzyme prodrug therapy, using the enzyme prodrug combination (b)HRP 
and indol-3-acetic acid. Moreover, the proof of the attachment of different biotinylated 
compounds such as the bGP or the bHRP are a promising finding concerning the 
multifunctionality of such BHS. Consequently, it is worth to fabricate BHS possessing both 
imaging moieties as well as other active targeting moieties.  
The formation of hydrogel particles based on host-guest interaction with (β-)cyclodextrin 
has been widely shown. With respect to the investigations in this work avidin/baGP BHS 
can be assumed as loose networks allowing the complexation of low molecular weight 
drugs. The high content of hydrophilic macromolecules such as avidin on the one hand 
and on the other hand the high content of hydrophobic ligands (C6B and C10A) along with 
the decreased amount of maltose units coupled to the dendritic scaffolds may allow not 
only the complexation of hydrophilic but also of hydrophobic drugs. Since the structure of 
the avidin/baGP BHS was found to be concentration dependent, this needs to be 
investigated with regard to an application in the biomedical field.  
In the case of the avidin/baGP/pCD BHS, the dependence of the resulting sizes on the 
total concentration of the conjugation solution needs to be investigated as well. 
Furthermore, it can be assumed that these networks possess a high content of available 
functionalities (biotin, adamantane or β-cyclodextrin), which potentially provide the 
incorporation or attachment of further functional or bioactive moieties to these 
structures. Due to the hydrophobicity of the β-cyclodextrin cavity and the generally 
hydrophilic character of the network, caused by its high glycopolymer and protein 
content, it is worth to study the uptake and release of both hydrophobic and hydrophilic 
(model) drugs, especially with respect to the pCD content. 
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5.1   Methods and Instruments 
 
1
H NMR spectroscopy 
 
The NMR experiments were performed on a Bruker Avance III 500 NMR spectrometer 
operating at 500.13 MHz for 
1
H NMR. DMSO-d6 or D2O were used as solvents. The spectra 
recorded from DMSO-d6 solutions were calibrated on the solvent signal 
(δ (
1
H) = 2.50 ppm). Spectra recorded from D2O or DMSO-d6 if required acidified with TFA 
were referenced on external sodium 3-(trimethylsilyl)-3,3,2,2-tetradeuteropropionate in 
D2O (δ(
1
H) = 0 ppm).  
 
Matrix-assisted laser desorption/ionization time of flight mass spectrometry 
(MALDI-TOF MS)  
 
The MALDI-TOF experiments were performed on a Autoflex Speed TOF/TOF 
(Bruker Daltonics GmbH) with 2,5-dihydroxybenzoic acid as matrix and and millipore 
water as solvent. The measurements were conducted in a linear mode with a positive 
polarity. The acceleration voltage was set to 20 kV. PMMA was used as a standard. 
Measurements were conducted with a suppression of molar masses below 2 kDa. 
 
Laser-induced liquid bead ion/desorption mass spectrometry (LILBID-MS) 
 
A liquid micro droplet of the aqueous fluid sample (ca. 50 µL) were irradiated by 
synchronized IR laser pulses (λ = 3 µm) generated by a home built optical parametric 
oscillator (OPO) based on a LiNbO3 crystal and pumped by a commercial pulsed Nd-YAG 
laser. The laser energy is absorbed by O-H stretch vibrations of water molecules, which 
leads to the superexcitation and subsequent explosive disruption of the droplet. The 
samples injected into vacuum were analysed by a TOF mass spectrometer. The dendrimer 
samples (PPI-DS-C6Bx, x = 0, 1, 2, 4; PPI-DS-PEG12Bx, x = 1, 2) were prepared in aqueous 
solution at concentrations of 4 × 10
-6
 M. All measurements were performed in anionic 
mode. LILBID-MS was used to determine the molar masses of compounds PPI-DS-C6B1 
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and avidin and to study selected BHS of avidin/PPI-DS-C6B1 (5 μM/5 μM and 
5 μM/20 μM) in 10 mM TRIS/HCl at pH 7.5 after an incubation time of 1 d. The technique 
is described more detailed elsewhere.
[214]
 
 
Elemental analysis 
 
Elemental analyses were carried out on a Hekatech EA 3000 Euro Vector CHNSO 
elemental analyser at Technical University of Dresden. 
 
Dynamic light scattering 
 
To characterize the particle size and size distribution, dynamic light scattering (DLS) 
measurements were carried out at 25 °C at a fixed angle of 173° using the Nano Zetasizer 
(Malvern), equipped with a He–Ne laser (4 mW) and a digital autocorrelator. The 
observed data was analysed very carefully. Thus only measurements with a good fit and 
an exponential graphic representation were considered here. The particle size 
distribution was determined using a multimodal peak analysis by intensity, volume and 
number, respectively.  
 
UV/Vis spectroscopy 
 
UV/Vis spectra were recorded at room temperature (25 °C) on a Varian Cary 50 UV/Vis 
spectrometer (Varian Inc.) or Specord 20 Plus UV/Vis spectrometer (Analytik Jena AG.). 
Slit width was 1 nm.  
 
Zetapotential measurements 
 
Zetapotential measurements were conducted at Zetasizer Nano S (Malvern Instruments 
GmbH, Germany). The concentration of the samples (PPI-DS-C6Bx, x = 1 or 2) amounted 
about 1 mg/mL in 1 mM KCl solution. Adjustment of the pH was done by an autotitrator 
by adding 0.1 M KOH and 0.1 M HCl, respectively. 
 
Asymmetrical flow field flow fractionation 
 
The AF4 instrument was an Eclipse 3 Separation System (Wyatt Technology Europe, 
Germany). The flow was controlled with an isocratic pump (1200 Series from Agilent 
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Technologies, USA) and all injections were performed with an autosampler (1200 Series 
from Agilent Technologies, USA). A long AF4-channel (Wyatt Technology Europe, 
Germany) with a tip-to-tip length of 26.65 cm and a nominal thickness of 490 µm was 
used. The ultra-filtration membrane forming the accumulation wall was made of 
regenerated cellulose with a molecular weight cut off of 10 kDa (Wyatt Technology 
Europe, Germany). The detection system consists of a multi angle laser light scattering 
detector (MALLS) (DAWN EOS from Wyatt Technology Europe, Germany) operating at 
ʎ = 690 nm and a refractive index detector (Dn 2010 from WGE Dr Bures, Germany) 
operating at ʎ = 620 nm. Additionally, the AF4 was coupled to a dynamic light scattering 
device, which measures at a fixed angle of 90° using the DynaPro NanoStar (Wyatt 
Technologies Europe, Germany) equipped with a laser (ʎ = 663 nm) and a digital 
autocorrelator. Carrier liquid was prepared with 50 mM nitrate buffer at a pH of 6.8 and 
0.02 % (w/v) NaN3 dissolved in pure water, which was deionised, UV treated and ultra-
filtrated by a Purelab Plus UV/UF equipment (ELGA LabWater, Germany). 
The sample injection of 100 µL into the channel was performed at a flow rate of 
0.2 mL/min during 2 min. The sample load was approximately 100 µg – 150 µg. 
Separation and determination of the molar masses of the samples was performed after 
focusing at 3 mL/min over a period of 2 min and elution with a linearly decaying cross 
flow from 3 mL/min to 0 mL/min in 15 min and afterwards without any cross flow for 
10 min. The detector flow rate was constant at 1 mL/min throughout the measurement. 
Two measurements of each sample were carried out. Afterwards a blank run was 
performed for the baseline subtraction of the pressure sensitive signal of the refractive 
index detector. Collecting and processing of detector data were done by the Astra 
software, version 5.3.4.20 (Wyatt Technology, USA). The molar mass dependence of the 
elution volume was fitted with 4
th
 degree exponential and for molar masses > 500 kg/mol 
fitted with the Berry model. For Mw determination the dn/dc values were externally 
determined at 25 °C using the refractive index detector of the system. The refractive 
index increments were initially determined for the light scattering calculations. Since the 
occurring differences in the determined dn/dc value showed to not significantly alter the 
final molar masses or molar mass distributions the dn/dc values were set to 0.140 mL/g 
for the functionalized glycopolymers and to 0.160 mL/g for the BHS if not otherwise 
denoted based on the determined dn/dc values (Table 5.1.1).  
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Table 5.1.1 dn/dc values and recoveries of samples analyzed by AF4. 
 dn/dc total recovery 
sample [mL/g] [%] 
avidin 0.174 86 
PPI-DS 0.149 87 
PPI-DS-C6B1 0.143 80 
PPI-DS-C6B2 0.148 84 
PPI-DS-C6B8 0.140 77 
PPI-DS-PEG12B1 0.135 82 
PPI-DS-PEG12B2 0.145 84 
PPI-DS-PEG12B4 0.140 97 
PPI-DS-PEG12B8 0.140 96 
avidin/PPI-DS-C6B1 1/1 0.160 77 
avidin/PPI-DS-C6B1 1/3 0.160 59 
avidin/PPI-DS-PEG12B1 1/3 0.160 68 
avidin/PPI-DS-PEG12B2 1/1 0.160 74 
purified avidin/PPI-DS-PEG12B2 1/1  0.160 60 
purified avidin/bHRP/PPI-DS-C6B1 1/0.5/0.5 0.218 35 
 
Transmission electron microscopy 
 
Libra 120 or Libra 200 (Carl Zeiss AG, Oberkochen, Germany) were used to gain brightfield 
images of the BHS. Samples were prepared by dropping sample solutions with an 
increased concentration of about 2 mg/mL and a decreased molarity of the buffer 
( ≤ 10 mM) or desalted and in milipore water on carbon coated gold grids (300-mesh, 
Plano GmbH, Wetzlar, Germany). The air dried samples were examined in the transmission 
electron microscope at an acceleration voltage of 120 kV and 200 kV, respectively.  
Polymer specimens for cryoTEM imaging were prepared with the help of a cryoplunger 
Leica EM GP (Leica Mikrosysteme Vertrieb GmbH, Germany) on Quantifoil R 1.2/1.3 holey 
carbon film grids (Science Services GmbH, Germany). 
 
Hollow fiber filtration – Purification of conjugation solutions 
 
Hollow fiber filtration method was done using the KrosFlo-Research-Iii 
(SpectrumLabs, USA). 
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5.2   Materials 
 
List of Chemicals  
1-adamantyl isothiocyanate Sigma Aldrich 
6-(N-biotinylamino)caproic acid Sigma Aldrich 
11-aminoundecanoic acid Merck 
β-cyclodextrin polymer Sigma Aldrich 
Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium 
hexafluorophosphate (BOP) 
Sigma Aldrich 
 
Biotin-PEG12-COOH Iris Biotech 
D-(+)-Maltose Monohydrat Sigma-Aldrich 
DAB-Am 64 (4
th
 generation poly(propylene imine) SyMO-Chem,Eindhoven 
Borane pyridine complex Fluka 
D2O (> 99.99 % D)  Euriso-top 
Dichloromethane Sigma-Aldrich 
DMSO (p.a.)  Fluka  
DMSO-d6 (> 99.9 % D)  Euriso-top 
Horseradish peroxidase Life Technologies 
Horseradish peroxidase, biotin-XX conjugate Life Technologies 
Hydrochloric acid (Tritisol®) Merck 
Hydrogen peroxide VWR 
Lupasol WF; poly(ethylene imine) Mw = 25000 g/mol BASF, Ludwigshafen 
Monopotassium phosphate Sigma Aldrich 
Nitrate buffer Merck 
N,N - dimethylformamid Fluka 
Pyrrogallol Sigma Aldrich  
Sodium azide Carl Roth GmbH 
Sodium chloride (>99.5%)  Sigma-Aldrich  
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List of Chemicals  
Sodium hydroxide Sigma-Aldrich 
Sodium tetraborate decahydrate Sigma-Aldrich 
TFA-d Euriso-top 
Triethylamine Fluka 
Tris(hydroxymethyl)aminomethane) Sigma-Aldrich 
 
List of Materials  
Regenerated Celluloses tubings membranes:  Carl Roth 
MWCO 1000, MWCO 2000  
Hollow fiber filtration modules: Spectrum Labs 
Modified Polyethersulfone (mPES) with MWCO of  
100 kDa, 300 kDa, 500 kDa, 0.2 µm   
Mixed Cellulose Ester (ME) with MWCO of 0.1 µm  
UV (Semi-)Microcuvettes Carl Roth 
 
Used buffer solutions  
0.1 M TRIS/HCl/NaCl at pH 7.5  
20 mL of 1 M HCl, 3.029 g of TRIS and 2.630 g of NaCl was dissolved in 430 mL milipore 
water. 
0.1 M Phosphate buffer solution at pH 7.4  
0.136 g of KH2PO4 was dissolved in 40 mL of milipore water. The pH of the solution was 
adjusted to 7.4 by adding 0.1 M NaOH. 
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5.3   Syntheses 
 
5.3.1   Syntheses of Biotinylated Dendritic Glycopolymers 
 
Synthesis of biotinylated poly(propylene imine) dendrimers 
 
General procedure for the synthesis of the precursor PPI-C6Bx, PPI-PEG12Bx, x = 1, 2, 4 
and 8 
 
4
th
 generation PPI dendrimer (PPI, 7168 g/mol), 6-(N-biotinylamino)caproic acid (C6B, 
357.47 g/mol) or biotin-PEG12-COOH (PEG12B, 844.0 g/mol), benzotriazole-1-yl-oxy-tris-
(dimethylamino)-phosphonium hexafluorophosphate (BOP, 442.28 g/mol) and 
triethylamine (Et3N, 0.73 g/mL, 101.19 g/mol) were taken up in DMSO (ca. 10 mL). The 
solution was stirred at room temperature for two days. The crude product was purified by 
dialysis in deionized water for two days with regenerated celluloses tubing membranes 
with either 1 kDa or 2 kDa of MWCO. A yellowish, viscous substance was obtained by 
freeze drying. The product was yielded quantitatively as a solid. The weight ins of these 
syntheses are summarized in Table 5.3.1.  
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Table 5.3.1 Weight ins of the syntheses of biotinylated poly(propylene imine). 
 
 
 PPI C6B PEG12B BOP NEt3 
 
 
compound 
eq 
[mol] 
[mg] 
eq 
[mol] 
[mg] 
eq 
[mol] 
[mg]] 
eq 
[mol] 
[mg] 
eq 
[mol] 
[mL] 
PPI-C6B1 
1.0 
1.395 × 10
−5 
100.0 
1.1 
1.535 × 10
−5 
5.5 
- 
2.5 
3.488 × 10
−5
 
15.5 
103.4 
1.44 × 10
−3
 
0.1 
PPI-C6B2 
1.0 
1.395 × 10
−5 
100.0 
2.2 
1.535 × 10
−5 
11.0 
- 
5.0 
6.975 × 10
−5
 
31.0 
103.4 
1.44 × 10
−3
 
0.1 
PPI-C6B4 
1.0 
1.395 × 10
−5 
100.0 
4.4 
1.535 × 10
−5 
22.0 
- 
11.0 
16.89 × 10
−5
 
62.0 
103.4 
1.44 × 10
−3
 
0.1 
PPI-C6B8 
1.0 
1.395 × 10
−5 
100.0 
8.4 
11.72 × 10
−5 
42.0 
- 
16.8 
23.44 × 10
−5 
94.7 
103.4 
1.44 × 10
−3
 
0.1 
PPI-PEG12B1 
1.0 
1.395 × 10
−5 
100.0 
- 
1.1 
1.535 × 10
−5 
13.0 
5.0 
6.975 × 10
−5
 
31.0 
103.4 
1.44 × 10
−3
 
0.1 
PPI-PEG12B2 
1.0 
1.395 × 10
−5 
100.0 
- 
2.2 
1.535 × 10
−5 
26.0 
10.0 
13.95 × 10
−5
 
62.0 
103.4 
1.44 × 10
−3
 
0.1 
PPI-PEG12B4 
1.0 
1.395 × 10
−5 
100.0 
- 
4.4 
3.07 × 10
−5 
52.0 
8.8 
13.95 × 10
−5
 
54.6 
103.4 
1.44 × 10
−3
 
0.1 
PPI-PEG12B8 
1.0 
1.395 × 10
−5 
100.0 
- 
8.4 
11.72 × 10
−5 
99.3 
16.8 
23.44 × 10
−5 
94.7 
103.4 
1.44 × 10
−3
 
0.1 
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PPI-C6Bx and PPI-PEG12Bx 
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PPI-C6Bx (x = 1, 2, 4 or 8): 
1
H NMR (D2O): 4.60 (10), 4.41 (9), 3.32 (12), 3.2–2.3 (18, b, c, e, 
f, h, I, k, l, n, o, q of IIb), 2.89 (q of I), 2.99 and 2.78 (11), 2.24 (16,22), 1.9-1.6 (1H of 13, a, 
d, g, j, m, p), 1.6-1.25 ppm (1H of 13, 14, 15, 19-21). Free ligand (-COOH): 1.55 (21), 2.17 
(22); IR: 3298 (NH2), 2865 (CH, CH2), 2802 (CH, CH2), 1646 (C=O), 1566 (N-H, NH2), 1384 
(CH2, CH3) 1009 cm
-1
 (C-O); molar masses: PPI-C6B1: MHT = 7500 g/mol, 
MNMR = 7540 g/mol, MMALDI-TOF MS = 7400 g/mol (Figure 4.1.6b); PPI-C6B2: 
MHT = 7850 g/mol, MNMR = 7850 g/mol; PPI-C6B4: MHT = 8500 g/mol, MNMR = 8560 g/mol, 
MMALDI-TOF MS = 8100 g/mol (Figure 4.1.6b); PPI-C6B8: MNMR = 9850 g/mol, , MMALDI-
TOF MS = 1100 g/mol (Figure 4.1.6d). 
 
PPI-PEG12Bx (x = 1, 2, 4 or 8): 
1
H NMR (D2O): 4.60 (10), 4.41 (9), 3.77 (21), 3.69 (20), 3.62 
(19), 3.38 (18), 3.33 (12), 3.3–2.3 (b, c, e, f, h, I, k, l, n, o, q of IIb), 2.93 (q of I), 2.99 and 
2.78 (11), 2.52 (22), 2.27 (16), 1.9-1.6 (1H 0f 13, a, d, g, j, m, p), 1.6-1.35 ppm (1H of 13, 
14, 15). Free ligand (-COOH): 3.73 (21), 2.45 (22); IR: 3305 (NH2), 2870 (CH, CH2), 2802 
(CH, CH2), 1646 (C=O), 1566 (N-H, NH2), 1384 (CH2, CH3) 1010 cm
-1
 (C-O). 
molar masses: PPI-PEG12B1: MHT = 8000 g/mol, MNMR = 8000 g/mol; 
PPI-PEG12B2: MHT = 8820 g/mol, MNMR = 8900 g/mol; PPI-PEG12B4: MHT = 10500 g/mol, 
MNMR = 10560 g/mol; PPI-PEG12B8: MNMR = 13940 g/mol.  
 
Molar masses were obtained by summation of the molar mass of the dendritic scaffold 
and the attached ligands. The degree of biotinylation was either determined by HABA 
displacement titrations (MHT) and/or by a NMR approach (MNMR). 
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General procedure for the synthesis of the maltose modified dense shell 
poly(propylene imine) glycodendrimers 
 
The precursor, maltose monohydrate (360.31 g/mol) and borane-pyridine complex 
(BH3 × Pyr, 8 M) were taken up in a sodium borate buffer (ca. 25 ml, 0.1 M). The solution 
was stirred at 50 °C for seven days. The crude product was purified twice by dialysis with 
regenerated celluloses tubings membranes with MWCO of 2 kDa with deionized water for 
four days to ensure the capture of impurities. The white, solid product was obtained by 
freeze drying. The weight ins and yields of these syntheses are summarized in Table 5.3.2. 
 
Table 5.3.2 Molar mass of the precursors, weight ins and overall yield of the PPI-(b)GP syntheses. 
 
 Precursor Maltose BH3 × Pyr Yield 
 
 
compound 
 
eq 
[mol] 
[mg] 
eq 
[mol] 
[g]] 
eq 
[mol] 
[mL] 
[%] 
PPI-DS 
PPI 
7168 g/mol 
1.0 
1.395 × 10
−5 
100.0 
1280.0 
17.86 × 10
−3 
6.44 
1280.0 
17.86 × 10
−3 
2.24 
94 
PPI-DS-C6B1 
PPI-C6B1 
7500 g/mol 
1.0 
1.379 × 10
−5 
105.0 
1280.0 
17.65 × 10
−3 
6.36 
1280.0 
17.65 × 10
−3 
2.22 
95 
PPI-DS-C6B2 
PPI-C6B2 
7850 g/mol 
1.0 
1.388 × 10
−5 
109.0 
1280.0 
17.77 × 10
−3 
6.40 
1280.0 
17.77 × 10
−3 
2.24 
92 
PPI-DS-C6B4 
PPI-C6B4 
8500 g/mol 
1.0 
1.282 × 10
−5 
109.0 
1280.0 
16.41 × 10
−3 
5.91 
1280.0 
16.41 × 10
−3 
2.07 
96 
PPI-DS-C6B8 
PPI-C6B8 
9850 g/mol 
1.0 
0.58 × 10
−5 
57.3 
1280.0 
7.42 × 10
−3 
2.67 
1280.0 
7.42 × 10
−3 
0.45 
99 
PPI-DS-PEG12B1 
PPI-PEG12B1 
8000 g/mol 
1.0 
1.377 × 10
−5 
110.2 
1280.0 
17.63 × 10
−3 
6.35 
1280.0 
17.63 × 10
−3 
2.22 
93 
PPI-DS-PEG12B2 
PPI-PEG12B2 
8820 g/mol 
1.0 
1.385 × 10
−5 
122.2 
1280.0 
17.73 × 10
−3 
6.39 
1280.0 
17.73 × 10
−3 
2.23 
95 
PPI-DS-PEG12B4 
PPI-PEG12B4 
10500g/mol 
1.0 
0.842 × 10
−5
 
88.4  
1280.0 
10.78 × 10
−3 
6.39 
1280.0 
10.78 × 10
−3 
1.36 
92 
PPI-DS-PEG12B8 
PPI-PEG12B8 
13940 g/mol 
1.0 
0.313 × 10
−5
 
52.9 
1280.0 
4.0 × 10
−3 
6.39 
1280.0 
4.0 × 10
−3 
0.5 
94 
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1
H NMR: (D2O). 4.4–3.3 (2-6,2’-6’,12), 3.3–2.2 (1’, b, c, e, f, h, I, k, m, n, o, q), 2.2–1.1 ppm 
(a, d, g, j, m, p); IR: 3305 (NH2), 2870 (CH, CH2), 2802 (CH, CH2), 1646 (C=O), 1566 (N-H, 
NH2), 1384 (CH2, CH3) 1010 (C-O); molar masses: MLILBID MS = 46900 g/mol (Figure A4.1.9a). 
 
PPI-DS-C6Bx and PPI-DS-PEG12Bx 
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PPI-DS-C6Bx (x = 1, 2, 4 or 8): 
1
H NMR (D2O): 5.4–5.0 (1), 4.60 (10), 4.43 (9), 4.4–3.3 (2-
6,2’-6’,12), 3.3–2.2 (1’, 11, 16, 18, 22, b, c, e, f, h, I, k, l, n, o, q), 2.2–1.1 ppm (13-15, 19-
21, a, d, g, j, m, p); IR: 3298 (NH2), 2865 (CH, CH2), 2802 (CH, CH2), 1646 (C=O), 1566 (N-H, 
NH2), 1384 (CH2, CH3) 1009 cm
-1
 (C-O); molar masses: PPI-DS-C6B1: 
MLILBID MS = 45900 g/mol, PPI-DS-C6B2: MLILBID MS = 46100 g/mol, PPI-DS-C6B4: 
MLILBID MS = 47650 g/mol (cf. Figures A4.1.9b, A4.1.10a, A4.1.11b); PPI-DS-C6B8: 
MAF4 = 47150 g/mol (cf. Figure A4.1.13a). 
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PPI-DS-PEG12Bx (x = 1, 2, 4 or 8): 
1
H NMR (D2O): 5.4–5.0 (1), 4.60 (10), 4.43 (9), 4.4–3.3 
(2-6,2’-6’,12,18,19,21), 3.70 (20), 3.3–2.2 (1’, 11, 12, 16, 22, b, c, e, f, h, I, k, l, n, o, q), 2,27 
(16), 2.2–1.1 (13-15, a, d, g, j, m, p); IR: 3305 (NH2), 2870 (CH, CH2), 2802 (CH, CH2), 1646 
(C=O), 1566 (N-H, NH2), 1384 (CH2, CH3) 1010 (C-O); molar masses: PPI-DS-PEG12B1: 
MLILBID MS = 45900 g/mol, PPI-DS-PEG12B2: MLILBID MS = 45700 g/mol (cf. Figures A4.1.10b 
and A4.1.11a); PPI-DS-PEG12B4: MAF4 = 41930 g/mol; PPI-DS-PEG12B8: 
MAF4 = 43090 g/mol (cf. Figures A4.1.12 and A4.1.13b). 
 
Molar masses were obtained by LILBID MS or AF4. 
 
Synthesis of biotinylated hyperbranched poly(ethylene imine) polymers 
 
General procedure for the synthesis of the precursor PEI-C6Bx, PEI-PEG12Bx, 
x = 1, 2 and 4 
 
Hyperbranched poly(ethylene imine) of (PEI, Mn = 9600 g/mol, Mw = 25000 g/mol), 6-(N-
biotinylamino)caproic acid (C6B, 357.47 g/mol) or biotin-PEG12-COOH 
(PEG12B, 844.0 g/mol), benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium 
hexafluorophosphate (BOP, 442.28 g/mol) and triethylamine (Et3N, 0.73 g/mL, 
101.19 g/mol) were taken up in DMSO (ca. 10 mL). The solution was stirred at room 
temperature for two days. The crude product was purified by dialysis in deionized water 
for two days with regenerated celluloses tubing membranes with either 1 kDa or 2 kDa of 
MWCO. A yellowish, viscous substance was obtained by freeze drying. The product was 
yielded quantitatively as a solid. The weight ins of these syntheses are summarized in 
Table 5.3.3.  
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Table 5.3.3 Weight ins of the syntheses of biotinylated poly(ethylene imine). 
 
 PEI C6B PEG12B BOP NEt3 
 
compound 
eq 
[mol] 
[mg] 
eq 
[mol] 
[mg] 
eq 
[mol] 
[mg]] 
Eq 
[mol] 
[mg] 
eq 
[mol] 
[mL] 
PEI-C6B1 
1.0 
1.041 × 10
−5 
100.0 
1.1 
1.146 × 10
−5 
4.1 
- 
2.2 
2.292 × 10
−5
 
10.1 
103.4 
1.44 × 10
−3
 
0.1 
PEI-C6B2 
1.0 
1.041 × 10
−5 
100.0 
2.2 
2.292 × 10
−5 
8.2 
- 
4.4 
4.584 × 10
−5
 
20.2 
103.4 
1.44 × 10
−3
 
0.1 
PEI-C6B4 
1.0 
1.041 × 10
−5 
100.0 
4.4 
4.584 × 10
−5 
16.4 
- 
8.8 
9.168 × 10
−5
 
40.4 
103.4 
1.44 × 10
−3
 
0.1 
PEI-PEG12B1 
1.0 
1.041 × 10
−5 
100.0 
- 
1.1 
1.146 × 10
−5 
9.7 
2.2 
2.292 × 10
−5
 
10.1 
103.4 
1.44 × 10
−3
 
0.1 
PEI-PEG12B2 
1.0 
1.041 × 10
−5 
100.0 
- 
2.2 
2.292 × 10
−5 
19.4 
4.4 
4.584 × 10
−5
 
20.2 
103.4 
1.44 × 10
−3
 
0.1 
PEI-PEG12B4 
1.0 
1.041 × 10
−5 
100.0 
- 
4.4 
4.584 × 10
−5 
38.8 
8.8 
9.168 × 10
−5
 
40.4 
103.4 
1.44 × 10
−3
 
0.1 
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PEI-C6Bx (x = 1, 2 or 4): 
1
H NMR (D2O): 4.60 (10), 4.41 (9), 3.5–2.5 (11, 18, NCH2 of PEI), 
3.33 (12), 2.24 (16, 22), 1.72 and 1.64 (13), 1.59 (15,21), 1.51 (19), 1.40 (14), 1.31 ppm 
(20) (cf. Figure A4.1.5). Free ligand (-COOH): 1.55 (21), 2.17 ppm (22); molar masses: PEI-
C6B1: MHT = 9940 g/mol, MNMR = 9940 g/mol; PEI-C6B2: MHT = 10280 g/mol, 
MNMR = 10300 g/mol; PEI-C6B4: MHT = 10960 g/mol, MNMR = 10900 g/mol. 
 
PEI-PEG12Bx (x = 1, 2 or 4): 
1
H NMR (D2O): 4.60 (10), 4.41 (9), 3.77 (21), 3.69 (20), 3.62 
(19), 3.5–2.5 (11, NCH2 of PEI), 3.38 (18), 3.33 (12), 2.53 (22), 2.27 (16), 1.72 and 1.59 (13), 
1.63 (15), 1.41 ppm (14). Free ligand (-COOH): 3.73 (21), 2.45 ppm (22); molar masses: 
PEI-PEG12B1: MHT = 10430 g/mol, MNMR = 10450 g/mol; PEI-PEG12B2: MHT = 11250 g/mol, 
MNMR = 11300 g/mol; PEI-PEG12B4: MHT = 12900 g/mol, MNMR = 12900 g/mol. 
 
Molar masses were obtained by summation of the molar mass of the dendritic scaffold 
and the attached ligands. The degree of biotinylation was determined by HABA 
displacement titrations (MHT) and by a NMR approach (MNMR). 
 
General procedure for the synthesis of the maltose modified dense shell hyperbranched 
poly(ethylene imine) glycopolymers 
 
The precursor, maltose monohydrate (360.31 g/mol) and borane-pyridine complex 
(BH3 × Pyr, 8 M) were taken up in a sodium borate buffer (ca. 25 ml, 0.1 M). The solution 
was stirred at 50 °C for seven days. The crude product was purified twice by dialysis with 
regenerated celluloses tubings membranes with MWCO of 2 kDa with deionized water 
with for four days to ensure the capture of impurities. The white, solid product was 
obtained by freeze drying. The weight ins and yields of these syntheses are summarized in 
Table 5.3.4. 
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Table 5.3.4 Molar mass of the precursors, weight ins and overall yield of the PEI-(b)GP syntheses. 
 
 Precursor Maltose BH3 × Pyr Yield 
 
 
compound 
 
eq 
[mol]  
[mg] 
eq 
[mol] 
[g]] 
eq 
[mol] 
[mL] 
[%] 
PEI-DS 
PEI 
9600 g/mol 
1.0 
2.17 × 10
−6 
20.0 
2232.6 
4.85 × 10
−3 
1.75 
2232.6 
4.85 × 10
−3 
2.15 
95 
PEI-DS-C6B1 
PEI-C6B1 
9940 g/mol 
1.0 
2.19 × 10
−6 
20.8 
2232.6 
4.89 × 10
−3 
1.76 
2232.6 
4.89 × 10
−3 
2.16 
70 
PEI-DS-C6B2 
PEI-C6B2 
10280 g/mol 
1.0 
2.15 × 10
−6 
21.3 
2232.6 
4.80 × 10
−3 
1.73 
2232.6 
4.80 × 10
−3 
2.12 
69 
PEI-DS-C6B4 
PEI-C6B4 
10960 g/mol 
1.0 
2.13 × 10
−6 
22.5 
2232.6 
4.76 × 10
−3 
1.71 
2232.6 
4.76 × 10
−3 
2.11 
76 
PEI-DS-PEG12B1 
PEI-PEG12B1 
10430 g/mol 
1.0 
2.11 × 10
−6 
22.2 
2232.6 
4.71 × 10
−3 
1.70 
2232.6 
4.71 × 10
−3 
2.08 
89 
PEI-DS-PEG12B2 
PEI-PEG12B2 
11250 g/mol 
1.0 
2.28 × 10
−6 
24.8 
2232.6 
5.09 × 10
−3 
1.83 
2232.6 
5.09 × 10
−3 
2.25 
80 
PEI-DS-PEG12B4 
PEI-PEG12B4 
12900 g/mol 
1.0 
1.85 × 10
−6
 
21.4  
2232.6 
4.13 × 10
−3 
1.49 
2232.6 
4.13 × 10
−3 
1.83 
76 
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PEI-DS: 
1
H NMR (D2O): 5.4–5.0 (1), 4.4–3.3 (2-6,2’-6’), 3.5–2.0 (1’, NCH2 of PEI); 
molar mass: PEI-DS: MEA = 74500 g/mol. 
 
+ 
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PEI-DS-C6Bx or PEI-DS-PEG12Bx 
 
 
PEI-DS-C6Bx (x = 0, 1, 2 or 4): 
1
H NMR (D2O): 5.4–5.0 (1), 4.60 (10), 4.43 (9), 4.4–3.3 (2-
6,2’-6’), 3.5–2.0 (1’, NCH2 of PEI), 3.38 (12), 3.20 (18), 2.98 and 2.79 (11), 2.25 (16,22), 
1.8–1.5 (13,15,19,21), 1.43 (14), 1.35 ppm (20); molar masses: PEI-DS: MEA = 74500 
g/mol, PEI-DS-C6B1: MEA = 74020 g/mol, PEI-DS-C6B2: MEA = 70680 g/mol, PEI-DS-C6B4: 
MEA = 72100 g/mol. 
 
PEI-DS-PEG12Bx (x = 1, 2 or 4): 
1
H NMR (D2O): 5.4–5.0 (1), 4.60 (10), 4.43 (9), 4.4–3.3 (2-
6,2’-6’,18,19,21), 3.70 (20), 3.5–2.0 (1’, NCH2 of PEI), 3.38 (12), 2.98 and 2.79 (11), 2.58 
(22), 2.27 (16), 1.8–1.5 (13,15), 1.42 ppm (14); molar masses: PEI-DS-PEG12B1: MEA = 
70300 g/mol, PEI-DS-PEG12B2: MEA = 71200 g/mol, PEI-DS-PEG12B4: MEA = 72200 g/mol.  
 
Molar masses were obtained by Elemental analysis (cf. Table 5.3.5). 
 
Elemental analysis of PEI-bGP 
 
The degree of maltosylation and the corresponding molar masses of the PEI-bGP were 
calculated according to the reported protocol based on the carbon and nitrogen content 
of the sample determined by elemental analysis.
2
 For instance, the carbon and nitrogen 
content of PEI-DS-C6B4 are 41.81 % and 4.35 %, respectively. With the number average of 
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the molar mass of hb poly(ethylene imine) of 9600 g/mol and the molar mass of one 
monomer of about 43 g/mol the degree of polymerization (DP) can be calculated to 223. 
The molar mass of the final polymer is: 
 
Mpolymer = (C2H5N)·DP + a·(C16H27N3O4S - H2O) + b·(C12H23O10 - H2O) with  
 
DP = degree of polymerization  
a = degree of biotinylation = 4 
b = degree of maltosylation 
(C2H5N)·= molar mass of a monomer 
(C16H27N3O4S - H2O) = molar mass of a coupled biotin ligand 
(C12H23O10 - H2O) = molar mass of a coupled maltose moiety 
 
carbon content = C = 
223·2·12.01	+ a·16·12.01+b·12·12.01
Mpolymer
 
 
nitrogen content = N = 
223·14.01+a·3·14.01
Mpolymer
 
 
with 
C
N
 = 
41.81 
4.35
  → b = 176 
 
The measured C and N values for PEI-DS-C6Bx with x = 1, 2 and PEI-DS-PEG12Bx with 
x = 0, 1, 2, 4 are summarized in Table 5.3.5. 
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Table 5.3.5 Determinations of the carbon and nitrogen content of (non-)biotinylated 
PEI glycopolymers, degrees of maltose functionalization and resulting molar masses. 
 
 C content N content Number of Molar Mass 
compound [%] [%] Maltose [g/mol] 
PEI-DS 
41.09 
41.00 
3.94 
3.91
 190 (229)
 74500
 
PEI-DS-C6B1 
41.52 
41.45 
4.10 
4.13
 188 (227)
 74000
 
PEI-DS-C6B2 
41.81 
41.71 
4.35 
4.39 
178 (225)
 70700
 
PEI-DS-C6B4 
41.81 
41.71 
4.35 
4.39 
182 (221)
 72100
 
PEI-DS-PEG12B1 
42.00 
42.04 
4.30 
4.34 
177 (227)
 70300
 
PEI-DS-PEG12B2 
42.00 
42.04 
4.30 
4.34 
180 (225)
 71200
 
PEI-DS-PEG12B4 
42.00 
42.04 
4.30 
4.34
 155 (221)
 72200
 
 
  
 
5.3 Syntheses 
 
164 
 
 
5.3.2   Syntheses of Biotinylated and Adamantylated Dendritic Glycopolymers 
 
Synthesis of 11-(N-(adamantane-1-yl-thiocarbamoyl)amino)-undecanoic acid 
 
1-adamantyl isothiocyanate (1.5 eq, 193.3 g/mol, 1.035 × 10
-3
 mol), 11-aminoundecanoic 
acid (1 eq, 201.3 g/mol, 0.695 × 10
-3
 mol) and triethylamine (3 eq, 101.19 g/mol, 2.09 × 
10
-3
 mol) was taken up in dry DMF at 70 °C under inert gas atmosphere. The dispersion 
was stirred at 70 °C until a clear solution resulted. The solvent was removed under 
reduced pressure and the crude product was washed copiously with ethyl acetate. A 
yellowish solid with a yield of 97.7 % was obtained.  
1
H NMR (DMSO-d6): 1.25 (m, 12 H), 1.42 (quin, J = 7.00 Hz, 2 H), 1.48 (quin, J = 7.00 Hz, 2 
H), 1.61 (m, 6 H), 2.02 (m, 3 H), 2.17 (m, J = 8.00 Hz, 6 H), 2.18 (t, 2 H), 3.29 (q, J = 6.00 Hz, 
3 H), 6.81 (s, 1 H), 7.14 (t, J = 5.00 Hz, 1 H) 11.86 (s, 1 H). 
 
Synthesis of adamantylated (and biotinylated) hb dendritic polymers 
 
General procedure for the synthesis of the precursor PPI-C6Bx-C10A6 or PEI-C6Bx-
C10A6, x = 0 o 4 
 
The precursor, 11-(N-(adamantane-1-yl-thiocarbamoyl)amino)-undecanoic acid 
(C10A, 394.61 g/mol, 6.6 eq, 9.207 mol), benzotriazole-1-yl-oxy-tris-(dimethylamino)-
phosphonium hexafluorophosphate (BOP, 442.28 g/mol) and triethylamine (Et3N, 
0.73 g/mL, 101.19 g/mol) were taken up in DMSO (ca. 10 mL). The solution was stirred at 
room temperature for two days. The crude product was purified by dialysis in deionized 
water for two days with regenerated celluloses tubings membranes with 2 kDa of MWCO. 
Yellowish viscous substances were obtained by freeze drying. The products were yielded 
quantitatively as solids. The weight ins of theses syntheses are summarized in Table 5.3.6.  
 
 
HO NH2
O SCN
HO N
H
N
H
SO
NEt3, DMF, 70°C
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Table 5.3.6 Molar mass of the precursors and weight ins of the syntheses of the biotinylated and 
adamantylated dendritic polymers. 
 
 Precursor  C10A BOP NEt3 
compound  
eq 
[mol] 
[mg] 
eq 
[mol] 
[mg] 
eq 
[mol] 
[mg] 
eq 
[mol] 
[mL] 
PPI-C10A6 
PPI 
7168 g/mol 
1.0 
3.24 × 10
−5 
232.0 
6.6 
2.13 × 10
−4 
84.0 
13.2 
4.26 × 10
−4
 
188.9 
103.4 
2.88 × 10
−3
 
0.2 
PPI-C6B4-C10A6 
PPI-C6B4 
8500 g/mol 
1.0 
2.55 × 10
−5 
217.3.0 
6.3 
1.61 × 10
−4 
63.3 
12.6 
3.22 × 10
−4
 
142.1 
103.4 
2.88 × 10
−3
 
0.2 
PEI-C10A6 
PEI 
9600 g/mol 
1.0 
1.0 × 10
−5 
100.0 
6.3 
6.6 × 10
-5
 
25.9 
12.6 
1.31 × 10
-4
 
58.1 
36 
3.61 × 10
-4
 
0.05 
PEI-C6B4-C10A6 
PEI-C6B4 
10960 g/mol  
1 
7.3 × 10
-6
 
80.0 
6,3 
4.6 × 10
-5
 
18.0 
12,6 
9.1 × 10-5 
40.4 
49 
3.61 × 10
-4
 
0.05 
 
 
PPI-C10A6 
 
N N N NRR´NN
2 2 2 2
a
b
c
d
e f
g
h i
j
k l
m
n o
p q 2 2
N
H
N
H
N
H
SO x
y
z
wv23
24
25
26
27
28
29
30
31
32
surface species IIc: R = H (I), R´=
surface species I: R, R´= H
 
1
H NMR (DMSO-d6 + TFA-d): 3.75-2.7 (23, b, c, e, f, h, i, k, l, n, o, q), 2.45 (32), 2.35-1.85 
(a, d, g, j, m, p), x (2.1), 2.05 (y), 1.65 (z), 1.45 (31), 1.4 (24), 1.3-1.1 (25-30); molar 
masses: MMALDI-TOF MS = 7780 g/mol (Figure 4.3.7a); MNMR = 9400 g/mol. 
 
  
 
5.3 Syntheses 
 
166 
PPI-C6B4-C10A6 
 
H
N
O
N
H
O
S
NHHN
O
H
Hq
7
8
9
10
11
1213
14
15
16
17
20
21
22 18
19
surface species IIa: R = H (I), R´=
N N N NRR´NN
2 2 2 2
a
b
c
d
e f
g
h i
j
k l
m
n o
p q 2 2
N
H
N
H
N
H
SO x
y
z
wv23
24
25
26
27
28
29
30
31
32
surface species IIc: R = H (I), R´=
surface species I: R, R´= H
 
1
H NMR (DMSO-d6 + TFA-d): 4.35 (9), 4.15 (10), 3.75-2.7 (11, 18, 23, b, c, e, f, h, i, k, l, n, o, 
q), 2.45 (32), 2.4-1.9 (16, 22, a, d, g, j, m, p), 2.1 (x), 2.05 (y), 1.65 (z), 1.6-1.15 (13-15, 19-
21, 24, 31), 1.25 (25-30); molar masses: MMALDI-TOF MS = 9960 g/mol (Figure 4.3.8b); 
MNMR = 10800 g/mol. 
 
Molar masses were obtained by summation of the molar mass of the dendritic scaffold 
and the attached ligands. The degree of biotinylation and adamantylation was 
determined by a NMR approach (MNMR). 
 
PEI-C10A6 
 
 
1
H NMR (DMSO-d6 + TFA-d): 4.0- 2.55 (23, NCH2 PEI), 2.45 (32), 2.15 (x), 2.0 (y), 1.6 (z), 
1.6-1.15 (24, 31), 1.25 (25-30); molar masses: MNMR = 12200 g/mol and 
MEA = 12000 g/mol.  
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PEI-C6B4-C10A6 
 
 
 
1
H NMR (DMSO-d6 + TFA-d): 4.35 (9), 4.15 (10),4.0- 2.55 (11, 18, 23, NCH2 PEI), 2.45 (32), 
2.15 (x), 2.1 (16, 22), 2.0 (y), 1.6 (z), 1.6-1.15 (13-15, 19-21, 24, 31), 1.25 (25-30); molar 
masses: MNMR = 13900 g/mol and MEA = 13100 g/mol.  
 
Molar masses were determined by a NMR approach and elemental analysis, respectively. 
(cf. Table 5.3.7). 
 
Synthesis of adamantyated (and biotinylated) poly(propylene imine) glycodendrimers 
and hyperbranched poly(ethylene imine) glycopolymers 
 
The precursor, maltose monohydrate (360.31 g/mol) and borane-pyridine complex 
(BH3 × Pyr, 8 M) were taken up in a sodium borate buffer (15 ml, 0.1 M). The solution was 
stirred at 50 °C for seven days. The crude product was purified by dialysis with deionized 
water for four days. The white, solid product was obtained by freeze drying. The molar 
masses of the precursor, the weight ins and yields of these syntheses are summarized in 
Table 5.3.7.  
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Table 5.3.7 Weight ins and molecular weight of the precursors of synthesis of biotinylated and 
adamantylated dendritic glycopolymers and overall yield. 
  
 Precursor  maltose BH3 × Pyr yield 
 
 
compound 
 
eq 
[mol] 
[mg] 
eq 
[mol] 
[g]] 
eq 
[mol] 
[mL] 
[%] 
PPI-DS-C10A6 
PPI-C10A6 
9400 g/mol 
1.0 
9.724 × 10
−6 
74.0 
1280.0 
12.45 × 10
−3 
4.48 
1280.0 
17.65 × 10
−3 
1.56 
100 
PPI-DS-C6B4-C10A6 
PPI-C6B4-C10A6 
10800 g/mol 
1.0 
5.093 × 10
−6 
54.9 
1280.0 
6.519 × 10
−3 
2.35 
1280.0 
16.41 × 10
−3 
0.82 
70 
PEI-DS-C10A6 
PEI-C10A6 
12200 g/mol 
1.0 
2.159 × 10
−6 
25.8 
2570.9 
5.551 × 10
−3 
2.00 
3668.3 
7.920 × 10
−3
 
0.8 
84 
PEI-DS-C6B4-C10A6 
PEI-C6B4-C10A6 
13900 g/mol  
1.0 
1.879 × 10
−6 
24.6 
2954.2 
5.551 × 10
−3 
2.00 
4215.0 
7.920 × 10
−3
 
0.8 
70 
 
 
PPI-DS-C10A6 
 
N N N NRR´NN
2 2 2 2
a
b
c
d
e f
g
h i
j
k l
m
n o
p q 2 2
N
H
N
H
N
H
SO x
y
z
wv23
24
25
26
27
28
29
30
31
32
surface species IIc: R = H (I), R´=
surface species I: R, R´= H
OH
OH
O
OH
HO
O
OH
OH
OH
OH
surface species III: R, R´= 1´
2´
3´
4´
5´
6´
1
2 3
4
5
6
 
 
1
H NMR (D2O): 5.4–5.0 (1), 4.5–3.35 (2-6,2’-6’), 3.25–2.4 (1’, 23, b, c, e, f, h, i, k, l, n, o, q), 
2.35-2.1 (32, x, y), 2.1–1.55 ppm (24, 31, a, d, g, j, m, p, z), 1.5-1.3 (25-30); molar masses: 
MAF4 = 45500 g/mol. (Figure A4.3.4a). 
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PPI-DS-C6B4-C10A6 
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1
H NMR (D2O): 5.4–5.0 (1), 4.7 (10), 4.5 (9), 4.45–3.45 (2-6,2’-6’), 3.45–2.4 (1’, 11, 12, 18, 
23, 32, b, c, e, f, h, I, k, l, n, o, q), 2.4-2.25 (16, 22, x), 2.2 (y), 2.1–2.55 ppm (a, d, g, j, m, p, 
13, 14, 24, 31, z), 2.55-1.15 (13-15, 19-21, 25-30); molar masses: MAF4 = 31440 g/mol 
(Figure A4.3.4b). 
 
PEI-DS-C10A6 
 
 
1
H NMR (D2O): 5.4–5.0 (1), 4.5–3.4 (2-6,2’-6’), 3.35–2.35 (1’ 23, 32, NCH2 PEI), 2.35-2.05 
(x, y), 1.9–1.7 ppm (24, 31), 1.7-1.6 (z), 2.55-1.2 (25-30); molar masses: 
MEA = 69100 g/mol.  
 
N
H
N
H
SO x
y
z
wv23
24
25
26
27
28
29
30
31
32
surface species IIc: R = H (I), R´=
OH
OH
O
OH
HO
O
OH
OH
OH
OH
surface species III: R, R´= 1´
2´
3´
4´
5´
6´
1
2 3
4
5
6
PEI N
R
N R´
R
PEI N
R´
N R´
R
+
surface species I: R, R´= H
 
5.3 Syntheses 
 
170 
PEI-DS-C6B4-C10A6 
 
 
1
H NMR (D2O): 5.4–5.0 (1), 4.5–3.4 (2-6,2’-6’), 3.35–2.35 (1’, 11, 12, 18, 23, 32, NCH2 PEI), 
2.35-2.05 (16, 22, x, y), 1.9–1.7 ppm (13, 14, 24, 31), 1.7-1.6 (z), 2.55-1.2 (13-15, 19-21, 
25-30); molar masses: MEA = 67700 g/mol.  
 
Molar masses were obtained by Elemental analysis (cf. Table 5.3.8). 
 
Elemental analysis of PEI-(b)aGP 
 
Table 5.3.8 Determinations of the carbon and nitrogen content of (non-)biotinylated and 
adamantylated PEI glycopolymers, degrees of functionalization and resulting molar 
masses. 
 C content N content Number of Number of Number of M 
compound [%] [%] C6B C10A Maltose [g/mol] 
PEI-C10A6 
44.80 
44.60 
20.14 
20.08 
-
 
6 (6)
 
-
 
12000
 
PEI-DS-C10A6 
43.88 
43.51 
4.43 
4.46 
- 6 (6) 176 (215) 69100 
PEI-C6B4-C10A6 
51.06 
50.99 
22.59 
22.54 
5 (4) 6 (6) - 13300 
PEI-DS-C6B4-C10A6 
44.54 
44.38 
5.05 
5.04 
5 (4)
 
6 (6)
 
159 (209)
 
67700
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5.4   Formation Protocolls 
 
5.4.1   BHS Based on Avidin and Biotinylated Dendritic Glycopolymers 
 
BHS based on avidin and bGP for DLS and UV/Vis investigations 
 
An [avidin.HABA] solution with an avidin (66 kDa) concentration of 2 mg/mL was 
prepared with a 16-fold excess of HABA to avidin. This solution was converted with the 
biotinylated compounds (PPI-DS-C6Bx; PPI-DS-PEG12Bx, x = 0, 1, 2, 4, 8; PEI-DS-C6Bx; PEI-
DS-PEG12Bx, x = 0, 1, 2, 4) in 0.1 M TRIS/HCl/NaCl buffer at pH 7.5. The final avidin 
concentration was 6.25 μM within all samples. The probed molar ratios are summarized 
in Table 5.4.1. The resulting BHS were measured by UV/Vis spectroscopy (HABA 
displacement assay) and DLS after 1 d and 14 d, respectively. All measurements were 
conducted in disposable UV microcuvettes in a threefold fashion, if not otherwise 
denoted.  
 
Table 5.4.1 Probed molar ratios of avidin and bGP. 
 
bGP  molar ratio 
non-valent  1/1 and 1/3 
monovalent  1/1, 1/2, 1/3 and 1/4 
bi-, tetra- or octavalent  1/0.25, 1/0.5, 1/1, 1/1.5 and 1/2 
 
 
HABA displacement titrations – Spectrophotometric determination of avidin binding 
capacity with biotin and its analogs
[225] 
 
The titration experiments with the [avidin.HABA] complex were carried out with biotin 
(cbiotin = 0.185 mM) and the bGP (c(ba)GP = 0.15 mM) in a 3-fold determination in disposable 
UV microcuvettes. Therefore the solution [avidin.HABA] complex (cavidin = 10.1 M and 
cHABA = 16 × cavidin) was titrated by appropriate amounts of a concentrated biotin 
(derivative) solution in 0.1 M TRIS/HCl/NaCl buffer at pH 7.5. At the end of the titration, 
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the titrated solution was diluted by approximately 70 % of the starting volume. The 
resulting spectrum for each titration step was corrected by the appropriate dilution 
factor. This procedure was also used to determine the degree of biotin ligand 
functionalization through intersection of the regression of the two linear regions of the 
titration curves before and after the equivalence point.  
 
Determination of bound bGP to avidin 
 
The measured absorbance values at ʎ = 500 nm of [avidin.HABA] complex and the 
[avidin.HABA]/bGP mixtures in combination with the linear regression of the lower part of 
the titration curves were used in order to calculate the corresponding amount of bGP 
coupled to avidin. 
 
Hollow fiber filtration – Purification of avidin/PPI-bGP solutions of different 
compositions and molar ratios 
 
5.4 mL of a 0.1 M TRIS/HCl/NaCl at pH 7.5 solution of avidin (66 kDa) and bGP 
(cbGP = 1 mg/mL) were equilibrated for 1 d. The resulting solution was diluted up to 
approximately 35 mL and subsequently filtrated with different modified polyethersulfone 
membranes with MWCO of 100 kDa, 300 kDa, 500 kDa or 0.2 µm for up to 100 mL with an 
approximate pressure of 200 mbar and a volume flow of 15 mL/s. During the filtration 
procedure samples were taken for DLS measurements.  
 
 
5.4.2   BHS Based on Avidin, Biotinylated dendritic Glycopolymers and 
Biotinylated Horseradish Peroxidase 
 
Preparation of BHS based on avidin, (b)HRP and PPI-DS-PEG12B1 or PPI-C6B4 
 
An [avidin.HABA] solution with an avidin (66 kDa) concentration of 2 mg/mL was 
prepared with a 16-fold excess of HABA to avidin. This solution was converted with the 
biotinylated compounds in a stepwise formation process in 0.1 M TRIS/HCl/NaCl buffer at 
pH 7.5. The final avidin concentration was 6.25 μM within all samples. After equilibration 
of the preconjugates ([avidin.HABA]/bHRP 1/0.25, [avidin.HABA]/bHRP 1/0.5 and 
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[avidin.HABA]/PPI-DS-C6B4 1/0.5) for 1 d the second component was added. The 
resulting BHS ([avidin.HABA]/bHRP/PPI-DS-PEG12B1 1/0.25/1, [avidin.HABA]/bHRP/PPI-
DS-C6B4 1/0.5/0.5 and [avidin.HABA]/PPI-DS-C6B4/bHRP 1/0.5/0.5) were measured in 
disposable UV microcuvettes by UV/Vis spectroscopy and dynamic light scattering after 
one day of equilibration of the resulting [avidin.HABA]/bHRP/PPI-DS-PEG12B1, 
[avidin.HABA]/bHRP/PPI-DS-C6B4 and [avidin.HABA]/PPI-DS-C6B4/bHRP samples. 
 
Determination of bound PPI-bGP and bHRP to avidin 
 
To determine the apparent amount of coupled biotinylated compound to avidin the 
measured differences of absorbance values at ʎ = 500 nm between [avidin.HABA] and 
[avidin.HABA]/bHRP/bGD or [avidin.HABA]/bGD/bHRP mixtures and the linear regression 
of the lower part of the [avidin.HABA]-biotin titration curve were used to calculate the 
apparent amount of biotin moieties coupled to avidin. The [avidin.HABA]-biotin titration 
curve and the corresponding linear regression of the lower part of the titration curve can 
be seen in Figure 5.4.1. In order to determine the amount of bound bHRP or PPI-bGP the 
determined equivalents of bound biotin moieties were multiplied by the degree of 
biotinylation of the particular compounds.  
 
Figure 5.4.1 Titration curve and corresponding lineare fit of its lower part of [avidin.HABA] titrated 
by biotin in 0.1 M TRIS/HCl/NaCl buffer at pH 7.5 and measured by UV/Vis 
spectroscopy. 
 
Horseradish peroxidase activity assay 
 
The enzyme activity of horseradish peroxidise was probed by the conversion of pyrogallol 
to purpurogallin in the presence of H2O2. Therefore 30 % H2O2 was diluted 1:1125 
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(A ≈ 0.4). 0.1 mL of the derived H2O2 solution and 0.15 mL of a 53.3 mg/mL pyrrogallol 
solution was added to 1.2 mL 0.1 M phosphate buffer at pH 7.4. Subsequently 50 μL of a 
0,005mg/mL (b)HRP solution as (A) pure (b)HRP solution or (B) as total amount of (b)HRP 
in the BHS in 0.1 M phosphate buffer at pH 7.4 were added. Followed by immediate 
measurement of the changes in absorbance at λ = 420 nm by UV/Vis spectroscopy for 
20 s. All measurements were done in a 3 fold fashion in disposable UV semi-
microcuvettes. The average slopes of the increasing absorbance values at λ = 420 nm 
were used to quantify the enzymatic activity of (b)HRP within the probed samples. The 
bHRP content in the purified BHS was determined using the bHRP absorbance maximum 
at λ = 400 nm (A400 nm). The standard curve of the A400 nm of bHRP can be seen in 
Figure 5.4.2. 
 
Figure 5.4.2 Standard curve of bHRP at A400 nm measured by UV/Vis spectroscopy in 0.1 M 
TRIS/HCl/NaCl at pH 7.5. 
 
Hollow fiber filtration – Purification of BHS solutions composed of avidin, bHRP and PPI-
DS-C6B4 
 
5.4 mL of a 0.1 M TRIS/HCl/NaCl at pH 7.5 solution of avidin/PPI-DS-C6B4/bHRP or 
avidin/PPI-DS-C6B4/bHRP with a concentration of the PPI-DS-C6B4 of 0.5 mg/mL was 
prepared. After every adding of the first and second component to avidin the reaction 
mixture was equilibrated for 1 d. The resulting solution was diluted up to approximately 
35 mL and subsequently filtrated with a modified polyethersulfone membrane with 
MWCO of 500 kDa for up to 100 mL with an approximate pressure of 200 mbar and a 
volume flow of 15 mL/s. During the filtration procedure samples were taken for DLS 
measurements.  
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5.4.3   BHS Based on Avidin, Biotinylated and/or Adamantylated Dendritic 
Glycopolymers and β-cyclodextrin Polymer 
 
Preparation of BHS based on avidin and biotinylated and/or adamantylated GP 
 
A [avidin.HABA] solution with an avidin (66 kDa) concentration of 2 mg/mL was prepared 
with a 16-fold excess of HABA to avidin. This solution was converted with the 
biotinylated and/or adamantylated GP to reach molar ratios of avidin/baGP of 1/0.25, 
1/0.5, 1/1, 1/1.5 and 1/2 (baGP) or molar ratios of avidin/PPI-aGP of 1/0.5, 1/1, 1/1.5 in 
0.1 M TRIS/HCl/NaCl at pH 7.5. The final avidin concentration was 6.25 μM within all 
samples. The resulting bioconjugates were measured by UV/Vis spectroscopy (HABA 
displacement assay) and DLS after 2 h in disposable UV microcuvettes. Stocksolutions of 
(b)aGP were filtrated by 0.45 µm nylon syringe filters. 
 
Preparation of biohybrid structures based on biotinylated or adamantylated dendritic 
glycopolymers and β-cyclodextrin polymer 
 
A 0.3 mL PPI-DS-C10A6 or PPI-DS-C6B4 containing solution with a concentration of 
1 mg/mL was mixed with a 6 mg/mL solution of β-cyclodextrin polymer (pCD, 3.5 kDa) in 
1/12, 1/24, 1/48 and 1/96 molar ratios in 0.1 M TRIS/HCl/NaCl at pH 7.5. The final PPI-
DS-C10A6 and PPI-DS-C6B4 concentration was approximately 8.5 μM within all samples. 
The resulting samples were measured by DLS after 1 d in disposable UV microcuvettes. 
Stocksolutions of pCD and PPI-DS-C6B4-C10A6 were filtrated by 0.45 µm nylon syringe 
filters. 
 
Preparation of biohybrid structures based on avidin, biotinylated and adamantylated 
dendritic glycopolymer and β-cyclodextrin polymer 
 
An avidin (66 kDa) solution with a concentration of 2 mg/mL was converted with baGP 
(PPI-DS-C6B4-C10A6 and PEI-DS-C6B4-C10A6). After 2 h the pCD (3.5 kDa) was added in 
order to adjust the molar ratios of avidin/baGP/pCD of 1/1.5/1 - 1/1.5/65 in 0.1 M 
TRIS/HCl/NaCl at pH 7.5. The final avidin concentration was 6.25 μM within all samples. 
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The resulting BHS were measured by DLS after 1 d in disposable UV microcuvettes. All 
reference experiments were carried out according to these to protocols. Stocksolutions of 
avidin, pCD, PEI-DS-C6B4-C10A6and PPI-DS-C6B4-C10A6 were filtrated by 0.45 µm nylon 
syringe filters. 
 
Preparation of biohybrid structures based on purified avidin/PPI-DS-C6B4-C10A6 and 
β-cyclodextrin polymer 
 
12 mL of a solution of avidin (66 kDa) (cavidin = 0.4 mg/mL) and PPI-DS-C6B4-C10A6 
(cPPI-DS-C6B4-C10A6 = 0.3 mg/mL) in 0.1 M TRIS/HCl/NaCl at pH 7.5 was equilibrated for 2 h. 
The resulting solution was diluted up to approximately 30 mL and subsequently filtrated 
with mixed cellulose ester membranes with MWCO of 0.1 µm for up to 100 mL with an 
approximate pressure of 200 mbar and a volume flow of 15 mL/s. Samples of the initial 
solution and filtrated solution with an volume of about 12 mL and the concentrated 
filtrated solution with an volume of 2 mL were taken for DLS measurements. 
Subsequently, 200 µL of the concentrated filtrated sample were mixed with 1 - 87 eq of 
pCD (ca. 3 mg/mL) assuming the same concentration of avidin as in the non-purified 
solution. Samples were measured by DLS in disposable UV microcuvettes at the same day 
of their preparation. 
Stocksolutions of avidin, pCD and PPI-DS-C6B4-C10A6 were filtrated by 0.45 µm nylon 
syringe filters. 
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Figure A4.1.1 
1
H NMR spectra of PPI-C6Bx, x = 1, 2 and 4 (solvent: D2O) with assignment of 
representative ligand signals. A summary of the signal assignments of all PPI-C6Bx 
with x = 1, 2, 4 and 8 can be found in the experimental part chapter 5.3.1. 
 
 
Figure A4.1.2 
1
H NMR spectra of PPI-PEG12Bx, x = 1, 2 and 4 (solvent: D2O) with assignment of 
representative ligand signals. A summary of the signal assignments of all PPI-
PEG12Bx with x = 1, 2, 4 and 8 can be found in the experimental part chapter 5.3.1. 
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Figure A4.1.3 
1
H NMR spectra of PPI-DS-C6Bx, x = 1, 2 and 4 (solvent: D2O) with assignment of 
representative ligand signals. A summary of the signal assignments of all PPI-DS-
C6Bx with x = 1, 2, 4 and 8 can be found in the experimental part chapter 5.3.1. 
 
 
Figure A4.1.4 
1
H NMR spectra of PPI-DS-PEG12Bx, x = 1, 2 and 4 (solvent: D2O) with assignment 
of representative ligand signals. A summary of the signal assignments of all PPI-DS-
PEG12Bx with x = 1, 2, 4 and 8 can be found in the experimental part chapter 5.3.1. 
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Figure A4.1.5 
1
H NMR spectra of PEI-25k-C6Bx, x = 1, 2 and 4 (solvent: D2O) with assignment of 
ligand signals (H11 and H18 are overlapped). A summary of the signal assignments of 
all PEI-C6Bx with x = 1, 2 and 4 can be found in the experimental part chapter 
5.3.1. 
 
 
Figure A4.1.6 
1
H NMR spectra of PEI-25k-PEG12Bx, x = 1, 2 and 4 (solvent: D2O) with assignment 
of ligand signals (H11 is overlapped). A summary of the signal assignments of all PEI-
PEG12Bx with x = 1, 2 and 4 can be found in the experimental part chapter 5.3.1. 
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Figure A4.1.7 1H NMR spectra of PEI-25k-DS-C6Bx, x = 1, 2 and 4 (solvent: D2O). A summary 
of the signal assignments of all PEI-DS-C6Bx with x = 1, 2 and 4 can be found in the 
experimental part chapter 5.3.1. 
 
 
Figure A4.1.8 
1
H NMR spectra of PEI-25k-DS-PEG12Bx, x = 1, 2 and 4 (solvent: D2O). A summary 
of the signal assignments of all PEI-DS-PEG12Bx with x = 1, 2 and 4 can be found in 
the experimental part chapter 5.3.1. 
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Figure A4.1.9 LILBID MS spectra of a) PPI-DS and b) PPI-DS-C6B1. 
 
 
Figure A4.1.10 LILBID MS spectra of a) PPI-DS-C6B2 and b) PPI-DS-PEG12B1. 
 
 
Figure A4.1.11 LILBID MS spectra of a) PPI-DS-PEG12B2 and b) PPI-DS-C6B4. 
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Figure A4.1.12 AF4-LS fractogramms of PPI-DS-PEG12B4 with molar mass (symbols), LS (solid 
line) and RI-signal (broken line) as a function of elution time. The shoulders result 
from the chosen separation method and show marginal aggregation. 
 
Figure A4.1.13 AF4-LS fractogramms of a) PPI-DS-C6B8 and b) PPI-DS-PEG12B8 with molar mass 
(symbols), LS (solid line) and RI-signal (broken line) as a function of elution time. 
The shoulders result from the chosen separation method and show marginal 
aggregation. 
 
Figure A4.1.14 AF4-LS-fractogram of a) avidin and PPI-DS-C6B1 and b) avidin, PPI-DS-PEG12B1 
and PPI-DS-PEG12B2 with molar mass (symbols), LS (solid line) and RI-signal 
(broken line) as a function of elution time. The shoulders result from the chosen 
separation method and show marginal aggregation. 
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Figure A4.1.15 AF4-LS-fractograms for the conversion of avidin with PPI-DS-PEG12B1 in a 1/3 
molar ratio with light scattering (LS) signal, refractive index (RI) signal and molar 
masses (symbols) of different fractions (green – PPI-DS-PEG12B1, grey –
 1/2 conjugation adduct, black – nanostructure) as a function of elution time, 
b) HABA displacement titrations of PPI-DS and PEI-DS. 
 
 
Figure A4.1.16 DLS volume plot of different molar ratios of a) avidin/PPI-DS-C6B1 and 
b) avidin/PEI-DS-C6B1 after 1 d measured in 0.1 M TRIS/HCl/NaCl at pH 7.5 by 
DLS in batch. 
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Figure A4.1.17 DLS volume plot of different molar ratios of a) avidin/PPI-DS-C6B2 and 
b) avidin/PEI-DS-C6B2 after 1 d measured in 0.1 M TRIS/HCl/NaCl at pH 7.5 by 
DLS in batch. 
 
Figure A4.1.18 DLS volume plot of different molar ratios of a) avidin/PPI-DS-C6B4 and 
b) avidin/PEI-DS-C6B4 after 1 d measured in 0.1 M TRIS/HCl/NaCl at pH 7.5 by 
DLS in batch. 
 
Figure A4.1.19 DLS volume plot of different molar ratios of a) avidin/PPI-DS-PEG12B1 and 
b) avidin/PEI-DS-PEG12B1 after 1 d measured in 0.1 M TRIS/HCl/NaCl at pH 7.5 by 
DLS in batch. 
 
1 10 100
0
5
10
15
20
V
ol
%
Dh [nm]
 [avidin.HABA]
 PPI-DS-C6B2
 1/0.25
 1/0.5
 1/1
 1/1.5
 1/2
1 10 100
0
5
10
15
20
V
ol
%
Dh [nm]
 [avidin.HABA]
 PEI-DS-C6B2
 1/0.25
 1/0.5
 1/1
 1/1.5
 1/2
a) b)
1 10 100
0
5
10
15
20
V
ol
%
Dh [nm]
 [avidin.HABA]
 PPI-DS-C6B4
 1/0.25
 1/0.5
 1/1
 1/1.5
 1/2
1 10 100
0
5
10
15
20
V
ol
%
Dh [nm]
 [avidin.HABA]
 PEI-DS-C6B4
 1/0.25
 1/0.5
 1/1
 1/1.5
 1/2
a) b)
1 10 100
0
5
10
15
20
V
ol
%
Dh [nm]
 [avidin.HABA]
 PPI-DS-PEG12B1
 1/1
 1/2
 1/3
 1/4
1 10 100
0
5
10
15
20
V
ol
%
Dh [nm]
 [avidin.HABA]
 PEI-DS-PEG12B1
 1/1
 1/2
 1/3
 1/4
a) b)
 
Appendix of Chapter 4.1 
 
186 
 
Figure A4.1.20 DLS volume plot of different molar ratios of a) avidin/PPI-DS-PEG12B2 and 
b) avidin/PEI-DS-PEG12B2 after 1 d measured in 0.1 M TRIS/HCl/NaCl at pH 7.5 by 
DLS in batch. 
 
 
Figure A4.1.21 DLS volume plot of different molar ratios of a) avidin/PPI-DS-PEG12B4 and 
b) avidin/PEI-DS-PEG12B4 after 1 d measured in 0.1 M TRIS/HCl/NaCl at pH 7.5 by 
DLS in batch. 
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Figure A4.1.22 DLS volume plot of a) avidin/PPI-DS-C6B8 and b) avidin/PPI-DS-PEG12B8 after 1 d 
(left) and 14 d (right) measured in 0.1 M TRIS/HCl/NaCl at pH 7.5 by DLS in batch. 
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Table A4.1.1 Average amount of bound bGP (Av) and standard deviations (SD) based on the 
displacement of HABA molecules from the avidin binding sites measured after 1 d, 
7 d and 14 d determined by the amount of displaced HABA. 
 
  bound PEI-DS-(…) bound PPI-DS-(…) 
(…) = molar ratio 1 d  7 d 14 d 1 d 7 d  14 d 
avidin/bGP Av SD Av SD Av SD Av SD Av SD Av SD 
C6B1 
1/1 0.50 0.06 0.52 0.04 0.51 0.06 0.50 0.05 0.57 0.07 0.52 0.05 
1/2 1.06 0.09 1.08 0.07 1.10 0.09 1.10 0.05 1.18 0.07 1.15 0.04 
1/3 1.50 0.04 1.54 0.03 1.57 0.06 1.60 0.09 1.68 0.16 1.67 0.10 
1/4 1.75 0.01 1.79 0.01 1.85 0.04 1.73 0.09 1.84 0.14 1.83 0.08 
C6B2 
1/0.25 0.11 0.01 0.11 0.02 0.11 0.01 0.13 0.04 0.16 0.08 0.13 0.05 
1/0.5 0.27 0.01 0.27 0.01 0.28 0.01 0.29 0.08 0.33 0.05 0.31 0.08 
1/1 0.52 0.02 0.53 0.02 0.55 0.02 0.48 0.02 0.53 0.03 0.52 0.04 
1/1.5 0.85 0.05 0.87 0.05 0.89 0.06 0.85 0.04 0.87 0.04 0.88 0.05 
1/2 0.95 0.05 0.97 0.06 1.00 0.06 0.97 0.06 0.99 0.06 1.02 0.06 
C6B4 
1/0.25 0.14 0.01 0.15 0.01 0.15 0.02 0.18 0.01 0.18 0.01 0.19 0.01 
1/0.5 0.28 0.02 0.29 0.02 0.29 0.02 0.32 0.01 0.32 0.01 0.32 0.02 
1/1 0.53 0.02 0.53 0.02 0.55 0.02 0.60 0.03 0.59 0.05 0.62 0.03 
PEG12B1 
1/1 0.43 0.04 0.42 0.04 0.43 0.04 0.45 0.11 0.43 0.09 0.45 0.13 
1/2 1.00 0.04 1.01 0.04 1.03 0.05 0.92 0.13 0.89 0.09 0.96 0.13 
1/3 1.49 0.08 1.51 0.09 1.54 0.09 1.36 0.09 1.36 0.07 1.40 0.09 
1/4 1.87 0.06 1.89 0.06 1.93 0.06 1.78 0.12 1.80 0.13 1.83 0.13 
PEG12B2 
1/0.25 0.12 0.01 0.12 0.01 0.12 0.01 0.11 0.03 0.11 0.03 0.11 0.04 
1/0.5 0.22 0.05 0.22 0.05 0.23 0.05 0.21 0.05 0.21 0.05 0.21 0.06 
1/1 0.48 0.01 0.48 0.01 0.49 0.01 0.44 0.07 0.45 0.07 0.45 0.08 
1/1.5 0.75 0.01 0.75 0.01 0.77 0.01 0.65 0.04 0.65 0.02 0.67 0.04 
1/2 0.90 0.04 0.91 0.04 0.92 0.03 0.83 0.02 0.83 0.01 0.85 0.02 
PEG12B4 
1/0.25 0.13 0.01 0.14 0.01 0.13 0.02 0.15 0.01 0.15 0.01 0.15 0.02 
1/0.5 0.25 0.00 0.25 0.00 0.26 0.01 0.30 0.02 0.30 0.02 0.31 0.02 
1/1 0.44 0.01 0.44 0.01 0.44 0.01 0.47 0.04 0.48 0.04 0.48 0.04 
no ligand 
1/1 0.04 0.07 0.04 0.06 0.04 0.05 -0.02 0.05 -0.02 0.04 -0.03 0.06 
1/3 0.07 0.08 0.07 0.11 0.06 0.12 0.00 0.05 0.00 0.04 -0.01 0.05 
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Table A4.1.2 Average hydrodynamic diameters Dh and standard deviations (SD) based on DLS 
volume distribution (Vol%) of BHS and references after 1 d and 14 d with and the 
standard deviation SD measured in 0.1 M TRIS/HCl/NaCl at pH 7.5 by DLS in batch. 
 
  avidin/PPI-DS-(…) avidin/PEI-DS-(…) 
(…) =  
molar ratio 1 d 14 d 1 d 14 d 
avidin/bGP Dh SD Dh SD Dh SD Dh SD 
C6B1 
1/1 9 < 1 9 < 1 12 < 1 13 < 1 
1/2 12 < 1 11 1 18 < 1 18 2 
1/3 12 < 1 12 2 21 < 1 22 < 1 
1/4 10 1 10 1 18 < 1 19 < 1 
C6B2 
1/0.25 8 < 1 8 < 1 10 1 10 < 1 
1/0.5 13 2 12 1 15 < 1 16 < 1 
1/1 16 2 21 3 22 < 1 27 3 
1/1.5 23 2 28 < 1 29 2 34 4 
1/2 17 3 20 3 28 2 29 2 
C6B4 
1/0.25 21 16 22 16 35 5 40 7 
1/0.5 37 10 49 13 38 3 53 11 
1/1 46 10 59 19 53 3 68 12 
1/1.5 21 2 21 2 38 5 44 6 
1/2 14 < 1 15 1 24 1 25 < 1 
PEG12B1 
1/1 9 < 1 9 < 1 13 < 1 12 < 1 
1/2 11 < 1 10 < 1 17 < 1 16 < 1 
1/3 13 1 12 1 21 1 21 < 1 
1/4 15 3 13 2 20 < 1 21 1 
PEG12B2 
1/0.25 8 < 1 7 < 1 9 2 11 1 
1/0.5 10 < 1 10 1 14 < 1 12 2 
1/1 16 3 14 2 20 1 21 1 
1/1.5 18 2 17 2 29 1 29 < 1 
1/2 21 2 20 1 32 2 42 15 
PEG12B4 
1/0.25 44 11 45 15 32 10 45 11 
1/0.5 50 14 54 17 38 7 59 20 
1/1 40 3 51 15 57 11 77 19 
1/1.5 26 8 27 7 36 3 45 7 
1/2 22 10 19 3 24 4 33 16 
no ligand 1/1 6 < 1 6 < 1 8 < 1 8 < 1 
1/3 6 < 1 6 < 1 9 < 1 9 < 1 
references
a
 
 PPI-DS-(…) PEI-DS-(…) 
(…) = Dh SD Dh SD 
C6B1 5 < 1 11 < 1 
C6B2 6 < 1 11 < 1 
C6B4 6 < 1 11 < 1 
PEG12B1 6 < 1 11 < 1 
PEG12B2 5 < 1 11 < 1 
PEG12B4 6 < 1 11 < 1 
no ligand 6 < 1 10 < 1 
[avidin.HABA] 7 1 7 1 6 < 1 6 < 1 
a 
references were only measured after 1 d. 
 
 
 
Appendix of Chapter 4.1 
 
190 
 
Figure A4.1.23 DLS volume plots of samples of the HFF purification of avidin/PPI-DS-PEG12B1 
1/1 with a) 100 kDa and b) 300 kDa mPES membranes measured in 0.1 M 
TRIS/HCl/NaCl at pH 7.5 by DLS in batch. 
 
Figure A4.1.24 DLS volume plots of samples of the HFF purification of avidin/PPI-DS-PEG12B1 
1/2 with a) 100 kDa and b) 300 kDa mPES membranes measured in 0.1 M 
TRIS/HCl/NaCl at pH 7.5 by DLS in batch. 
 
      
Figure A4.1.25 DLS volume plots of samples of the HFF purification of avidin/PPI-DS-PEG12B2 
1/1 with 100 kDa membrane measured in 0.1 M TRIS/HCl/NaCl at pH 7.5 by DLS 
in batch. 
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Figure A4.1.26 DLS volume plots of samples of the HFF purification of avidin/PPI-DS-PEG12B2 1/2 
with a) 100 kDa and b) 300 kDa mPES membranes measured in 0.1 M 
TRIS/HCl/NaCl at pH 7.5 by DLS in batch. 
 
Figure A4.1.27 DLS volume plots of samples of the HFF purification of avidin/PPI-DS-PEG12B4 1/1 
with a) 100 kDa and b) 300 kDa mPES membranes measured in 0.1 M 
TRIS/HCl/NaCl at pH 7.5 by DLS in batch. 
 
Figure A4.1.28 DLS volume plots of samples of the HFF purification of avidin/PPI-DS-PEG12B4 1/1 
with a) 500 kDa and b) 0.2 µm mPES membranes measured in 0.1 M 
TRIS/HCl/NaCl at pH 7.5 by DLS in batch. 
1 10 100
0
5
10
15
20
25
V
ol
%
D
h
 [nm]
 initial composition
 final structure
 removed particles
1 10 100
0
5
10
15
20
25
V
ol
%
D
h
 [nm]
 initial composition
 final structure
 removed particles
a) b)
1 10 100 1000
0
5
10
15
20
25
V
ol
%
D
h
 [nm]
 initial composition
 final structure
 
1 10 100 1000
0
5
10
15
20
25
V
ol
%
D
h
 [nm]
 initial composition
 final structure
 % (3)
a) b)
1 10 100 1000
0
5
10
15
20
25
V
ol
%
D
h
 [nm]
 initial composition
 final structure
 removed particles
1 10 100 1000
0
5
10
15
20
25
V
ol
%
D
h
 [nm]
 initial composition
 final structure
 removed particles
a) b)
 
Appendix of Chapter 4.2 
 
192 
 
Figure A4.2.1 Zetapotential of PPI-DS-C6Bx, x = 1 or 2 in 1 mM KCl solution with a concentration 
of 1 mg/mL. A similar dependence of the zetapotential of PPI-DS-C6B4 on the pH is 
assumed. 
 
 
Figure A4.2.2 Overview spectrum of different concentrations of bHRP in 0.1 M TRIS/HCl/NaCl at 
pH 7.5. 
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Figure A4.2.3 AF4-LS-fractogram of the enzymatic BHS avidin/bHRP/PPI-DS-C6B4 with light 
scattering (LS) signal and refractive index (RI) signal as well as molar mass as a 
function of elution time, samples were measured in in 50 mM nitrate buffer at pH 
6.8 and 0.02 % (w/v) NaN3. 
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Figure A4.3.1 
1
H NMR spectrum of PPI-C10A6 at δ = 6.5 – 8.5 ppm: a) assignment of the protons 
u, v, and w. Proton u proofs the successful coupling of the adamantane ligand by 
an amide bond formation (solvent: DMSO-d6) and b) the addition of TFA-d clarified 
the signals as residual benzotriazole. 
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Figure A4.3.2 
1
H NMR spectrum of a) PEI-C10A6 (solvent: DMSO-d6 with additional TFA-d) and b) 
of PEI-DS-C10A6 (solvent: D2O). The signals of the adamantane ligand C10A and of 
the the PEI-25k core are assigned in a). Ligand signals that are well observable also 
after maltosylation are assigned in b). A summary of the signal assignments can be 
found in the experimental part chapter 5.3.2. 
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Figure A4.3.3 
1
H NMR spectrum of a) PEI-C6B4-C10A6 (solvent: DMSO-d6 with additional TFA-d)
and b) of PEI-DS-C6B4-C10A6 (solvent: D2O). The signals of the adamantane ligand 
(C10A), the biotin (C6B) ligands and of the PEI-25k core are assigned in a). 
Maltosylation results in additional broad signals, which are assigned in b). Ligand 
signals that are well observable also after maltosylation are assigned in b). A 
summary of the signal assignments can be found in the experimental part chapter 
5.3.2. 
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Figure A4.3.4 AF4-LS fractogramms of a) PPI-DS-C10A6 and b) PPI-DS-C6B4-C10A6 with molar 
mass (symbols), LS (solid line) and RI-signal (broken line) as a function of elution 
time. The signals at higher elution times show aggregation and result from the 
chosen separation method. 
 
Table A4.3.1 Dh of used single components used for BHS formation taken from the DLS volume 
distribution analysis. 
 
 
 
Dh, 1 
 
  Dh, 1  
 [nm] Vol %   [nm] Vol % 
[avidin.HABA] 6 99.4  pCD 13 99.9 
avidin 7 100     
       
PPI-DS-C6B4-C10A6 8 99.9  PEI-DS-C6B4-C10A6 16 98.9 
PPI-DS-C10A6 9 100  PEI-DS-C10A6 21 97.6 
PPI-DS 5 100  PEI-DS 17 100 
 
 
Table A4.3.2 Dh of certain molar ratios of PPI-DS-C10A6/pCD and of PPI-DS-C6B4/pCD taken 
from the DLS volume distribution analysis.
a
 
 
 
Dh    Dh  
PPI-DS-C10A6/pCD [nm] Vol %  PPI-DS-C6B4/pCD [nm] Vol % 
1/7 23 97.0  1/7 9 98.4 
1/14 25 93.7  1/14 16 99.9 
1/28 22 51.7  1/28 14 100.0 
 
8 48.3     
1/56 12 99.8  1/56 9 99.9 
a 
Sizes of the single components can be found in Table A4.3.1. 
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Table A4.3.3 Dh of different molar ratios of [avidin.HABA]/PPI-DS-C6B4-C10A6 and avidin/PPI-
DS-C6B4-C10A6 taken from the DLS volume distribution analysis.
a
 
 
[avidin.HABA]/PPI-DS-C6B4-C10A6  avidin/PPI-DS-C6B4-C10A6 
 
Dh, 1 
 
Dh, 2 
 
  Dh, 1  Dh, 2  
 [nm] Vol % [nm] Vol %   [nm] Vol % [nm] Vol % 
1/0.5 32 98.8 3373 1.2  1/0.5 199 90.7 3765 9.3 
1/1 161 100 0 0  1/1 1147 93.1 102 6.1 
1/1.5 71 98.9 4509 1.1  1/1.5 170 96.7 4500 3.3 
1/2 33 99.6 3849 0.4  1/2 69 99.7 4651 0.3 
a 
Sizes of the single components can be found in Table A4.3.1. 
 
Table A4.3.4 Dh of different molar ratios of [avidin.HABA]/PEI-DS-C6B4-C10A6 and avidin/PEI-DS-
C6B4-C10A6 taken from the DLS volume distribution analysis.
a
 
 
 
[avidin.HABA]/PEI-DS-C6B4-C10A6  avidin/PEI-DS-C6B4-C10A6 
 
Dh, 1 
 
Dh, 2 
 
  Dh, 1  Dh, 2  
 [nm] Vol % [nm] Vol %   [nm] Vol % [nm] Vol % 
1/0.5 50 88.2 3450 11.8  1/0.5 86 97.4 4137 2.6 
1/1 92 98.9 3795 1.1  1/1 521 76 86 20.3 
1/1.5 83 99.2 4619 0.8  1/1.5 378 80.3 56 17.6 
1/2 73 94.1 4144 5.9  1/2 127 97.9 4134 2.1 
a 
Sizes of the single components can be found in Table A4.3.1. 
 
Table A4.3.5 Dh of different molar ratios of avidin/pCD, PPI-DS/pCD, PEI-DS/pCD, avidin/PPI-DS-
C10A6, [avidin.HABA]/PPI-DS-C10A6 and [avidin.HABA]/PEI-DS-C10A6 taken from 
the DLS volume distribution analysis.
a
 
 
 Dh, 1 
 
  Dh, 1  
avidin/pCD [nm] Vol %  avidin/PPI-DS-C10A6 [nm] Vol % 
1/24 8 99.9  1/0.5 8 99.9 
1/48 9 99.9  1/1 7 100 
1/96 9 99.9  1/1.5 7 99.9 
PPI-DS/pCD 
 
   PEI-DS/pCD 
 
[nm] Vol % 
1/24 7 99.9  1/24 19 97.1 
1/48 7 100  1/48 21 99.3 
1/96 10 100  1/96 16 99.2 
[avidin.HABA]/PPI-DS-C10A6
b 
   [avidin.HABA]/PEI-DS-C10A6
b 
  
1/1 8 99.7  1/1 12 99.1 
1/3 8 99.7  1/3 13 99 
a 
Sizes of the single components can be found in Table A4.3.1; 
b 
No change of A500 nm for both 
probed ratios. 
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Table A4.3.6 Dh of different molar ratios of avidin/PPI-DS-C6B4-C10A6/pCD and avidin/PEI-DS-
C6B4-C10A6/pCD taken from the DLS volume distribution analysis.
a
 
 
 
 
avidin/PPI-DS-C6B4-C10A6/pCD  avidin/PEI-DS-C6B4-C10A6/pCD 
 
Dh, 1 
 
Dh, 2 
 
  Dh, 1  Dh, 2  
 [nm] Vol % [nm] Vol %   [nm] Vol % [nm] Vol % 
1/1.5/32 1828 90.4 292 2.8  1/1.5/43 2560 97.1 343 2.2 
1/1.5/43 1811 97 271 3  1/1.5/54 1806 96.1 344 3 
1/1.5/54 821 96.7 121 3.3  1/1.5/65 1139 97.8 4683 2.2 
a 
Sizes of the single components can be found in Table A4.3.1. 
 
Table A4.3.7 Dh of samples of the HFF purification of avidin/PPI-DS-C6B4-C10A6 in a molar ratio 
of 1/1.5 taken from the DLS volume distribution analysis.
a
 
 
 
Dh, 1 
 
Dh, 2 
 
avidin/PPI-DS-C6B4-C10A6 1/1.5 [nm] Vol % [nm] Vol % 
non-purified  257 97 39 3 
purified 306 100 0 0 
purified, desalted and concentrated 329 59 81 39.9 
a 
Sizes of the single components can be found in Table A4.3.1. 
 
Table A4.3.8 Dh of different molar ratios of purified avidin/PPI-DS-C6B4-C10A6 in an initial molar 
ratio of 1/1.5 and pCD. Values were taken from the DLS volume distribution
analysis.
a
 
 
avidin/PPI-DS-C6B4-C10A6
HFF
/pCD 
 
Dh, 1 
 
Dh, 2 
 
added eq of pCD [nm] Vol % [nm] Vol % 
21 5388 90.3 157 4.8 
32 4305 92.8 438 7.2 
43 2004 95 287 5 
54 950 87.1 168 7.9 
65 890 92.2 4460 7.8 
76 633 83.5 129 13.3 
87 448 84.6 86 9.5 
a 
Sizes of the single components can be found in Table A4.3.1. 
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